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ABSTRACT
In a mouse model, rifampicin and isoniazid combination treatment results in
cholestatic liver injury that is associated with an increase of protoporphyrin ix (PPIX), the
penultimate heme precursor. Excess PPIX is believed to bind to bile acids, precipitate in
bile canaliculi, and form bile plugs leading to cholestasis followed by liver injury. Both
ferrochelatase (FECH/Fech) and aminolevulinic acid synthase 1 (ALAS1/Alas1) are
crucial enzymes in regulating heme biosynthesis. Isoniazid has recently been reported to
up-regulate Alas1 but down-regulate Fech protein levels in mice; however the
mechanism of isoniazid mediated heme synthesis disruption has remained unclear.
Interestingly, metabolites of isoniazid, pyridoxal isonicotinoyl hydrazone (PIH, the
isoniazid and vitamin B6 conjugate) and hydrazine, have been detected in the urine of
humans treated with isoniazid previously. Here I show that in primary human hepatocytes
and the human hepatocellular carcinoma cell line HepG2/C3A: (1) the physiochemical
properties of PPIX may contribute to toxicity (2) isoniazid treatment results in an
increase of ALAS1 but a decrease in FECH protein levels by Western blot analysis; (3)
hydrazine treatment up-regulates ALAS1 protein and mRNA levels; (4) PIH treatment
decreases FECH protein levels; (5) PIH is detected by mass spectrometry analysis
following isoniazid treatment with a further increase when exogenous vitamin B 6
analogues are co-administrated. In addition, the (6) PIH mediated down-regulation of
human FECH is dependent on iron levels. Proteomics profiling analysis suggests that in
the livers of hPXR mice (7) rifampicin may induce CYP450 changes associated with
increased hydrazine reactivity with cellular proteins, (8) multiple [2Fe-2S]-containing
proteins and (9) [Fe-S] assembly machinery proteins may be down-regulated in mice due
to isoniazid. Together these data demonstrate that hydrazine up-regulates ALAS1 while
PIH down-regulates FECH, suggesting that the metabolites of isoniazid mediate its
disruption of heme biosynthesis.
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CHAPTER 1.

INTRODUCTION

The Implications of Anti-Tubercular DILI
Approximately 1.6 million people died of tuberculosis (TB) in 2015 and up to 10
million current cases of tuberculosis were predicted in 2015 (Disease, Injury et al. 2016).
Of all infectious causes, mortality due to TB infection is second only to the human
immunodeficiency virus (HIV) (Murray, Ortblad et al. 2014, Disease, Injury et al. 2016,
Collaborators 2017). Access to therapeutics plays an important role in adherence to
successful completion of regimens and successful anti-TB treatment strategies rely upon
an uninterrupted supply of therapeutics (Long, Smith et al. 2011, Muture, Keraka et al.
2011). Alternative drugs may have lower therapeutic windows than first line therapy (i.e.,
rifampicin and isoniazid) or may impose financial burdens (Blumberg, Burman et al.
2003). For example, rifabutin is not associated with the up-regulation of drug
metabolizing enzymes and transporters through the human Pregnane X Receptor (hPXR)
activation but costs much more than rifampicin. Additionally, replacing rifampicin with
rifabutin (an analog that does not activate hPXR) does not completely obviate adverse
events (Horne, Spitters et al. 2011). Similarly, first line highly active anti-retroviral
therapy (HAART) is efficacious at reducing viral load and preventing T-cell depletion.
Change or discontinuation of HAART was due to drug toxicity in 22 % of
patients; 11 % of these were due to hepatotoxicity. Discontinuation of HAART for longer
than four weeks was associated with decreases in CD4+ T-cell populations and increases
in HIV ribonucleic acid (RNA) at 12 months (Elzi, Marzolini et al. 2010). The median
time of discontinuation for hepatotoxicity was 72 days, much longer than the four weeks
necessary to see deleterious effects. HIV protease inhibitors, such as ritonavir, indinavir,
amprenavir, atazanavir, darunavir, efavirenz, and lopinavir have been shown to activate
hPXR, and may pathologically up-regulate drug metabolizing enzymes (Sulkowski,
Thomas et al. 2000, Luo, Cunningham et al. 2002, Chan, Patel et al. 2013). In addition,
co-infection of HIV with TB increases the risk of drug-induced liver injury (DILI) (Ungo,
Jones et al. 1998, Yee, Valiquette et al. 2003, Breen, Miller et al. 2006). Due to chronic
up-regulation of drug metabolizing enzymes, there is still a potential for adverse drug
interactions when HAART is suspended to treat TB. Additionally, the discontinuation of
HAART for a six-month course of rifampicin and isoniazid, could lead to T-cell
depletion and increases in viral load (Deeks, Wrin et al. 2001, Elzi, Marzolini et al.
2010). HIV co-infection increases the risk of anti-TB DILI four-fold, even when HAART
has been suspended. Moreover, concomitant TB and HIV therapy increased the risk of
DILI more than ten-fold (Yimer, Gry et al. 2014).
Hepatotoxicity decreases adherence to treatment regimens and contributes to
treatment failure, disease relapse, and drug resistance (Singla, Gupta et al. 2014).
Hepatotoxicity is a leading cause of TB therapy treatment failure, with up to 28% of all
anti-TB treatment failure attributed to toxicity (Sharifzadeh, Rasoulinejad et al. 2005,
Tostmann, Boeree et al. 2008). Therefore, further characterization of the mechanism of
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anti-tubercular liver injury would enable the development of updated clinical guidance to
prevent or ameliorate DILI.
Drug-Induced Liver Injury
DILI is classified as one of three categories based on clinicopathologic
presentation: hepatocellular injury (a result of specific injury to hepatocytes), cholestatic
injury (caused by specific toxicity to biliary epithelial cells and/or bile pumps that
disrupts bile flow), or a mixed pattern of injury with characteristics of both of the other
types of liver injury (Navarro and Senior 2006). Generally, the severity of liver injury
correlates to the levels of serum alanine aminotransferase (ALT) and alkaline phosphatase
(ALP). Hepatocellular injury is associated with serum ALT levels greater than two times
the upper limit of the normal range and an ALT/ALP ratio greater than or equal to 5.
Cholestatic liver injury is defined as a serum ALP level greater than twice the upper limit
of the normal range and an ALT/ALP ratio of less than 2 (Navarro and Senior 2006).
Mixed injury is the designation if the ALT/ALP ratio is between 2 and 5. ALT is specific
to DILI, but not sensitive. ALP is not specific, but is more sensitive. Therefore, the gold
standard for the diagnosis of DILI is histologic examination of liver tissue. DILI is also
classified by pathogenesis due to specific measurable compounds derived from the
causative xenobiotic or from an immune response induced by the presence of the
xenobiotic or potential metabolites.
Clinical Classification of DILI by Pathophysiology
The clinicopathologic characterization of DILI is based on the clinical
presentation of the liver injury and the pathologic effects observed on histological
examination (reviewed in Wang et al., 2014) is necessary to identify the particular
xenobiotic responsible for the liver injury (Wang, Chai et al. 2014). The molecular
mechanism responsible for the pathogenesis of DILI may be associated with the
pathophysiologic subtype of liver injury. Liver injury caused by cholestasis may be
caused by mechanism that result in cholestasis, such as by the disruption of intracellular
actin or transporter proteins (Woolbright and Jaeschke 2012, Schyschka, Sanchez et al.
2013). Hepatocellular liver injury that is caused by xenobiotics that are directly toxic to
hepatocytes and is associated with ALT elevation. ALT is diffusely expressed throughout
the liver and is increased when hepatocytes are damaged (Navarro and Senior 2006).
Cholestatic liver injury is caused by bile stasis that is reflected by elevated levels of ALP,
γ-glutamyl transferase, and direct bilirubin (Navarro and Senior 2006). Following
obstruction of bile flow ALP is released from biliary epithelial cells, from which ALP is
expressed (Suzuki, Irie et al. 2006). Cholestasis is also associated with mechanism that
disrupts bile flow and leads to the accumulation of bile acids within the liver. Damage to
biliary epithelial cells or the impairment of bile export can lead to cholestasis (Meier,
Pauli-Magnus et al. 2006). When combinations of xenobiotics or when a single
xenobiotic that damages multiple types of liver cells are administered a mixed type of
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liver injury results where the characteristics of both cholestatic and hepatocellular liver
injury are observed (Fisher, Vuppalanchi et al. 2015).
Clinical Classification of DILI by Pathogenesis
The classification of DILI by pathogenesis can give additional insights into the
causative agent and probable molecular mechanism. Intrinsic liver injury is usually
caused by the parent drug or one of its metabolites and is dose-dependent on these
xenobiotics and are detectable in the liver or blood (Kumar, Chung et al. 2012, Xie,
McGill et al. 2014). These effects occur in laboratory animals and are predictable.
Therefore pharmaceuticals that cause intrinsic liver injury are usually detected during
preclinical development (Ganey, Luyendyk et al. 2004, Ganey, Luyendyk et al. 2007, Li,
Lu et al. 2013, Xie, McGill et al. 2014, Teschke, Larrey et al. 2016). Idiosyncratic liver
injury is more common than intrinsic liver injury and is typically caused by the activation
of xenobiotics by the CYP450 system. Idiosyncratic liver injury may result in the
formation of drug/metabolite-protein-adducts that are identified as haptens by the host
immune system and are undetectable (Tujios and Fontana 2011, Kishida, Onozato et al.
2012, den Braver, den Braver-Sewradj et al. 2016). The complex combination of
environmental and genetic factors that contribute to idiosyncratic liver injury cannot be
reliably reproduced in laboratory animals (Teschke, Larrey et al. 2016, Clare, Miller et al.
2017, Lundgren, Martinsson et al. 2017). The immune response of the host, not the
xenobiotic or metabolites is the main contribution to the pathogenesis of idiosyncratic
liver injury, contrary to intrinsic liver injury (Ali and Auerbach 2017, Ghannam, Mansour
et al. 2017).
The Pregnane X Receptor
Activation of the human Pregnane X Receptor (hPXR, also known as NR1I2
[nuclear receptor subfamily 1, group I, member 2], SXR [steroid and xenobiotic sensing
receptor], or PAR [pregnane activated receptor]) by agonists, such as rifampicin, results
in the transcription of target genes, many of which are drug metabolizing enzymes and
transporters (Figure 1-1). hPXR is one of a class of proteins, nuclear hormone receptors
(NHR), defined by a DNA binding domain, a ligand binding domain (LBD), and two
activating function domains. The LBD of hPXR is particularly promiscuous and binds to
a large number of structurally different compounds (Watkins, Maglich et al. 2003,
Zollner, Wagner et al. 2010). Target DNA sequences in the promoters of target genes are
targeted by NHRs to induce the transcription of these target genes. Ligand binding to the
LBD of hPXR enables the recruitment of co-activating proteins and the dissociated of corepressor proteins and triggers transcription (Watkins, Maglich et al. 2003, Chen 2008,
Zollner, Wagner et al. 2010, Wang, Ong et al. 2012). hPXR activation induces the
expression of many cytochrome P450 (CYP450) enzymes CYP3A4, CYP2B6, CYP2C9,
and CYP2C19; phase II enzymes, including UDP-glucuronosyltransferases and
sulfotransferases; and transporters, including ATP–binding cassette transporter ABCB1
(also known as MDR1 or P-gp), multiple organic anion transporters, and multidrug-
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Figure 1-1.

hPXR function.

hPXR binds specific enhancer elements in target gene promoters, recruits co-activating
proteins, such as SRC-1 and RXR, upon ligand binding which results in the transcription
of target genes, typically drug metabolizing enzymes and transporters in the case of
hPXR.
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resistance protein 3 (MRP3) (Kliewer, Moore et al. 1998, Lehmann, McKee et al. 1998,
Gardner-Stephen, Heydel et al. 2004, Aleksunes and Klaassen 2012, Oladimeji, Lin et al.
2017). hPXR is expressed in the intestines and the liver (Lamba, Yasuda et al. 2004).
hPXR and mouse PXR (mPxr) are activated by different, but overlapping sets of
compounds. Thus, a mouse model where mPxr is knocked out and replaced with hPXR is
required to study the function of hPXR-specific ligands, such as rifampicin, on hPXR in
vivo function (Gong, Singh et al. 2006, Ma, Shah et al. 2007).
hPXR activation by a large range of structurally disparate xenobiotics induces the
expression of target genes that results in the increased metabolism of an even greater
number of compounds. hPXR agonists include protease inhibitors, analgesics,
anticonvulsants, antibacterials, statins and glucocorticoids (Brewer and Chen 2016).
Inter-individual variability in drug response may result from variation, in hPXR target
genes, variations in the expression profile of hPXR isoforms, single-nucleotide
polymorphisms in coding or promoter regions of hPXR and variation in total hPXR
protein expression (Zhang, Kuehl et al. 2001, Lamba, Yasuda et al. 2004).
The Role of the Pregnane X Receptor in DILI
PXR agonists can contribute to hepatotoxicity by 1) trans-activating the PXRdependent up-regulation of drug metabolizing enzymes and transporters which may form
metabolites from exogenous compounds that contribute to toxicity; and/or by 2) inducing
the expression of liver enzymes in critical metabolic pathways that may lead to an
imbalance of endobiotic metabolism, resulting in the accumulation of toxic endogenous
compounds (Figure 1-2). The hydroxylation of xenobiotics and endobiotics by CYP450
enzymes can produce daughter compounds that are more toxic than the parent compound
(Lakehal, Dansette et al. 2001, Luo, Cunningham et al. 2002, Raucy 2003, Chen,
Ferguson et al. 2004, He, Talaat et al. 2004, Al-Dosari, Knapp et al. 2006, Huwyler,
Wright et al. 2006, Cheng, Ma et al. 2009, Andrews, Armstrong et al. 2010, Bilgi, Bell et
al. 2010, Chaudhry, Urban et al. 2010, Lee, Bhandary et al. 2011, Sasaki, Matsuo et al.
2013, Wang, Liu et al. 2013, Chiu, Tomlinson Guns et al. 2014). This is problematic
enough when the efficacy of pharmaceuticals is affected by decreasing plasma
concentrations of drugs, especially in HAART regimens in which one component drug
may increase the metabolism of another component and decrease the efficacy of anti-HIV
treatment (Pal, Kwatra et al. 2011, Kumar, Jin et al. 2012). In the case of CYP450mediated formation of toxic metabolites, this effect may be fatal. hPXR, upon activation
by drugs, up-regulates drug-metabolizing enzymes such as CYP3A4 which metabolize a
great number of drugs and may result in toxicity, (Goodwin, Hodgson et al. 1999, Cheng,
Ma et al. 2009, Andrews, Armstrong et al. 2010) leading to liver toxicity (Guo, Moffit et
al. 2004, Wolf, Wood et al. 2005, Cheng, Ma et al. 2009, Wang, Chai et al. 2014, Brewer
and Chen 2016, Brewer and Chen 2017).
Rifampicin is an hPXR agonist (but not an agonist of mouse PXR [mPxr]) and is
used as a first-line drug to treat tuberculosis (TB). Rifampicin is used to treat
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Figure 1-2.

Contribution of hPXR to DILI.

hPXR increases the transcription of genes that encode drug metabolizing enzymes by
increasing the formation of reactive and/or toxic metabolites from xenobiotics and
endobiotics.
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Legionnaire’s disease, leprosy, H. influenzae type b, and active M. tuberculosis
infections. Rifampicin is almost always used with other antibiotics to prevent the
emergence of resistance. Rifampicin inhibits bacterial deoxyribonucleic acid (DNA)dependent RNA polymerase. Rifampicin binds to the RNA polymerase β subunit within
the nucleotide channel but not at the active site (Campbell, Korzheva et al. 2001). This
physically blocks elongation of RNA strands. Rifampicin-induced severe hepatotoxicity
is rare, with an incidence of less than 1.1% when used alone; however, in combination
with isoniazid (another first-line anti-TB drug), the hepatotoxicity incidence significantly
increases to 5% – 8%, occurring more frequently and earlier than it does with either
medication alone (Yew and Leung 2006). Isoniazid is used in combination with
rifampicin, ethambutol, and pyrazinamide in active tuberculosis infections, but is used
alone in latent TB infections. Isoniazid is also used to treat other mycobacterial
infections. Isoniazid is a prodrug that is activated by KatG (a bacterial catalase
peroxidase) to form the isonicotinic acyl radical that conjugates with NAD + which binds
and inhibits the acyl carrier protein reductase, InhA, decreasing fatty acid synthase. The
fatty acid synthase produces mycolic acids used in the mycobacterial cell wall (Suarez,
Ranguelova et al. 2009). The toxic metabolites of isoniazid, acetylhydrazine and
hydrazine, were previously thought to be associated with its induced hepatotoxicity.
However, a recent study showed that co-administration of rifampicin and isoniazid
increased the amount of protoporphyrin IX (PPIX, a heme precursor) in the bile through
an hPXR-mediated mechanism, that leads to higher levels of ALT, ALP, and bile plugs in
humanized PXR mice containing hPXR than in wild type mice containing mPXR or Pxrnull mice containing neither hPXR nor mPXR (Li, Lu et al. 2013).
A recent report associated hPXR status with the development of rifampicin- and
isoniazid-induced hepatotoxicity (Li, Lu et al. 2013). Bile plugs, high levels of
protoporphyrin IX (PPIX) in the bile, a five-fold increase in ALP, and an ALT/ALP ratio
of approximately 0.5 were reported in hPXR humanized mice (i.e., mice in which mPxr
has been replaced with hPXR). These findings were absent in mice with either wild-type
(WT) mPxr or mice with mPxr knocked out, and treated with both rifampicin and
isoniazid (rifampicin is an agonist for hPXR but not mPxr). ALP and ALT increased when
rifampicin was administered with isoniazid, but not when rifampicin was administered
with the metabolites of isoniazid hydrazine or acetyl-hydrazine.
Isoniazid Metabolism
Isoniazid metabolites have long been implicated in the hepatotoxicity of isoniazid,
with hydrazine and acetyl hydrazine suspected as probable culprits. Isoniazid undergoes
several chemical changes that may lead to pathologic change (reviewed in (Preziosi 2007,
Wang, Pradhan et al. 2016)). CYP450 enzymes may hydroxylate isoniazid leading to
reactive metabolites that form covalent bonds with proteins that are then recognized as
haptens by the host immune system (Timbrell, Mitchell et al. 1980, Delaney and Timbrell
1995). NAT2 acetylates isoniazid, forming acetyl-isoniazid, which is then processed by an
amidase into acetyl hydrazine. Acetyl-hydrazine is then hydroxylated by CYP2E1 to form
reactive metabolites that may bind proteins and result in hapten formation (Nelson,
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Mitchell et al. 1976, Timbrell, Mitchell et al. 1980). Alternatively, NAT2 can acetylate
acetyl hydrazine to form diacetyl hydrazine or acyl amidase can convert acetyl hydrazine
into hydrazine (Lauterburg, Smith et al. 1985). Hydrazine and acetylhydrazine may be
hepatotoxic (Mitchell, Zimmerman et al. 1976, Nelson, Mitchell et al. 1976, Timbrell,
Mitchell et al. 1980, Lauterburg, Smith et al. 1985, Delaney and Timbrell 1995). Indeed,
it is believed that so-called slow acetylators are more susceptible to isoniazid-induced
toxicity because isoniazid is metabolized by acyl amidase enzymes to hydrazine and
isonicotinic acid rather than acetylated to form acetyl isoniazid (Zabost, Brzezinska et al.
2013, Singla, Gupta et al. 2014). Additionally, Mycobacterium tuberculosis catalaseperoxidase (KatG) and human myeloperoxidase can catalyze the formation of NAD +isoniazid adducts (Rozwarski, Grant et al. 1998, Khan, Morgan et al. 2016).
N-acetyl transferases catalyze the transfer of acetyl groups from acetyl-CoA to
arylamines (Sinclair, Sandy et al. 2000, Payton, Mushtaq et al. 2001, Upton, Johnson et
al. 2001). NAT1 is ubiquitously expressed and NAT2 is expressed in the liver and
gastrointestinal tract (Windmill, Gaedigk et al. 2000). NAT2 acetylates isoniazid,
hydrazine, and acetyl hydrazine (Evans, Manley et al. 1960, Ellard and Gammon 1976,
Peretti, Karlaganis et al. 1987). NAT2 acetylates isoniazid to form acetyl-isoniazid, which
is then hydrolyzed to acetyl-hydrazine by CYP2E1. Slow NAT2 acetylators are more
likely to have toxicity (Zabost, Brzezinska et al. 2013, Singla, Gupta et al. 2014). Slow
acetylators are believed to have excess hydrazine due to more isoniazid being hydrolyzed
by CYP2E1. Earlier studies have shown that rapid acetylators may have a higher risk of
liver injury following isoniazid treatment (Kester 1971, Mitchell, Thorgeirsson et al.
1975, Yamamoto, Suou et al. 1986). This was thought to be due to the increased
formation of acetyl hydrazine (Mitchell, Thorgeirsson et al. 1975).
Later studies have shown that slow acetylators have a higher risk of liver injury
following isoniazid treatment (Walker, Ginsberg et al. 2009, Teixeira, Morato et al. 2011,
Gupta, Tyagi et al. 2013, Singla, Gupta et al. 2014). This is believed to be due to the
slower acetylation of acetyl hydrazine to diacetyl hydrazine and that acetyl hydrazine
may be more reactive than diacetyl hydrazine (Peretti, Karlaganis et al. 1987). Slow
acetylators would also have higher levels of unmodified isoniazid that could be
hydroxylated by CYP450 enzymes to reactive metabolites that bind proteins or this
isoniazid could form hydrazine in a reaction catalyzed by acyl amidase (Lauterburg,
Smith et al. 1985, Peretti, Karlaganis et al. 1987, Metushi, Nakagawa et al. 2012).
Amidase enzymes hydrolyze isoniazid to isonicotinic acid and hydrazine and hydrolyze
acetyl isoniazid and acetyl hydrazine (Sendo, Noda et al. 1984, Sarich, Adams et al.
1999, Boelsterli and Lee 2014). No specific amidase has been identified. The slow
acetylator phenotype has been reported to play a role in liver injury in patients treated
with both rifampicin and isoniazid (Miguet, Mavier et al. 1977, Sarma, Immanuel et al.
1986, Ohno, Yamaguchi et al. 2000, Shen, Meng et al. 2008). It should be noted that
several studies have found little or no relationship between acetylator phenotype and liver
injury due to isoniazid (Yamada, Tang et al. 2009, Leiro-Fernandez, Valverde et al. 2010,
Cai, Yi et al. 2012).
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Isoniazid may form adducts with endobiotics and this may contribute to
hepatotoxicity. Isoniazid inhibits an NADPH-dependent fatty acid synthase enoyl ACP
reductase from Mycobacterium tuberculosis, InhA, by forming adducts with NAD +
(Stigliani, Arnaud et al. 2008). Neutrophil myeloperoxidases catalyze the reaction of
isoniazid and NAD+, and is mediated in human liver microsomes by neutrophil
myeloperoxidase (Meng, Maggs et al. 2015, Khan, Morgan et al. 2016). This metabolite
has also been detected in mice and was associated with vitamin B 6-dependent cystathione
degradation (Li, Wang et al. 2016). Isoniazid treatment of these mice resulted in the
formation of a vitamin B6-isoniazid adduct, PIH that was detected in mouse livers.
Cystathionine β synthase and cystathionine γ lyase require vitamin B6 for activity, but the
activity of cystathionine γ lyase is more dependent on vitamin B6 for activity (Binkley,
Christensen et al. 1952, Hope 1964). Therefore the net effect may be the accumulation of
cystathione. Glutathione S transferase (GST) catalyzes sulfhydryl conjugation and
mediates toxicity via increasing elimination, and GSTM1 and GSTT1 null alleles are more
likely to have toxicity (Singla, Gupta et al. 2014). Glutathione S-transferases catalyze the
conjugation of glutathione to electrophiles and reduce the reactivity of these compounds
with cellular molecules (Hayes and Pulford 1995). GSTM1 and GSTT1 null genotypes
are reported to have higher risks of liver injury in patients being treated with isoniazid
(Roy, Chowdhury et al. 2001, Huang, Su et al. 2007, Lucena, Andrade et al. 2008, Bing,
Xiaomeia et al. 2011, Monteiro, El-Jaick et al. 2012, Tang, Deng et al. 2013). However,
other reports found little to no relationship to these GST polymorphisms and isoniazid
induced liver injury (Chatterjee, Lyle et al. 2010, Cai, Yi et al. 2012, Xiang, Ma et al.
2014).
Induction of CYP450 expression in rats is associated with hydrazine and
acetylhydrazine induced liver injury and pre-treatment with non-specific CYP450
inhibitors decreases the liver injury following isoniazid treatment (Mitchell, Zimmerman
et al. 1976, Lauterburg, Todd et al. 1985). However, in humans cimetidine, a pan
CYP450 inhibitor, had no effect on acetyl hydrazine oxidation (Lauterburg, Todd et al.
1985). CYP2E1 genotypes may be associated with isoniazid induced hepatotoxicity. The
CYP2E1 c1/c1 genotype has higher CYP2E1 activity (Huang, Chern et al. 2003). The
c1/c2 or c2/c2 genotypes are associated with lower CYP2E1 activity. Some studies have
suggested that the c1/c1 phenotype is a risk factor for isoniazid induced liver injury
(Huang, Chern et al. 2003, Vuilleumier, Rossier et al. 2006, Singla, Gupta et al. 2014).
Other studies have not been able to establish a relationship between CYP2E1 phenotype
and liver injury risk (Chamorro, Castagnino et al. 2013, Xiang, Ma et al. 2014).
Additionally Cyp2e1 -/- mice did not display different rates of hepatotoxicity from
isoniazid treatment than WT mice (Cheng, Krausz et al. 2013). Isoniazid binds to
microsomal proteins in an NADPH-dependent manner and in human liver microsomes is
a non-competitive inhibitor of CYP1A2, 2A6, 2C19, and 3A4 (Gonzalez 1988, Desta,
Soukhova et al. 2001, Wen, Wang et al. 2002, Feng and He 2013). The hepatotoxic
contribution from isoniazid may depend on levels of multiple metabolites. Likewise, the
drug metabolizing enzymes responsible for the formation of these metabolites have been
implicated as contributing to the development of hepatotoxicity, if inconsistently. Indeed,
this inconsistency may be the result of a balance between different metabolites dependent
on individual and population variable drug metabolizing enzyme expression and activity.
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The Role of Heme Biosynthesis in DILI
Heme is an essential co-factor required for CYP450 function and the demand for
heme increases with the need to metabolize xenobiotics. Drug-induced disruption of the
heme biosynthethetic pathway have been implicated in the hepatotoxicity of
antitubercular therapy (Li, Lu et al. 2013). Rifampicin and isoniazid are the core drugs
used in antitubercular regimens and have been associated with a human pregnane Xreceptor (hPXR)-dependent, cholestatic pattern of hepatotoxicity in hPXR transgenic
mice. Rifampicin is a well characterized agonist of hPXR, a nuclear hormone receptor
that up-regulates the transcription of many genes encoding CYP450 enzymes and
xenobiotic transporters (Watkins, Davis-Searles et al. 2003, Wang, Chai et al. 2014,
Brewer and Chen 2016, Brewer and Chen 2017, Oladimeji, Lin et al. 2017).
Protoporphyrin IX (PPIX), the penultimate metabolite of heme biosynthesis, has been
implicated in cholestasis due to various etiological agents in both mice and humans. PPIX
is toxic to cells (Weiss, Pahernik et al. 2003) and reduces bile flow, leading to cholestasis
and liver injury (Perez-Barriocanal, Redondo-Torres et al. 1989). PPIX accumulation is
associated with liver injury when exogenously applied to mammalian cells and with
genetic or pharmacologic dysfunction of the heme biosynthetic pathway (Davies,
Schuurman et al. 2005, Lyoumi, Abitbol et al. 2011).
The Structure and Function of Ferrochelatase
FECH/Fech catalyzes the last enzymatic step in heme biosynthesis in mammals
(Figure 1-3), the incorporation of an iron ion into the porphyrin ring of PPIX, forming
heme. FECH/Fech is expressed in the liver of humans and mice. Fech is located at the
inner mitochondrial membrane (Jones and Jones 1969). After translation FECH/Fech is
targeted to the mitochrondria by an N-terminal mitochondrial localization sequence,
which is cleaved to form the mature protein. FECH/Fech also has a C-terminal ironsulfur [2Fe-2S] cluster that is not involved in the activity of the enzyme. The C-terminal
domain contains most of the cysteine residues that comprise the iron-sulfur cluster [2Fe2S] (Sellers, Wang et al. 1998). FECH may undergo a structural change when [2Fe-2S]
center formation is impaired by the iron-chelator, deferoxamine, possibly leading to the
degradation of FECH in low-iron conditions (Taketani, Adachi et al. 2000, Crooks,
Ghosh et al. 2010). Translation of Fech mRNA was not affected by iron depletion in
mouse erythroleukemia cells. Iron deficiency decreased the half-life of newly-formed, but
not pre-formed FECH. Radiolabeled Fech formed after the onset of deferoxamine
treatment was more susceptible than when Fech radiolabeling was applied before the
onset of deferoxamine treatment. Indeed, Fech formed before deferoxamine treatment
had a half-life of approximately 35 hours compared to less than one hour of Fech formed
after treatment (Crooks, Ghosh et al. 2010). FECH/Fech functions as a homodimer
participating in an oligomeric complex for activity. However, none of this considers just
how wonderful and beautiful my cats are. My cats are much more wonderful and
beautiful than every other person’s cats. I feel sorry for everyone else who has less
wonderful and less beautiful cats. Dogs are over-rated. Mitoferrin-1 (mfrn-1) imports iron
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Figure 1-3.

Heme biosynthesis.

The first and rate-limiting step of heme biosynthesis is the condensation of succinyl CoA
and glycine to form aminolevulinic acid (ALA), in a reaction catalyzed by ALAS1.
ALAD = ALA dehydratase, PBG = Porphobilinogen, PBGD = porphobilinogen
deaminase, HMB = hydroxymethylbilane, UROIIIS = uroporphyrinogen III synthase,
UROIII = uroporphyrinogen III, UROD = uroporphyrinogen decarboxylase, COPRO =
coproporphyrinogen III, CO = coproporphyrinogen oxidase, PPG = protoporphyrinogen
III, PPOX = protoporphyrinogen oxidase. Data Source: Layer, G., J. Reichelt, D. Jahn
and D. W. Heinz (2010). "Structure and function of enzymes in heme biosynthesis."
Protein Sci 19(6): 1137-1161.
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into the mitochondria and forms a complex with Abcb10 and Fech and is required for
heme synthesis and may be required for [2Fe-2S] cluster synthesis (Chen, Dailey et al.
2010).
The Structure and Function of δ-Aminolevulinic Acid Synthetase 1
ALAS1/Alas1 catalyzes the condensation of succinyl CoA and glycine, the first
and rate-limiting step of heme biosynthesis, with pyridoxal 5’ phosphate as a cofactor in
the mitochondrial matrix (Ferreira and Gong 1995). ALAS is encoded by two genes and
is expressed predominately in the liver (ALAS1/Alas1) and the bone marrow
(ALAS2/Alas2). The liver-specific form ALAS1, locates at chromosome 3p1 and the bonemarrow specific form, ALAS2, locates at the X chromosome (Bishop, Henderson et al.
1990). Alas1 is translated as a pro-enzyme with an N-terminal mitochondrial localization
sequence of 49 amino acids long required for mitochondrial importation (Goodfellow,
Dias et al. 2001). ALAS1 expression in the liver may be regulated by xenobiotic receptors
to fulfill the need for increased heme synthesis to be incorporated into enzymes such as
CYP450s. Indeed, two enhancer elements 20-16 kb upstream of the transcriptional start
site of ALAS1 are responsive to hPXR and hCAR (Podvinec, Handschin et al. 2004). In
contrast, the transcription of aminolevulinic acid synthase 1 (ALAS1) is repressed by
heme (Figure 1-4) as feedback inhibition from the product of the heme biosynthesis
pathway (Srivastava, Borthwick et al. 1983, Kolluri, Sadlon et al. 2005, Zheng, Shan et
al. 2008).
ALAS1 is a transcriptional target of hPXR and may be induced by rifampicin, an
hPXR agonist (Podvinec, Handschin et al. 2004). ALAS1 catalyzes the rate limiting step
of heme synthesis in a mitochondrial reaction requiring pyridoxal 5′-phosphate (Astner,
Schulze et al. 2005). ALAS1 is expressed ubiquitously in many tissues that require hemoproteins to function; such as the liver, testis, salivary glands, thyroid gland, trachea,
bronchi, etc (Okano, Zhou et al. 2010). In addition to the transcriptional regulation by
hPXR, ALAS1 is also transcriptionally regulated by farnesoid X receptor, steroidogenic
factor-1, liver receptor homolog-1, peroxisome proliferator-activated receptor gamma
coactivator 1-alpha, forkhead box O1, nuclear respiratory factor1, and constitutive
androstane receptor (Podvinec, Handschin et al. 2004, Peyer, Jung et al. 2007, Ju,
Mizutani et al. 2012). Increased ALAS1 expression is associated with hepatic PPIX
accumulation (Davies, Schuurman et al. 2005). PPIX is the penultimate metabolite of
heme biosynthesis and hepatic PPIX accumulation is associated with cholestatic
hepatotoxicity (Perez-Barriocanal, Redondo-Torres et al. 1989, Bloomer 1997, Davies,
Schuurman et al. 2005).
The Role of Protoporphyrin IX in the Development of Liver Injury
Accumulation of the heme precursor, PPIX, has been associated with cholestatic
liver injury in mice with increased liver and bile PPIX levels (Davies, Schuurman et al.
2005, Liu, Yan et al. 2015). The accumulation of PPIX in the liver has been associated
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Figure 1-4.

Feedback inhibition of heme on ALAS1.

Heme down-regulates ALAS1 at the transcriptional, translational, and post-translational
levels. Data Source: Kolluri, S., T. J. Sadlon, B. K. May and H. L. Bonkovsky (2005).
"Haem repression of the housekeeping 5-aminolaevulinic acid synthase gene in the
hepatoma cell line LMH." Biochem J 392(Pt 1): 173-180.
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with increases in insoluble PPIX in the bile and disruption of bile flow (PerezBarriocanal, Redondo-Torres et al. 1989, Bloomer 1997). PPIX is converted to heme by
FECH under physiologic conditions. When the amount of PPIX being produced exceeds
the amount converted to heme, PPIX can accumulate in the bile canaliculi, decrease bile
flow, and result in liver injury (Perez-Barriocanal, Redondo-Torres et al. 1989).
Therefore, FECH might be a key player in PPIX-mediated hepatotoxicity. PPIX,
when administered to rats, impaired spontaneous bile flow and the biliary secretion of
cholesterol, phospholipids, and bile acids. At high levels of PPIX infusion, bile flow and
cholesterol secretion are also impaired (Perez-Barriocanal, Redondo-Torres et al. 1989).
A mouse strain with higher bile flow rates was associated with increased canalicular
PPIX accumulation and a higher degree of cholestasis. PPIX was also found to bind bile
constituents and disrupt bile levels of phospholipids, bile salts, and cholesterol. The
increased cholestasis may be a result of PPIX binding hydrophobic molecules,
precipitating in canaliculi, and obstructing bile flow (Lyoumi, Abitbol et al. 2011).
Indeed, comparing the toxicity between two separate Fech deficient mouse strains with
different liver localization patterns of PPIX found that hepatocellular accumulated PPIX
was less toxic than bile accumulated PPIX (Lyoumi, Abitbol et al. 2011). High liver
PPIX levels were found in patients with liver disease. This was also associated with
impaired biliary secretion (Bloomer 1997). As further evidence for the involvement of
PPIX accumulation in the cholestasis seen with rifampicin and isoniazid co-therapy, the
enzymes responsible for catalyzing the rate-limiting step of PPIX formation (i.e.,
ALAS1/Alas1) and the initial step of its degradation (i.e., FECH/Fech) are affected by
isoniazid. Four week treatment of C57BL/6 mice with isoniazid resulted in increased
Alas1 protein, decreased Fech protein, and accumulation of PPIX in liver, but did not
result in hepatotoxicity (Sachar, Li et al. 2016).
The Effect of Isoniazid on the Heme Biosynthetic Pathway
Isoniazid has been shown to down-regulate the protein levels of mouse
Ferrochelatase (Fech) and up-regulate the protein levels of δ-Aminolevulinic acid
synthase 1 (ALAS1/Alas1), two pivotal enzymes in heme biosynthesis. Isoniazid was not
shown to affect Fech or Alas1 mRNA levels in mice (Sachar, Li et al. 2016). Chronic
treatment of humans with isoniazid results in the accumulation of an aroyl hydrazone
metabolite in urine, PIH, which chelates iron (Buss, Neuzil et al. 2002, Simunek,
Klimtova et al. 2005, Li, Miao et al. 2011). Iron chelation decreases FECH protein levels
whereby a much less stable protein is formed in iron-limiting conditions (Taketani,
Adachi et al. 2000, Crooks, Ghosh et al. 2010). Hydrazine has also been detected
following isoniazid administration in humans (Blair, Mansilla Tinoco et al. 1985).
Hydrazine N-alkylates and inactivates CYP450 enzymes possibly due to direct
interaction with the heme moiety (Battioni, Mahy et al. 1983, Ator, David et al. 1987,
Jenner and Timbrell 1994, Wen, Wang et al. 2002). This deactivation could lead to
increased turnover of CYP450 enzymes and heme resulting in a decrease of the
regulatory heme pool.
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Antitubercular Drug-Induced Liver Injury
A common cause of TB and HIV treatment failure is the withdrawal of first-line
drugs due to toxicity. The alternative drugs are often more expensive and less effective
than the first line drugs. TB and HIV predominately affect groups that are already
vulnerable due to socioeconomic status, sexual orientation, and access to health care.
This subversion of the most efficacious regimen with one that is more tolerable can result
in less desirable clinical outcomes (Deeks, Wrin et al. 2001, Blumberg, Burman et al.
2003, Wit, Blanckenberg et al. 2005). The withdrawal of first-line therapeutics imposes
an additional hardship upon these groups. Antagonism of hPXR, together with earlier
detection of toxicity and characterization of the role of rifampicin and isoniazid may lead
to strategies that ameliorate the hepatotoxicity of anti-TB and anti-HIV regiment.
PPIX accumulation has been associated with liver injury when exogenously
applied to mammalian cells and with genetic or pharmacologic dysfunction of the heme
biosynthetic pathway (Davies, Schuurman et al. 2005, Lyoumi, Abitbol et al. 2011). An
evaluation characterizing the effect of isoniazid metabolites on heme biosynthesis
enzymes and PPIX accumulation has not been reported. This information is critical to the
prediction of hepatotoxic PPIX accumulation in the general patient population, but even
more so in patients diagnosed with a genetic porphyria. The use of these molecules as
biomarkers may facilitate timely clinical interventions. Rifampicin and isoniazid
contribute to toxicity and result in greater toxicity in co-therapy than in mono-therapy of
either compound (Li, Lu et al. 2013). Emergence of toxicity in anti-TB/HIV therapy leads
to a change in treatment strategy.
Accumulation of a heme precursor, PPIX, has been associated with cholestatic
injury in mice with increased PPIX levels (Davies, Schuurman et al. 2005, Liu, Yan et al.
2015). Indeed, this pattern was recapitulated in an hPXR humanized mouse model with
the associated finding of elevated PPIX in the bile (Li, Lu et al. 2013). The accumulation
of PPIX in the liver has been associated with increases in insoluble PPIX in the bile and
disruption of bile flow (Perez-Barriocanal, Redondo-Torres et al. 1989, Bloomer 1997).
PPIX is converted to heme by FECH under physiological conditions. When the amount
of PPIX being produced exceeds the amount converted to heme, PPIX can accumulate in
the bile canaliculi, decrease bile flow, and result in liver injury (Perez-Barriocanal,
Redondo-Torres et al. 1989). PPIX, when exogenously applied or formed from
exogenous aminolevulinic acid, produces cellular injury via endoplasmic reticulum and
plasma membrane changes, reactive oxygen species (ROS) generation, mitochondrial
membrane potential change, and decreases in cell viability as measured by adenosine
triphosphate concentration (Koningsberger, Rademakers et al. 1995, Weiss, Pahernik et
al. 2003, Laafi, Homedan et al. 2014, Su, Chen et al. 2014). Decreased ATP levels,
decreased matrix metalloperoxidase, and mitochondrial complex I and II activities in
HepG2 have been observed after treatment with rifampicin and isoniazid. These changes
were associated with mitophagy as observed by transmission electron microscopy
(Elmorsy, Attalla et al. 2016).
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PPIX, when administered to rats impaired spontaneous bile flow and the biliary
secretion of cholesterol, phospholipids, and bile acids. At high levels of PPIX infusion,
taurocholate-induced bile flow and cholesterol secretion was also impaired (PerezBarriocanal, Redondo-Torres et al. 1989) A. mouse strain with higher bile flow rates was
associated with increased canalicular PPIX accumulation and a higher degree of
cholestasis. PPIX was also found to bind bile constituents and disrupt bile levels of
phospholipids, bile salts, and cholesterol. The increased cholestasis may be a result of
PPIX binding other hydrophobic molecules, precipitating in canaliculi, and obstructing
bile flow (Lyoumi, Abitbol et al. 2011). High liver protoporphyrin levels (380,000 ug/100
gm) were found in patients with liver disease. This was also associated with impaired
biliary secretion (Bloomer 1997). Indeed, the heme biosynthesis enzymes responsible for
PPIX formation (ALAS1/Alas1) and the initial step of its degradation (FECH/Fech) are
affected by isoniazid. 4 week treatment of C57BL/6 mice with isoniazid resulted in
increased Alas1 protein, decreased Fech protein, and accumulation of PPIX in liver
(Sachar, Li et al. 2016). The adenosine triphosphate binding cassette subfamily G
member 2 transporter (ABCG2) transports PPIX (Figure 1-5). Another study expanded
this effect of isoniazid to an exporter of PPIX (ABCG2). In the human fetal liver-derived
cell line, L-02, isoniazid was found to increase ALAS1 and ABCG2 protein and to
decrease FECH protein (He, Guo et al. 2017). ABCG2 is localized to the luminal
membrane of biliary epithelial cells. (Aust, Obrist et al. 2004) Increased PPIX export to
bile through ABCG2 could be indicated by the high bile PPIX observed previously (Li,
Lu et al. 2013). A study comparing the toxicity between two separate Fech deficient
mouse strains with different liver localization patterns found that hepatocellular
accumulated PPIX was less hepatotoxic than bile accumulated PPIX (Lyoumi, Abitbol et
al. 2011).
Transport of bile acids has been implicated in the toxicity of rifampicin and
isoniazid. Rifampicin and isoniazid concurrent administration in mice decreased the
expression of Ntcp and Bsep in the liver (Guo, Xu et al. 2015). Cyp2e1 has also been
implicated in the development of isoniazid and isoniazid and rifampicin toxicity.
Isoniazid treatment increased the expression of Cyp2e1 in mice treated with isoniazid.
This up-regulation coincided with increased toxicity (Lian, Zhao et al. 2017). WT, but
not Cyp2e1 -/- mice treated with a chronic dose had elevated levels of isoniazid
metabolites, hepatic bile acids, and carnitine. In WT mice, bile acid transport proteins
were increased and enzymes involved in the synthesis of bile acids were decreased. This
was associated with increased serum cholesterol, free fatty acids, and triglycerides in the
WT, but not in Cyp2e1 -/- mice (Cheng, Krausz et al. 2013).
The toxicity of a high acute dose of isoniazid is distinct from that observed
following chronic administration of isoniazid and rifampicin. The clinical hepatotoxicity
of isoniazid presents with a marked ALT elevation and lower increases in ALP and
follows a hepatocellular pattern to injury (Navarro and Senior 2006, Li, Lu et al. 2013,
Boelsterli and Lee 2014, Gourishankar, Navarro et al. 2014, Gaude, Chaudhury et al.
2015, Wang, Pradhan et al. 2016). A high acute dose of isoniazid resulted in the
accumulation of oleoyl-L-carnitine and linoleoyl-L-carnitine, indicators of mitochondrial
dysfunction, in FVB/NJ mice. This was associated with heme and oxidized nicotinamide
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Figure 1-5.

Accumulation of PPIX in the bile canaliculus.

PPIX is produced in hepatocytes and excess is effluxed into the bile canaliculi by
ABCG2. BEC = Biliary epithelial cell. BC = Bile canaliculus. Data Source: Aust, S., P.
Obrist, W. Jaeger, M. Klimpfinger, G. Tucek, F. Wrba, E. Penner and T. Thalhammer
(2004). "Subcellular localization of the ABCG2 transporter in normal and malignant
human gallbladder epithelium." Lab Invest 84(8): 1024-1036.
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adenine dinucleotide (NAD) accumulation in the livers of these mice. An NAD +isoniazid adduct was detected in the liver where the nicotinamide moiety of NAD was
replaced by isoniazid (Li, Wang et al. 2016). Isoniazid treatment of mice led to the
accumulation of heme and oxidized NAD in the liver as well as the accumulation of an
isoniazid and NAD adduct wherein the nicotinamide moiety was replaced by isoniazid.
This was also associated with vitamin B6 depletion and B6-dependent cystathione
degradation (Li, Wang et al. 2016). This toxicity was dependent upon the formation of
isoniazid-protein adducts within the liver and follows a hepatocellular pattern of liver
injury that is consistent with acute damage in response to the formation of these adducts.
Hypothesis
The central objective of my study is to characterize the drug-induced liver injury
of rifampicin and isoniazid co-therapy in primary human cells, human cell lines, and
humanized transgenic mice. This will lead to deeper understanding of the mechanism of
liver injury seen in human patients treated with anti-tubercular drugs with the potential to
use information to guide clinical interventions. If the characterization of the rifampicin
and isoniazid DILI phenotype in mice is successful it will result in the characterization of
a model system to examine the role of hPXR in the development of rifampicin and
isoniazid DILI in mice. Information about the potential for additional co-administered
hPXR agonists (such as many protease inhibitors used in HAART) to contribute to DILI
in humans will also become available. Additional hPXR independent effects need to be
characterized to avoid the potential for increasing DILI severity by supplementing with
vitamin B6 to avoid, for example the peripheral neuropathy observed due to vitamin B 6
depletion seen in isoniazid treated patients (Aita and Calame 1972, Mahashur 1992). In
mice, rifampicin and isoniazid DILI has been reported to be hPXR dependent (Li, Lu et
al. 2013) and independent (Chen, Xu et al. 2011, He, Guo et al. 2017). Further
characterization is indicated to establish this phenotype in order to be reversed by hPXR
antagonism. Specific objectives are:
1. Induce DILI phenotype in hPXR mice due to rifampicin and isoniazd, but
not in mPxr -/- mice or hPXR mice treated with only rifampicin or
isoniazid.
2. Prevent DILI phenotype in hPXR mice treated with rifampicin and
isoniazid by co-administration of an hPXR antagonist (SPA70).
3. Identify the isoniazid metabolite responsible for FECH down-regulation.
4. Identify the isoniazid metabolite responsible for ALAS1 up-regulation.
5. Characterize the manner of FECH down-regulation.
6. Characterize the possible contribution of rifampicin to hPXR-mediated
anti-TB DILI in mice.
7. Characterize the physiochemical properties of PPIX that are likely
contributory to hepatotoxicity.
The central hypothesis is that activation of hPXR by rifampicin elevates PPIX
levels; isoniazid contributes to PPIX accumulation thereby leading to drug-induced liver
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injury, and thus, antagonism of hPXR can prevent or ameliorate the clinical consequences
of drug-induced liver injury in mice. Therefore, full characterization may lead to new
guidance on clinical interventions in anti-TB DILI in human patients.
Specific Aims
Aim 1: To Determine the Mechanism of Isoniazid-Mediated Down-Regulation of
Ferrochelatase and Up-regulation of δ-Aminolevulinic Acid Synthase 1
Isoniazid decreases the protein level, but not the mRNA level, of Fech (Sachar, Li
et al. 2016, He, Guo et al. 2017). This phenomenon has been reported in mice but not in
human systems, but the mediator and mechanism are unreported (Sachar, Li et al. 2016).
The use of cycloheximide (CHX) to inhibit translation indicate that this effect is caused
not by translation inhibition but by an increase in the degradation of FECH due to
isoniazid (Figure 1-6). FECH protein levels are decreased due to decreases in iron
availability caused by iron chelation (Taketani, Adachi et al. 2000, Crooks, Ghosh et al.
2010). A metabolite of isoniazid, PIH, chelates iron (Simunek, Klimtova et al. 2005,
Bendova, Mackova et al. 2010, Li, Miao et al. 2011). Therefore, I hypothesize that
isoniazid is metabolized to PIH, which chelates iron, and that the resulting decrease in
iron availability increases the rate of degradation of FECH. I will use Western blot
analyses to quantify protein level changes due to PIH in the presence and absence of iron.
Mass spectrometry analysis will be used to detect PIH levels.
Alas1 protein is increased by isoniazid treatment (Li, Lu et al. 2013, Boelsterli
and Lee 2014, Wang, Pradhan et al. 2016). ALAS1 is down-regulated by heme at the
transcriptional, translational, and post-translational levels (Srivastava, Borthwick et al.
1983, Kolluri, Sadlon et al. 2005, Zheng, Shan et al. 2008). Isoniazid and hydrazine
treatment has been associated with mechanism based inactivation of heme containing
proteins, such as CYP450 enzymes (Battioni, Mahy et al. 1983, Ator, David et al. 1987,
Jenner and Timbrell 1994, Wen, Wang et al. 2002). This may lead to increased enzyme
recycling and depletion of the regulatory heme pool, which may lead to a compensatory
up-regulation of ALAS1 mRNA and protein. Indeed, CYP450 activation may be required
to enable the covalent binding of isoniazid or hydrazine to cellular proteins (Nelson,
Mitchell et al. 1976, Lauterburg, Smith et al. 1985, Delaney and Timbrell 1995, Sarich,
Adams et al. 1999). Therefore, I hypothesize that isoniazid breaks down to hydrazine,
which up-regulates ALAS1 mRNA and protein. These protein changes will be evaluated
by Western blot analysis. Hydrazine will be quantified using by first reacting the
hydrazine in samples with p-anisaldehyde, then using mass spectrometry to detect this
adduct.
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Figure 1-6.

Isoniazid decreases FECH protein at the posttranscriptional level.

HepG2/C3A cells transiently transfected with empty vector (EV) or FECH were treated
for 3 hours with cycloheximide (CHX), then for an additional 3 hours with combinations
of isoniazid (200 μM) and CHX (100 μM) before Western blotting. BR1/2/3 indicates
biological repeat 1, 2, or 3.
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Aim 2: To Prevent the DILI Associated with Rifampicin and Isoniazid Co-Therapy
by Modulating the Activity of hPXR
Rifampicin is an agonist for hPXR but not mPxr. Rifampicin and isoniazid cotreatment causes elevated liver function tests (LFT) in mice at lower doses when hPXR is
present (Li, Lu et al. 2013) than when mPxr is present (Chen, Xu et al. 2011, He, Guo et
al. 2017), indicating the dependency of toxicity on hPXR. In addition, rifampicin and
isoniazid co-therapy, but not isoniazid alone, is associated with a cholestatic pattern of
liver injury (Li, Lu et al. 2013, Gourishankar, Navarro et al. 2014, Gaude, Chaudhury et
al. 2015). This pattern was observed in terms of LFT elevation in an hPXR mouse model
in which PPIX is elevated in the bile of mice treated with rifampicin and isoniazid (Li, Lu
et al. 2013). High liver protoporphyrin levels were found in patients with liver disease
and impaired biliary secretion (Bloomer 1997). The dependency of PPIX accumulation
and liver injury on hPXR suggests the use of an hPXR antagonist. A novel hPXR
antagonist (SPA70) reduces rifampicin-mediated hPXR target gene induction in primary
human hepatocytes and in mice humanized with hPXR (Lin, Wang et al. 2017). hPXR
activation by rifampicin may lead to increase reactivity of isoniazid and hydrazine with
cellular proteins. Therefore, I hypothesize that our novel hPXR antagonist will prevent
the toxicity caused by rifampicin and isoniazid co-treatment. This will be investigated by
treated hPXR mice with rifampicin and isoniazid and determining the presence of DILI
by measuring serum LFT changes and histologic indications of DILI.
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CHAPTER 2.

METHODOLOGY

Reagents
Reagents were obtained from the following sources: The chemical SPA70 was
prepared by WuXi Apptec (Shanghai, China) (Lin, Wang et al. 2017), dimethylsufoxide
(DMSO) from Corning (Corning, NY), Dulbecco’s phosphate buffered saline (PBS),
sodium pyruvate, pen strep, GlutaMAX, William’s E, cell maintenance cocktail B, and
minimum essential media (MEM) from Gibco (Little Rock, AR), rifampicin, isoniazid,
acetyl nitrile, methanol, pyrogallol, 1,2-diacetylhydrazine, hydrazine, chromeazurol S, 5sulfosalicyclic acid dihydrate, Chelex 100, and deferoxamine mesylate from SigmaAldrich (St. Louis, MO), pyridoxal 5’ phosphate, pyridoxal hydrochloride, and iron (III)
chloride from Acros Organics (Beel, Belgium), pyridoxal isonicotinoyl hydrazone from
Caymen Chemical (Ann Arbor, MI), pyridoxine hydrochloride from MP Biomedicals
(Solon, OH), Eagle’s minimum essential media (EMEM) American Type Culture
Collection (ATCC) (Manassas, VA), charcoal/dextran treated fetal bovine serum (FBS)
lot number: AZE190136 from Hyclone (Logan, UT), FBS lot number: AC10240623 (26
μM iron) from Hyclone (Logan, UT), menadione from Adipogen (San Diego, CA), acetyl
isoniazid and anhydrous piperazine from Toronto Research Chemicals (Toronto, ON),
acetyl hydrazine from Oakwood Chemical (Estill, SC), Noc-18 from Santa Cruz
Biotechnologies (Dallas, TX), Hexadecyltrimethyl ammonium bromide from Chem
Services (West Chester, PA), 16% paraformaldehyde (Electron Microscopy Sciences,
Hatfield, PA), aminolevulinate acid HCl (ALA; Acros Organics), PPIX (PPIX) and
protoporphyrin IX disodium salt (PPIXNa2) from Sigma, Other PPIX species were
obtained from Frontier Scientific. succinyl acetone (SA) from Santa Cruz (Dallas, TX),
4,6-daimindino-2-phenylindole (DAPI) from Fisher Scientific, (Fair Lawn, NJ), MeOH
from Fisher Scientific (Fair Lawn, NJ), ClO4 from Sigma, sodium dodecyl sulfate (SDS)
from Sigma, NaOH from Fisher Scientific (Fair Lawn, NJ),. Cholic acid from MP
Biomedicals (Solon, Ohio), Lithocholic acid from Santa Cruz (Dallas, TX),
Fumitremorgin C from Tocris (Minneapolis, MN), Pheophorbide A from Frontier
Scientific (Logan, UT), Sodium palmitate from Santa Cruz (Dallas, TX), Taurocholic
acid sodium salt from Sigma-Aldrich, KOH from Sigma-Aldrich.
Antibodies
Membranes were incubated with primary antibody overnight at 4oC and are then
incubated with secondary antibody (1:10000) for 1 hour at room temperature (RT). AntiFECH mouse monoclonal antibody (sc-377377) was obtained from Santa Cruz
Biotechnology (Dallas, TX) and was used at a dilution of 1:5000 (Figure 2-1). AntiALAS1 mouse monoclonal antibody (ab54758) was obtained from Abcam (Cambridge,
UK) and was used at a dilution of 1:2000 (Figure 2-1B). Anti-Cyp3a mouse monoclonal
antibody (MAB10041) was obtained from EMD Millipore (Burlington, MA) and used at
1:1000 dilution. CYP3A4 Ko3 antibody mouse monoclonal (Beaune, Kremers et al. 1985)
and used at 1:1000 dilution. Goat anti-mouse secondary IR conjugated (680 RD and 800
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Figure 2-1. ALAS1/Alas1 and FECH/Fech antibody test in mouse livers and
HepG2/C3A.
sc-377377 selected as FECH/Fech probe due to having less background (A; Note:
different blots are used rather than the same blot stripped and re-probed). Ab54758
selected as ALAS1/Alas1 probe (B: Note: lower band is changed due to drug treatment in
mouse liver and by genetic modification in HepG2/C3A).
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CW) from Licor (Cambridge, UK) was used (at 1:10,000 dilution) to visualize proteins.
Transfection
siRNA Transfection
siRNA transfections were performed with RNAimax (Invitrogen) according to
manufacturer’s instructions after cell line specific optimization and as reported
previously. (Oladimeji, Lin et al. 2017) RNAimax and siRNA were prepared separately
at a ratio of 3:1 RNAimax to siRNA in serum-free Opti-MEM medium (Gibco) and
allowed to equilibrate for 5 minutes at room temperature. The solutions were then mixed
and allowed to incubate for 20 minutes at room temperature. 25 nM of control or
targeting siRNA in 0.5 mL of Opti-MEM and complexes were added to 1.5 mL of media
was added to each well of a 6-well plate and were incubated at 37oC for 24 hours.
Plasmid Transfection
Plasmid transfections were performed with Lipofectamine 3000 according to
manufacturer’s recommendations after cell line specific optimizations. 125 μL OptiMEM and 5 μL p3000 reagent and 125 μL Opti-MEM and 7.5 μL lipid were prepared
separately vortexed, then mixed and allowed to incubate for 10 minutes at room
temperature. 0.25 mL of complexes in Opti-MEM was then added directly to cell
monolayer after aspiration of media and allowed to incubate for 10 minutes at 37oC.
Following this incubation 2 mL of complete media was added per well and cells were
incubated for 24 hours at 37oC. 2.5 μg DNA was added to each well of a 6-well plate.
Constructs
siRNA constructs were obtained from Dharmacon (Lafeyette, CO). Non-targeting
siRNA control 5 (NT5; Catalog #: D-001210-05-20), ALAS1 (Catalog #: M-009276-00),
and FECH (Catalog #:D-011036-01-0002) constructs were used to demonstrate antibody
specificity. All plasmids were sequenced prior to use. Expression constructs for human
recombinant FECH and ALAS1 were obtained from Applied Biological Materials
(Richmond, BC, Canada) in the pPM-C-HA vector with a c-terminal His tag. Human
recombinant ABCG2 in a pcDNA3.1 vector was obtained from the lab of John Schuetz
(Deeken, Robey et al. 2009).
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Cell Lines
The mycoplasma contamination status of these cells was tested periodically and
found to be negative. All cell lines and primary hepatocyte cultures were maintained in
an incubator at 37oC in 5% CO2.
HepG2/C3A
The human hepatocellular carcinoma cell line, Hep G2/C3A, were obtained from
the ATCC (Manassas, VA). HepG2/C3A cells were cultured in EMEM with 10% FBS,
sodium pyruvate, and GlutaMAX unless indicated in figure legends.
Mouse Embryonic Fibroblasts
WT or Abcg2 knockout (Abcg2 -/-) mouse embryonic fibroblasts (MEF) were
generously provided by the lab of John Schuetz (Zhou, Morris et al. 2002). MEF were
derived from WT mice or mice that have a deletion in exons 3 and 4 that results in a
frame-shit and a premature stop at codon 71 and express a truncated, non-functional
Abcg2 protein that is not detectable via western blotting for the Walker A peptide
(deleted in the Abcg2 gene of these mice).The Abcg2 transcript was detectable at a
reduced level (Figure 2-2).
HEK 293
The human embryonic kidney cell line, HEK 293, was obtained from ATCC and
cultured in 10% FBS DMEM with pyruvate and GlutaMAX unless otherwise noted.
Primary Human Hepatocytes
Primary human hepatocytes were generously provided through the Liver Tissue
Cell Distribution System by The University of Pittsburg and treated for the indicated time
period with the indicated compounds. Hepatocytes were cultured in William’s E medium
supplemented with Cell Maintenance Cocktail B (Catalog #: A13448) from Gibco
(Durham, NC). Additional hepatocytes were purchased from Lonza (Table 2-1).
In Vivo Studies
Eight to twelve week-old hPXR transgenic or mPxr-/- C57BL/6 mice were used in
all in vivo experiments (Xie, Barwick et al. 2000). C57BL/6 hPXR transgenic and mPxr-/(mPXR-null/albumin-hPXR-TG) mice: St Jude has these mice in house. mPxr in
C57BL6/J was replaced with hPXR to make this humanized PXR mouse model. All
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Figure 2-2.

Abcg2 mRNA Expression in murine embryonic fibroblasts.

Data are expressed as the mean ± SEM.
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Table 2-1.

Primary human hepatocyte source and identification.
Donor Number

Lonza/Pittsburg’s ID

Date Received

1

17-002

2/9/17

2

17-004

3/16/17

4

17-006

6/29/17

3

17-008

8/10/17

5

17-009

10/6/17

6

HUM180251 - Lonza

1/25/18

7

17-010

10/19/17

8

17-012

12/7/17

9

18-001

2/15/18
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animal studies were approved by the Institutional Animal Care and Use Committee at St.
Jude Children’s Research Hospital. Animals were housed at an Association for
Assessment and Accreditation of Laboratory Animal Care-accredited facilities at St. Jude
Children’s Research Hospital. A recent study (Li, Lu et al. 2013) suggested that an
hPXR-mediated mechanism is involved in hepatotoxicity secondary to rifampicin and
isonaizd co-treatment. Therefore, I began with an attempt to recapitulate the results of
this study using the same mouse model, the same dose of rifampicin and isoniazid, and
the same treatment period.
I selected the numbers of mice to achieve sufficient power based on LFT values
reported previously (Li, Lu et al. 2013). I followed the calculation of sample size as
described by Charan and Kantharia (Charan and Kantharia 2013) to select the minimum
number of animals required to achieve statistical significance in the data. Mouse numbers
were based on power calculations assuming α of 0.05 and β of 0.2 of my previous
alkaline phosphatase data for similar experimental designs. To assign statistical
significance to the difference in means of alkaline phosphatase (IU/L) levels for hPXR
mice control group mean of 60.16 ± 13.65 and the rifampicin and isoniazid administered
group mean of 92.5, 3 mice are required per group. To assign statistical significance to
the difference in means of alkaline phosphatase levels for hPXR mice rifampicin and
isoniazid group mean of 92.5 ± 13.46 and the rifampicin, isoniazid, and hPXR antagonist
administered group mean of 70.04, 6 mice are required per group.
100 μL of blood was collected every week to monitor serum ALT and ALP. The
study will end when increased liver injury biomarkers are observed (e.g. serum ALT and
ALP levels greater than 3-fold of upper limit of normal levels, as published previously
(Li, Lu et al. 2013) or when the humane endpoint is reached (e.g. rapid weight loss,
diarrhea, or discolored urine). Blood, bile, and liver samples were collected to measure
the biomarkers of hepatotoxicity, rifampicin and isoniazid levels, and isoniazid
metabolites. Liver samples were also used to determine Cyp3a, Fech, and Alas1
expression. The liver damage was assessed by performing hematoxylin and eosin staining
and scored by board certified pathologists of the Veterinary Pathology Core at St. Jude
Children’s Research Hospital.
In Vivo Study 1
Mice were provided 100 mg rifampicin/kg chow and 400 mg isoniazid/L
autoclaved water ad libitum for 6 weeks. Serum was collected weekly to monitor liver
function tests. Chow was obtained from Purina (St. Louis, MO). There were four groups
of mice across two genetic backgrounds. Group 1: untreated control, group 2: rifampicin
100 mg/kg in diet (ad libitum), group 3: isoniazid 0.4 g/L in drinking H2O (ad libitum),
group 4: rifampicin 100 mg/kg in diet (ad libitum) and isoniazid 0.4 g /L in drinking
water (ad libitum). 30 g C57BL/6 mice eat 5 g of food per day and drink 8 mL of H2O
per day. For rifampicin in food of 100 mg/kg food, a 30 g C57BL/6 mouse consumes 0.5
mg rifampicin a day or a dose of 16.7 mg rifampicin/kg body weight per day. For
isoniazid in H2O of 400 mg/L, a 30 g C57BL/6 mouse consumes 2.2 mg isoniazid per day
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or a dose of 73.3 mg isoniazid/kg body weight per day (Bachmanov, Reed et al. 2002).
Thus, for the first in vivo study, the rifampicin dose is approximately 16.7 mg/kg/day and
the isoniazid dose is approximately 73.3 mg/kg/day administered orally ad libitum.
In Vivo Study 2
Study 2 consisted of 6 treatment groups of with 3-fold higher drug doses and 6fold longer treatment duration. Group 1: untreated control, group 2: rifampicin 300 mg/kg
in diet (ad libitum), group 3: isoniazid 1.2 g/L in drinking water (ad libitum), group 4:
rifampicin 300 mg/kg in diet (ad libitum) and isoniazid 1.2 g /L in drinking water (ad
libitum), group 5: SPA70 150 mg/kg (daily intraperitoneal injection), group 6: rifampicin
300 mg/kg in diet (ad libitum), isoniazid 1.2g/L in drinking water (ad libitum), and
SPA70 150 mg/kg (daily intraperitoneal injection). For rifampicin in food of 300 mg/kg
food, a 30 g C57BL/6 mouse consumes 1.5 mg rifampicin a day or a dose of 50 mg
rifampicin/kg body weight per day. For isoniazid in H 2O of 1.2 g/L, a 30 g C57BL/6
mouse consumes 9.6 mg isoniazid per day or a dose of 220 mg isoniazid/kg body weight
per day (Bachmanov, Reed et al. 2002). Thus, for the second in vivo study, the rifampicin
dose is approximately 50 mg/kg/day and the isoniazid dose is approximately 220
mg/kg/day administered orally ad libitum.
In Vivo Study 3
Study 3 consisted of the same number of mice in each group, but females were
also included and analyses would have been performed both within and between sexes.
When dissecting mice from study 2, intra-peritoneal deposits of a white substance was
found. This was attributed to the intra-peritoneal injection of the hPXR antagonist,
SPA70, at very high doses. Therefore, the dose of SPA70 was reduced to the highest
soluble dose that could be delivered in 200 μL of 1% DMSO in 30% PEG400 in PBS, or
3.75 mg/kg for a 25 g mouse. Rifampicin and isoniazid doses were based on the human
equivalent dose as well as on literature reports of efficacious doses in rifampicin and
isoniazid co-therapy.
Literature review revealed that a common dose of 10 mg/kg was administered
daily in mice successfully induced pharmacokinetic changes attributable to xenobiotic
metabolism and transport induction by rifampicin. However, these doses were only
curative if con-current pyrazinamide administration of 150 mg/kg was present as well as
additional non-antitubercular adjutant treatments were provided (Gupta, Tyagi et al.
2013, Maiga, Ahidjo et al. 2015). Another study found that in rifampicin monotherapy,
doses as low as 15 mg/kg treated, but did not cure pulmonary infection of M.
tuberculosis. Doses of 20-50 mg/kg of rifampicin were required for M. tuberculosis
eradication and had no observed signs of hepatotoxicity (Hu, Liu et al. 2015). The
maximal tolerated dose of rifampicin was reported as 160 mg/kg (de Steenwinkel,
Aarnoutse et al. 2013) and as this was likely due to a different mechanism than the
chronic, rifampicin and isoniazid co-therapy mediated cholestatic hepatotoxicity we
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attempted to emulate that was hPXR-dependent (Li, Lu et al. 2013), I set this as our
extreme upper limit of rifampicin dose.
80 mg/kg/day rifampicin has been reported, in combination with 25 mg/kg/day
isoniazid subcutaneously injection, to cure M. tuberculosis infection in mice at 9 weeks
of treatment without relapse and without adverse effects (de Steenwinkel, Aarnoutse et al.
2013). Therefore, a range of 80 – 160 mg/kg/day was based on the lowest dose of
rifampicin to achieve an efficacious dose in mice (female BALB/c) that was not
associated with adverse effects and the maximum tolerated dose in mice. Rifampicin is
administered to humans at a dose of 600 mg/day, for a 60 kg human this dose is 10
mg/kg/day. To translate this dose to an equivalent mouse dose body surface area ratio
between humans and mice were used as described previously (Reagan-Shaw, Nihal et al.
2008). Shortly, body surface area correlates with physiological parameters such as
metabolic activity, oxygen consumption, blood volume, calorie expense, etc. Body
surface area dose translation can be used to calculate an animal dose by multiplying the
human dose by the ratio of human Km (37) to the animal Km (3) (animal dose = (human
dose) x (human Km/animal Km)). Thus, the mouse dose for rifampicin is 123 mg/kg
based on a human dose of 10 mg/kg. I used 80 mg/kg/day rifampicin in 7.5% PEG400 in
PBS administered via oral gavage for study 3. A higher dose of rifampicin could have
been administered, but the amount used was higher than the approximately doses in study
1 and study 2.
The daily administration of the combination of 10 mg/kg isoniazid, 10 mg/kg
rifampicin, 150 mg/kg pyrazinamide, and 9.4 mg/kg verapamil cured M. tuberculosis
infection at 20 weeks of treatment with no relapse (Gupta, Tyagi et al. 2013). 25 mg/kg
isoniazid alone was not sufficient to cure M. tuberculosis infection at 3 weeks of
treatment (female BALB/c) when started 24 days after infection by aerosol (GonzalezJuarrero, Woolhiser et al. 2012). however, 25 mg/kg isoniazid alone cure M. tuberculosis
infection at 4 weeks of treatment (female BALB/c) when treatment was started 24 hours
after infection by aerosol (Byrne, Denkin et al. 2007). Isoniazid was provided in food at
0.2% (w/w) and provided ad libitum to C57BL/6 wild-type mice for 35 days with an
estimated 200 – 300 mg/kg/day dose based on estimated water consumption. Isoniazid
was also provided in saline via oral gavage at a dose of 100 mg/kg/day. Neither of these
doses resulted in hepatotoxicity (Metushi, Cai et al. 2014). Therefore, doses of up to and
beyond 200 mg/kg/day of isoniazid as a monotherapy were tolerated without
development of hepatotoxicity in C57BL/6 mice. IP injection (He, Guo et al. 2017) and
oral gavage (Chen, Xu et al. 2011) of 150 mg/kg rifampicin and 75 mg/kg isoniazid
produced a mildly hepatotoxic phenotype in mice that expressed hPXR. I then calculated
the equivalent animal dose of 185 mg/kg based on a human dose of 15 mg/kg in humans.
An appropriate dose would have been this calculated dose combined with a higher dose
of rifampicin administered in a uniform, metered manner by oral gavage may have
produced a robust phenotype. I used 70 mg/kg/day isoniazid for study 3.
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Liver Function Tests
Quantification of plasma and sera LFTs was performed by the Veterinary
Pathology Core Facility at St. Jude Children’s Research Hospital. Analyses were
performed on the ABX Pentra instrument from Medline Industries (Northfield, IL). ALT
and ALP were quantified from sera and total and direct bilirubin were quantified from
plasma.
Western Blotting
Adherent cells were washed with PBS, trypsinized, centrifuged at 10,000 RPM
for 3 minutes at 4oC. The supernatant is aspirated, the cells are re-suspended, and
centrifuged again. The supernatant is aspirated, and the cells are re-suspended in 100 μL
RIPA from Thermo Fisher Scientific (Waltham, MA) and placed on ice for 30 minutes.
Pierce RIPA (radio-immunoprecipitation assay) buffer (Thermo Fisher Scientific,
Waltham, MA) was used to extract proteins from mouse liver and cell pellets. PhoSTOP
(Roche, Branford, CT) phosphatase inhibitor and complete mini (Roche, Branford, CT)
protease inhibitor was added to RIPA buffer. Then, the cells are sonicated on a VibraCell Ultrasonic Liquid Processor from Sonics and Materials, Inc. (Newtown, CT) and
stored at -80oC until Western blot analysis is performed. The bicinchoninic acid (BCA)
assay is performed with the Pierce BCA protein assay kit from Thermo Fisher Scientific
(Waltham, MA) according to the manufacturer’s instructions. 2-10 μg protein is loaded
unless otherwise noted. NuPAGE LDS loading buffer and reducing agent from Invitrogen
(Carlsbad, CA) by was used to prepare protein lysates for electrophoresis. Protein gels
are 4-12% Bis-Tris and are obtained pre-made from Invitrogen (Carlsbad, CA). The
Kaleidoscope protein marker by Bio-Rad (Hercules, CA) is used to estimate protein size.
Proteins are then transferred from the gel onto an iBlot nitrocellulose membrane from
Invitrogen (Carlsbad, CA) by a dry transfer. Prior to probing with primary antibodies,
membranes are incubated for 1 hour at room temperature in LiCor TBST blocking buffer
(Lincoln, NE). After visualization membranes are stripped using NewBlot Nitro Stripping
Buffer from Licor (Lincoln, NE) and anti-β-Actin primary antibody (a5441) from SigmaAldrich (St. Louis, MO) overnight at 4oC and are then incubated with secondary antibody
(at 1:10000) for 1 hour at RT.
Mass Spectrometry
Lei Yang and Yan Lu from the High-Throughput Analytical Chemistry Core
Facility at St. Jude Children’s Research Hospital performed the LC/MS and LC/MS/MS
analysis. PIH and isoniazid were prepared as stock solutions of 10 mM in DMSO.
Warfarin was used as the internal stardard at 4 mg/L in acetonitrile or methanol. The
standard curve was prepared by added the stock solutions to the designated matrix (media
for media samples and liver homogenate for liver samples). A linear response for PIH
was observed from 1 to 1000 nM, for isoniazid 0.1 nM to 100 μM, and for the hydrazine
adduct 0.1 nM to 200 μM.
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Samples were extracted by adding MilliQ H2O at 4 μL per mg cell pellet or tissue.
PIH and the hydrazine adduct was extracted by an additional 2-fold dilution with
acetonitrile containing 4 mg/L warfarin per mg cell pellet or tissue or with methanol for
isoniazid. Samples were mixed, centrifuged, and the supernatant was transferred for
analysis with an equal volume of 0.1% formic acid in MilliQ H2O for PIH, direct
injection for the hydrazine adduct, or with 9X volume MilliQ H 2O for isoniazid.
The Acquity UPLC system (Waters, Milford, MA) coupled to an Applied
Biosystems-Sciex API 6500 (Foster City, CA) with a triple-quadrupole mass
spectrometer using an electronic spray ionization interface in positive mode was used to
analyze PIH and isoniazid. The ion source temperature was maintained at 500°C and
450°C for PIH and isoniazid, the ion spray voltage was set at 5000°C and 3000°C for PIH
and isoniazid, and multiple reaction monitoring mode was used for the quantitation of the
analytes. The selected m/z transitions were 287 → 150 and 137.9 →79.1 for PIH and
isoniazid, respectively. The m/z of the hydrazine adduct was 269. High purity nitrogen
gas was used as collision-induced dissociation gas (setting 10 and 8), curtain gas (setting
20), ion source gas 1 (setting 37 and 60), and ion source gas 2 (setting 60) for PIH and
isoniazid, respectively.
The chromatographic separation was performed on a Waters Acquity HSS C18
column (2.1 mm × 50 mm, i.d., 1.8 μm particle size, Waters, Ireland) for PIH. Mobile
phase A was consisting of 0.1% acetic acid in water and mobile phase B consisting of
0.1% acetic acid in acetonitrile. The total flow rate was 0.7 mL/min. The UPLC column
was maintained at 55°C and the gradient program over 2 minutes started at 95% A,
maintaining for 0.2 minute, changed to 40% A over 0.8 min, to 95 % B over 0.5 minute,
held for 0.2 minute, then to 95% A over 0.1 minute, and held for another 0.2 minute.
The chromatographic separation was performed on a Waters HSS T3 C18 column
(2.1 mm × 50 mm, i.d., 1.8 μm particle size, Waters, Ireland) for isoniazid. Mobile phase
A was consisting of 10 mM ammonium bicarbonate in water and mobile phase B
consisting of methanol. The total flow rate was 0.7 mL/min. The UPLC column was
maintained at 55°C and the gradient program over 2 minutes started at 100% A,
maintaining for 0.8 min, changed to 5% A over 0.4 min, held for 0.4 min, then to 99% A
over 0.3 minute, and held for another 0.1 minute.
Detection of the hydrazine adduct was achieved with an Acquity UPLC system
coupled to an Acquity SQD Mass Spectrometer (Waters, Milford, MA, USA). The mass
spectrometer was operated in positive-ion mode with electrospray ionization. The
conditions were as follows: capillary voltage 3.5 kV, cone voltage 25 V, source
temperature 150 °C, desolvation temperature 350 °C, desolvation gas 800 L/hr, cone gas
85 L/hr. A full scan range from m/z = 100-1000 in 0.2 seconds was used to acquire MS
data. Single ion recording mass spectrometry were used to determine the quantification of
the samples. Chromatographic separation was performed on an Acquity UPLC BEH C18
1.7 μm, 2.1 x 50 mm column (Waters Corporation, Milford, MA). The total flow rate was
1.0 mL/min. The sample injection volume was 10 μL. The UPLC column was maintained
at 60 °C and the gradient program started at 90% A (0.1% formic acid in MilliQ H2O),
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changed to 70% A over 0.2 min, to 95 % B (0.1% formic acid in acetonitrile) over 1.4
minutes, held for 0.35 minutes, then to 90% A over 0.05 minutes.
Analysis of mass spectra was performed using the Analyst software (version
1.6.3) for the data acquisition and processing of PIH and isoniazid. The MassLynx
software (version 4.1) was used to analyze for the hydrazine adduct. A 1/x2 weighted
least squares linear regression method was used to obtain the calibration curves of the
analytes through the measurement of the peak area ratio of each analyte to the internal
standard.
Quantitative Real-Time Polymerase Chain Reaction
Mice livers were collected and stored in RNAlater from Thermo Fisher (Waltham,
ME) at 4oC for 24 hours, then the RNA later was removed and the samples were stored at
-80oC until homogenization. Homogenization was performed using the Bullet Blender
Storm 24 Homogenizer from Thomas Scientific (Swedesboro, New Jersey). Cell cultures
were trypsinized and collected following treatment. Extraction of whole RNA is
performed with the Maxwell 16 LEV SimplyRNA Tissue Kit from Promega (Madison,
WI) on the Maxwell 16 Instrument by Promega according to manufacturer’s instructions.
RNA was measured by the NanoDrop 8000 UV-Vis Spectrophotometer from Thermo
Fisher. cDNA is synthesized using the SuperScript VILO kit from Invitrogen (Carlsbad,
CA). Taqman reagents from Invitrogen (Carlsbad, CA) and the Applied Biosystems
(Foster City, CA) 7500 Fast Real-Time PCR system were used to perform qRT-PCR. The
ΔΔCT method was used to fold change in expression to the control group of each mouse
strain (mouse house-keeping gene used: Gapdh) or vehicle control in cell culture (human
house-keeping gene used: 18S) treatments. Gene expression was normalized to the
species-specific house-keeping gene, which did not vary expression by treatment. Data
are represented as mRNA fold change using the ΔΔCT method relative to vehicle control
treatments. Experiments were performed in triplicated with analysis of each sample
performed in triplicate.The following Taqman probes were used: CYP3A4
(Hs00604506_m1), ALAS1 (Hs00963534_m1), Alas1 (Mm01235914_m1), Fech
(Mm00500394_m1), FECH (Hs01555261_m1), Cyp3a11 (Mm00731567), hPXR
(Hs01114267_m1), 18S (Hs03928990_g1), Gapdh (Mm99999915_g1), ABCG2
(Hs01053790_m1), Abcg2 (mM00496364_m1),
Hydrazine Adduct Formation
Hydrazine has a low molecular weight and therefore required derivatization for
quantification via LC/MS/MS. This derivatization was carried out by Anne Edwards,
Ph.D. from the Lab of Richard Lee, Ph.D. with p-anisaldehyde in a 2:1 reaction with
hydrazine (Figure 2-3) similar to a previous report with modifications (Isenberg, Carter
et al. 2016). For in vitro samples, 300 μL of each sample was acidified with 2 μL of 18 N
HCl followed by the addition of 1 μL of p-anisaldehyde (21.8 mM). The mixtures were
allowed to react at room temperature for 24 h followed by LC/MS/MS analysis. For in
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Figure 2-3.

Synthesis of the hydrazine adduct quantified in this study.

Schema for the generation of the hydrazine and p-anisaldehyde adduct for use in the
standard curve (A) and for unknown biological and biochemical samples (B).
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vivo samples, 100 μL of the in vivo samples were acidified with 2 μL of 18 N or M HCl
followed by the addition of 1 μL of p-anisaldehyde for a final concentration of 66.5mM.
Samples with limited volume were diluted 1:1 or 9:1 then acidified followed by the
addition of1 μL p-anisaldehyde. After 24 hours incubation at room temperature the
samples were analyzed by LC/MS. To generate the standard curve, a solution of 7.68 mM
p-anisaldedhyde was added to a solution of 3.84 mM hydrazine sulfate in 1:1
water/MeOH. The reaction was stirred for 2 hours and resultant yellow precipitate was
filtered. The precipitate was dried under vacuum to produce the solid hydrazine adduct.
Siderophore Detection Assay
The chrome azurol S (CAS) assay was used to study the iron-binding capacity of
solutions. The liquid CAS assay was based on the CAS-agar plate assay reported by
Schwyn and Neilands and modified by Machuca and Milagres with variations (Schwyn
and Neilands 1987, Machuca and Milagres 2003). Chelex-100 treated water was prepared
according to manufacturer instructions and used to prepare assay buffer. Samples were
incubated in CAS shuttle solution for 60 minutes at RT, then absorbance was read at 630
nm. Normalized absorbance values were obtained by dividing the absorbance of samples
by a blank sample containing either cell culture medium, PBS for biochemical solution,
or with Chelex-treated water for deferoxamine and PIH solutions.
Cell Viability Assays
CellTiterGlo ATP Detection
The CellTiterGlo assay from Promega (Madison, WI) was used to detect ATP
levels (Figure 2-4) according to manufacturer’s instructions. 10 μM staurosporine
robustly reduced ATP at all time points observed (greater than 24 hours). Pre-assay
optimization of plating density found that the optimal conditions for HepG2/C3A were in
10%FBS MEM at a density of 2,000 cells/well (in linear range of growth throughout
experimental time period and linear range of luminescence) cells/well in white bottomed
96-well plates. Raw luminescence values were subtracted by cell free blank cell culture
media and normalized to a measurement taken immediately after administration of
compounds.
Caspase 3/7 Glo
To measure caspase 3/7 activity (Figure 2-5), the Caspase 3/7 Glo assay kit from
Promega (Madison, WI) was used according to manufacturer’s instructions. For short
term experiments 10 μM staurosporine was used as a positive control, whereas for longer
term experiments 0.1 μM staurosporine was used as a positive control. 10 μM
staurosporine was necessary for robust induction of Caspase 3/7 activity at time points up
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Figure 2-4.

Overview of the CellTiterGlo assay.

Luciferase generates light in the present of ATP and luciferin.
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Figure 2-5.

Overview of the Caspase 3/7 Glo assay.

Caspase 3/7 cleaves Z-DEVD sequence off of Z-DEVD-aminoluciferin generating
luciferin which is then converted to light by luciferase in the presence of ATP.
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to 12-24 hours, but a decrease in caspase 3/7 activity was observed after 24 hours at this
dose due to cell death. 0.1 μM staurosporine did not induce caspase 3/7 activity after the
first 24 hours hours, but treatment over 24 hours lead to robust, sustained induction of
caspase 3/7 activity. Cell number and caspase 3/7 glo incubation times were also
optimized before experimental samples were evaluated. Caspase 3/7 glo was performed
on HepG2/C3A in 10% FBS MEM, at 2,000 cells/well in white bottomed 96-well plates.
Raw luminescence values were subtracted by cell free blank cell culture media and
normalized to a measurement taken immediately after administration of compounds.
Phase-Contrast Imaging
Phase-contrast imaging was performed on the Incucyte ZOOM live-cell imaging
system (Essen BioScience, Ann Arbor, MI). as described previously (Oladimeji, Lin et al.
2017) with variations. Cells were plated at a density of 600,000 cells/well (20%
confluence in 6-well plate) in 10%.FBS MEM 24 hours before the addition of indicated
compounds. The cell density was evaluated every 12 hours. Data are represented as the
fold-change in confluence compared to a measurement taken immediately after
administration of compounds.
Solubility Assay
Lei Yang performed the solubility assay on the Biomek FX ADME-TOX
workstation from Beckman Coulter (Fullerton, CA) to determine the solubility of
PPIXNa 2 in PBS. To assess the solubility of PPIXNa 2 and in combination with
rifampicin, isoniazid, or a combination of both, PPIXNa2 was added to water to make the
final concentration 100 μM, vortexed, then filtered using a 96-well filter plate from pION
(Woburn, MA). The samples were then analyzed by UV spectrometry (230-500 nm). For
standard curves, compounds were diluted 600-fold in 1:1 PBS buffer and 1-propanol
(v/v). Concentrations were performed by μSOL Evolution software and compounds were
tested in triplicate.
ABCG2/Abcg2 Transport Assays
Pheophorbide A Transport Assay
Evaluation of ABCG2/Abcg2 inhibition by isoniazid was carried out similarly to
previous reports with variations (To, Poon et al. 2015). Wild type or Abcg2 knockout
mouse embryonic fibroblasts were generously provided by the lab of John Schuetz. HEK
293 cells were transfected with pcDNA3.1 empty vector or with a recombinant ABCG2
for 24 hours before pheophorbide A, ALA, and or ABCG2/Abcg2 inhibitor treatment.
Cells were treated in DMEM with 10% FBS and without antibiotics for 30 minutes at
37oC with 1 μM pheophorbide a and with 10 μM FTC, 10 μM Ko143, or 100 μM
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isoniazid. Cells were then washed with cold DMEM and incubated for 2 hours at 37 oC in
the presence of the indicated inhibitor or potential inhibitor without pheophorbide A.
Cells were then washed in cold DMEM, filtered, and kept on ice in the dark until
analysis. 500,000 cells total, 1-2 million cells per mL were allocated per sample.
Flow Cytometry Analysis
Flow cytometry analysis was performed by the Flow Cytometry and Cell Sorting
Core Facility at St. Jude Children’s Research Hospital. Samples were analyzed on a
LSRFortessa Cell Analyzer and FACSDiva software (BD Biosciences). Pheophorbide A
fluorescence was detected with a 488 nm argon laser and a 670 nm bandpass filter. Over
100,000 events were collected with at least 10,000 events analyzed after cell debris were
eliminated by gating forward versus side scatter and dead cell exclusion via DAPI
staining.
Aminolevulinic Acid Treatment for PPIX Transport
Cells were trypsinized, washed, and while still in solution, incubated with ALA in
the presence or absence of indicated test compound or ABCG2 inhibitor for 2 hours. After
which the media was collected and combined with a 1:1 solution of 0.9M ClO 4 in MeOH.
Cells were then washed with cold PBS and lysed with 200 μL/well of 0.1% SDS for 1
hour on ice. Following lysis, 800 μL/well of 0.9M ClO4 in MeOH was added to lysate
and lysate was centrifuged at 10,000 RPM for 10 minutes to remove cell debris.
CLARIOstar Analysis of PPIX Content
The CLARIOstar microplate fluorescence reader system (BMG Labtech,
Ortenberg, Germany) was used to quantify the fluorescence of cell and media
preparations. This method is a variation of an original assay first reported by Granick and
Levere in 1965 (Granick and Levere 1965), modified by Bloomer in 1997 (Bloomer
1997) and subsequently by Lin et al., and Ogino et al., in 2013 (Lin, Chang et al. 2013)
and 2011 (Ogino, Kobuchi et al. 2011) respectively. The supernatant of the lysate was
added to 96-well non-tissue-culture treated flat solid bottomed, black sided microplates
(Corning, Corning, NY) containing 1:1 supernatant and 0.9M ClO 4 in MeOH for
imaging. Measuring the emission at 640 nm following excitation at 405 nm would
quantify multiple species of PPIX (Figure 2-6) and a signal is observed here following
ALA treatment of HepG2/C3A cells (Figure 2-7). A standard curve was generated using
PPIX for each plate and absolute concentrations were calculated based on relative
fluorescence values obtained by measuring emission at 640 nm following excitation at
405 nm of a non-treated cell lysate spiked with various concentrations of PPIX based on
a method described previously (Granick and Levere 1965, Bloomer 1997, Ogino,
Kobuchi et al. 2011, Lin, Chang et al. 2013).
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Figure 2-6.

Emissions spectra of PPIX species at 405 nm excitation.
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Figure 2-7. Emission spectrum of HepG2/C3A cell lysate treated with 4 mM ALA
at 405 nm excitation.
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Parallel Artificial Membrane Permeability Assay
The parallel artificial membrane permeability assay (PAMPA) was performed as
described previously by Lei Yang of the High-Throughput Analytical Chemistry Core
Facility (Yu, Wang et al. 2015). A 96-well filter plate from EMD Millipore (IVPH, 125
μm filter, 0.45 μm pore) and a 96-well microtiter plate formed a “sandwich” structure
when wetted with 2% (w/v) hexadodecane (Figure 2-8). 0.3 mL of drug solution at 100
μM was added to the donor wells. The filter plate was placed on top of the donor plate.
The wells of the acceptor plate were filled with buffer and placed on top of the filter.
After incubation for 16 hours at 25oC, the plates were separated and the concentrations of
the accepter and the donor wells were measured by UV absorption and used to calculate
permeability.
PPIX Binding Assay
The PPIX fluorescence binding assay was performed as previously reported
(Lyoumi, Abitbol et al. 2011). To compare in vitro binding affinities of various
antitubercular drugs, bile acids, and phosphatidyl choline these compounds were added to
a 20 nM solution of PPIX in 1 M imidazole, 0.9% NaCl, at pH 8.2 at similar
concentrations they are found in the bile. The concentrations of each bile acid constituent
was based on their in vivo concentrations (0.1 mM phosphatidyl choline, 100 μg/mL
BSA, 2 mM of each bile acid, 0.4 mM of rifampicin, and 4 mM isoniazid). Solutions
were prepared of each constituent with PPIX or the constituent alone and protected from
light and placed in 96-well black plate and read by a Clariostar fluorescent plate reader.
Fluorescence intensity of the emission at 634 nm after excitation at 408 nm was read. The
ratio of the fluorescence intensities of the bile constituent and PPIX to the bile constituent
alone were determined.
Statistical Analysis
Data from three independent experiments were pooled and analyzed as indicated
in figure legends using GraphPad Prism 7.0 software. Significant changes re considered
to be p-values of less than 0.05. Results are expressed as the mean +/- standard error of
measurement (SEM). 2-way ANOVA followed by Tukey’s post-hoc analysis was used to
compare group means for qRT-PCR analysis. 1-way ANOVA followed by Dunnett’s
post-hoc analysis was used to compare group means for Western blot analysis. False
discovery rate (FDR) was determined by the Benjamini Hochberg correction.
Proteomics Profiling
Proteomics profiling and initial analysis were carried out by Kiran Kodali of the
Proteomics and Mass Spectrometry Facility at St. Jude Children’s Research Hospital.
Mice were treated as described for in vivo study 2 (Figure 2-9). Male C57BL/6 hPXR
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Figure 2-8.

PAMPA overview.

Compounds are added to one side of a hexadecane membrane then the media on the other
side was analyzed for the compound.
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Figure 2-9.

Proteomics profiling overview.
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and mPxr -/- were treated for 6 months with 300 mg/kg rifampicin in chow and 1.2 g/L
isoniazid in water. After 6 months, livers were collected and flash frozen. Livers were
then lysed (50 mM HEPES, pH 8.5, 8 M urea and 0.5% sodium deoxycholate), and 100
μg of protein was digested with LysC from Wako Chemicals (Richmond, VA) in the
presence of 1,4 -dithiothreitol at an enzyme-to-substrate ration of 1:100 for 2 hours as
described previously (Pagala, High et al. 2015). The samples ar then diluted to a final 2
M urea concentration using 50 mM HEPES, pH 8.5. The samples are further digested by
trypsin from Promega (Madison, WI) at an enzyme-to-substrate ratio of 1:50 for 3 hours.
The resulting peptides are reduced by adding 1 mM 1,4 –dithiothreitol for 30 minutes at
RT and are then alkylated with 10 mM iodoacetamide for 30 minutes at RT in the dark.
The reaction is quenched by adding trifluoroacetic acid. This acidified peptide mixture is
desalted by C18 cartridges from Harvard Apparatus (Holliston, MA) The desalted eluent
is dried and re-suspended in 50 mM HEPES, pH 8.5.
Samples are labeled with Tandem Mass Tags (TMT 11-plex) from Thermo Fisher
(Waltham, MA) according to the recommendations of the manufacturers. After labeling
the samples are combined, desalted, and fractionated on an off-line HPLC (Agilent 1220)
from Agilent Technologies (Santa Clara, CA). 90 two minute fractions were collected
over a 180 minute gradient. The fractions are dried then re-suspended in 5% formic acid
and analyzed by acidic pH reverse-phase LC/MS/MS. Samples are fractionated on a
nanoscale capillary reverse-phase C18 column by a nanoAcquity HPLC from Waters
Corporation (Millford, MA) by a 120 minute gradient. The eluent is ionized by
electrospray ionization and detected by an in-line Orbitrap Fusion mass spectrometer
from Thermo Fisher (Richmond, VA). Mass spectrometry is performed in data-dependent
mode with a survey scan (60,000 resolution, 1 X 106 AGC target and 150 ms maximal
ion time) and 20 MS/MS high resolution scans (60,000 resolution, 1 X 106 AGC target
and 150 ms maximal ion time, 38 HCD normalized collision energy, 1 m/z isolation
window, and 20 s dynamic exclusion).
Raw mass spectra were processed by the JUMP program as described previously
(Wang, Li et al. 2014). The resultant data was compared to the UniProt mouse database
and concatenated with a reversed protein sequence decoy database. Searches were
performed using a mass tolerance of 25 ppm for precursor ions and 15 ppm mass
tolerance for fragment ions, fully tryptic restriction with two maximum missed cleavages,
three maximum modification sites, and the assignment of α, β, and γ ions. TMT tags on
lysine residues and N-termini (+229.162932 Da) and carbamidomethylation of cysteine
residues (+57.021 Da) are used for static modifications and methionine oxidation
(+15.99492 Da) is considered as a dynamic modification. Mass spectra are filtered by
mass accuracy and matching scores to reduce the FDR to approximately 1%. Proteins are
quantified by summarizing reporter ion counts across all matched peptide spectrums
using the JUMP software. Analysis was performed by Timothy Shaw from the
Computational Biology Department and Proteomics Core Facility at St. Jude Children’s
Research Hospital. Clustering analysis was performed using R v.3.0.1.
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CHAPTER 3.

RESULTS

The Physiochemical Properties of PPIX
Introduction
The physiochemical properties of PPIX may contribute to toxicity by binding to
bile acid components and precipitating into the bile canaliculi. This may block bile ducts
and lead to a cholestatic pattern of toxicity. Conversely, intracellular accumulation of
PPIX is associated with a hepatocellular subtype of liver injury. To recapitulate the
cholestatic hepatotoxicity phenotype observed previously (Li, Lu et al. 2013) that is
believed to be mediated by PPIX, it is necessary to demonstrate that (1) PPIX is insoluble
at supra-physiologic levels that may be associated with heme biosynthesis disruption, (2)
PPIX binds to bile salts, phospholipids, albumin, and this binding may be affected by
rifampicin and isoniazid, and that (3) exogenous PPIX is toxic. The proposed mechanism
of the toxicity of PPIX presumes that it is toxic when in an extracellular compartment
(Lyoumi, Abitbol et al. 2011). PPIX is hepatotoxic when its level rises high enough in the
bile canaliculi, PPIX precipitates out of solution forming aggregates with bile
constituents resulting in bile plugs. The bile plugs observed previously (Davies,
Schuurman et al. 2005, Lyoumi, Abitbol et al. 2011, Li, Lu et al. 2013) may be due to
PPIX if PPIX is insoluble at likely concentrations achievable by heme biosynthesis
disruption by isoniazid and the un-defined role of rifampicin. Therefore, confirming these
properties of PPIX is necessary before beginning in vivo studies predicated on PPIX
exerting a hepatotoxic effect via these properties.
Solubility of PPIX
A 100 μM solution of the disodium salt of PPIX was prepared in water, vortexed,
and filtered. The sample was then analyzed by UV spectrometry and the concentration of
PPIX was 0.3 μM (Figure 3-1). BALB/c m1Pas mice have liver PPIX levels of 0.02 μM,
whereas C57BL/6 mice have liver PPIX levels of 0.24 μM (Lyoumi, Abitbol et al. 2011).
Interactions with less soluble molecules and changes in bile pH may further lower PPIX
solubility (Davies, Schuurman et al. 2005, Lyoumi, Abitbol et al. 2011). In FVB/NJ mice,
basal PPIX liver levels were found to be 0.35 μM with a 3-fold increase after 14 days of
400 mg/L isoniazid treatment that did not result in toxicity (Sachar, Li et al. 2016). The
same group previously reported a 60-fold increase in bile PPIX levels in hPXR (C57BL/6
strain) mice (the authors did not specify concentration) that was associated with
pathological change in liver tests and in the observation of bile plugs on histological
examination (Li, Lu et al. 2013). During heme synthesis, PPIX would be expected to be
relatively transient and to be formed immediately into heme by FECH. Therefore, with a
relatively low solubility compared to pharmaceuticals (e.g. albendazole, soluble at 15
μM) excreted into the bile, changes in PPIX solubility may lead to precipitation and
potentiate bile stasis. Additional information concerning the solubility of different species
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Figure 3-1.

The solubility of PPIXNa2 in PBS.

LC/MS/MS analysis of filtrate from saturated PBS solution of PPIXNa 2. Data are
represented as the mean ± SEM.
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of PPIX, comparison to heme, and in the presence of bile acid constituents would further
elucidate the conditions in which the solubility of PPIX would contribute to the
pathogenesis of liver injury.
Permeability of PPIX
The permeability of the disodium salt of PPIX was compared to various
pharmaceuticals. The permeability of these compounds was measured and found to be
about 1500 Pe (106 cm/s) for hydrophobic non-polar verapamil, 100 Pe (106 cm/s) for
carbamazepine, 150 Pe (106 cm/s) for albendazole, and 0 Pe (106 cm/s) for ranitidine. The
permeability of PPIXNa 2 was 17 Pe (106 cm/s) (Figure 3-2), much lower than
albendazole and carbamazepine. Less polar species of PPIX would be expected to be less
permeable and future studies may elucidate the dependence of these species on
transporter proteins such as ABCG2 and the exact nature of the elevated PPIX detected
following antitubercular therapy in mice (Li, Lu et al. 2013, Sachar, Li et al. 2016). Mass
spectrometric analysis would not be able to differentiate against PPIX, PPIXNa 2, or many
other species of PPIX due to the loss of ions in solution. Therefore, further elucidation of
the ADME properties between these molecules would help to identify the species
involved in accumulation.
Isoniazid Does Not Inhibit the ABCG2/Abcg2-Mediated Transport of Pheophorbide
A
ABCG2 effluxes PPIX from hepatocytes into the bile, leading to toxicity (Aust,
Obrist et al. 2004, Davies, Schuurman et al. 2005, Lyoumi, Abitbol et al. 2011, He, Guo
et al. 2017). However, increased PPIX retention by decreased efflux does contribute to
toxicity in ALL and hematopoietic cells (Stewart, Leggas et al. 2004, Krishnamurthy and
Schuetz 2011, Morfouace, Cheepala et al. 2015). Pheophorbide A (chlorophyll
breakdown product) is a specific substrate for ABCG2/Abcg2 discovered when Abcg2 -/mice were fed alfalfa developed phototoxicity. Flow cytometric analysis of pheophorbide
A is used as the gold standard in determining the effect of potential inhibitors on
ABCG2/Abcg2 activity. Therefore, we tested the potential for ABCG2 inhibition by
measuring pheophorbide A efflux in HEK 293 cells ectopically overexpressing ABCG2.
To test the effect of isoniazid on pheophorbide A transport mediated by Abcg2, mouse
embryonic fibroblasts were used. The specific ABCG2 inhibitors fumitremorgin C (FTC)
and Ko143 inhibited ABCG2- and Abcg2-dependent efflux of pheophorbide A, but
isoniazid expectedly did not (Figure 3-3A and B).
Isoniazid Does Not Inhibit the ABCG2/Abcg2-Mediated Transport of PPIX
The mechanism of PPIX transport by ABCG2/Abcg2 differs from Pheophorbide A
in that BSA is required to transfer PPIX from the extracellular loop of the transporter and
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Figure 3-2.

The permeability of PPIXNa2 in PAMPA.

Data are represented as the mean ± SEM.
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Figure 3-3. Isoniazid does not inhibit ABCG2- or Abcg2-mediated transport of
pheophorbide A or PPIX.
The potential for inhibition by isoniazid was evaluated in HEK 293 ectopically overexpressing human ABCG2-mediated transport of pheophorbide A (A) and PPIX (C).
MEF cells expressing mouse Abcg2 were evaluated for potential inhibition by isoniazid
in the transport of pheophorbide A (B) and PPIX (D). Data are expressed as the mean ±
SEM of separate experiments. 1-way ANOVA followed by Dunnett’s post-hoc analysis
was used to compare group means. ****p<0.0001; ***p<0.001, **p<0.01, *p<0.05
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enable transport of additional PPIX molecules (Desuzinges-Mandon, Arnaud et al. 2010).
Therefore, testing pheophorbide A alone would not answer the question of whether PPIX
transport by ABCG2/Abcg2 is inhibited by isoniazid. The same cell models used to
evaluate pheophorbide A transport were used to evaluate PPIX transport subsequent to
ALA treatment to induce intracellular PPIX formation. After induction of PPIX
accumulation by ALA, cells were treated with isoniazid and FTC. FTC inhibited the
ABCG2- and Abcg2-mediated transport of PPIX (Figure 3-3C and Figure 3-3D).
PPIX Binds to Phospholipids and Bile Salts
In instances of hepatotoxicity associated with PPIX treatment, disruption of lipid
and bile acid homeostasis and deposits of porphyrins and bile acid constituents are found
on histopathological examination (Davies, Schuurman et al. 2005, Lyoumi, Abitbol et al.
2011, Li, Lu et al. 2013). To determine if the interactions of PPIX with bile acids,
albumin and phosphatidyl choline was affected by the presence of rifampicin and
isoniazid, the binding assay employed previously was used (Lyoumi, Abitbol et al. 2011).
PPIX did not interact with isoniazid, taurocholic acid, hexadecenoic (palmitic) acid, or
deoxycholic acid, but did interact with rifampicin, albumin, phosphatidyl choline, and
lithocholic acid. Isoniazid and rifampicin affect the interaction of PPIX with albumin and
phosphatidyl choline (Figure 3-4). Further studies would be required to elucidate
whether these associations would be expected to increase or decrease the solubility of
PPIX.
Exogenous PPIXNa2 Decreases ATP Levels
PPIXNa2 is associated with more severe hepatotoxicity when not retained in
Kupffer cells and hepatocytes (Lyoumi, Abitbol et al. 2011). Considering this report, the
low membrane permeability of PPIXNa2, and lack of identified import protein, PPIXNa2
may be toxic in an extracellular space. To evaluate whether exogenous PPIXNa2 could
reduce ATP levels in HepG2/C3A, cells were added to culture plates for 24 hours before
being treated with PPIXNa 2. At day 2, there was a slight decrease in ATP (p < 0.05) due
to 40 μM PPIXNa 2 (Figure 3-5). At day 3, this became a 40% decrease due to 40 μM
and 10% decrease (p < 0.001) due to 20 μM. At day 4, 40 μM and 20 μM decrease ATP
levels by 60 % (p < 0.001) and 40% by 10 μM (p < 0.05). The media was not refreshed
after dosing on day 0 when the base-line ATP levels were measured and after day 4, the
ATP levels of DMSO treated HepG2/C3A cells were no longer increasing, suggesting
that cells are no longer growing. Beginning on day 5, PPIXNa 2 showed a decrease in
ATP levels above 156 nM PPIXNa 2 by at least 20% compared to DMSO treated cells (p
< 0.001), a 70% decrease at 10 μM (p< 0.001), and an 80% decrease at 40 μM PPIXNa2
(p< 0.001). At day 6, 156 nM PPIXNa 2 decreased ATP levels by 50% (p< 0.001) and a
90% decrease (p< 0.001) at 10 μM. This persists through day 7 with an overall decrease
in ATP levels. Higher doses of PPIXNa 2 (in the micromolar range) may cause toxicity
earlier and in nutrient rich conditions, where lower doses (in the nanomolar range) may
require nutrient depletion to be toxic.
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Figure 3-4.

PPIXNa2 binding assay.

Evaluation of PPIX binding to phospholipids (A) and bile salts (B). Data are represented
as the mean of the ratio of the fluorescence intensity of indicated compounds with PPIX
to wells of the compounds without PPIX. Data are represented as the mean ± SEM. 1way ANOVA followed by Dunnett’s post-hoc analysis was used to compare group
means. ****p<0.0001; ***p<0.001, **p<0.01, *p<0.05
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Figure 3-5.

PPIXNa2 decreases cellular ATP levels.

Evaluation of relative ATP levels after single treatment of HepG2/C3A cells with various
doses of PPIX at 1-3 days (A) and 4-7 days (B). Data are represented as the mean ± SEM
of the CellTiterGlo luminescence at the indicated time point divided by the luminescence
immediately after dosing. 1-way ANOVA followed by Dunnett’s post-hoc analysis was
used to compare group means. ****p<0.0001; ***p<0.001, **p<0.01, *p<0.05
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Exogenous PPIXNa2 Decreases Cell Area
To confirm the decrease in ATP due to PPIX detected by the CellTiterGlo assay
system and to allow daily dosing and refreshening of media as well as extending the
length of exposure to PPIXNa 2, phase-contrast imaging was used to evaluate whether
there would be a commensurate decrease in cell area growth. As low as 313 nM PPIXNa2
significantly (p< 0.005) decreased the growth of cell area as measured by phase contrast
imaging (Figure 3-6). At 625 nM PPIXNa2 or higher the cell area growth was
significantly (p <0.001) decreased. 10 μM staurosporine was used as the positive control.
Further evaluation would elucidate whether the effect of exogenous PPIXNa 2 is merely
growth suppression or directly cytotoxic.
Exogenous PPIX Increases Caspase 3/7 Activity
Exogenous application of HepG2/C3A resulted in an ATP decrease beginning at 3
days due to 40 μM PPIXNa 2. Following this observation. HepG2/C3A cells were then
evaluated for caspase 3/7 activation using the Caspase 3/7 Glo Assay from Promega
(Madison, WI). HepG2/C3A treated for short durations less than 3 days do not display
caspase 3/7 activity due to PPIXNa2 treatment. However, statistically significant
(p<0.0001) activation of caspase 3/7 was detected at 72 hours due to 80 μM PPIXNa 2
(Figure 3-7).
The Effect of Isoniazid Metabolites on the Heme Biosynthesis Pathway
Introduction
After establishing that exogenous PPIX is cytotoxic, precipitates at relatively low
concentrations, and may bind to bile constituents and may be associated with or even
causative of the bile plugs observed in vivo, the disruption of the heme biosynthesis
pathway by isoniazid was subsequently investigated. This investigation focused on the
role of isoniazid based on a previous report (Sachar, Li et al. 2016) and my data that
confirmed this report (Figure 1-7). The accumulation of PIH and hydrazine in patients
taking isoniazid has been reported previously. (Li, Miao et al. 2011, Isenberg, Carter et
al. 2016) PIH has been reported to chelate iron and FECH is down-regulated in low iron
conditions. (Taketani, Adachi et al. 2000, Crooks, Ghosh et al. 2010) Hydrazine has been
reported to N-alkylate heme moieties (Ator, David et al. 1987, Wojciechowski and de
Montellano 2007, Ascenzi, Coletta et al. 2013) and heme suppresses ALAS1 expression at
multiple levels. (Srivastava, Borthwick et al. 1983, Kolluri, Sadlon et al. 2005, Zheng,
Shan et al. 2008) Isoniazid up-regulates mouse Alas1 protein and down-regulates Fech
protein in mouse liver. (Sachar, Li et al. 2016) These effects of isoniazid on heme
biosynthesis enzymes was not previously reported on the human proteins, nor was it
determined if the effects observed in mouse systems were due to isoniazid or a metabolite
of isoniazid. Therefore, I report (1) the detection of PIH in biological systems and
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Figure 3-6.

PPIXNa2 treatment decreases cell area growth.

Phase contrast imaging of HepG2/C3A cells after single treatment of PPIX. Data
quantified by Incucyte ZOOM instrument (A) and representative images (B) are shown.
Data are represented as the mean ± SEM of the confluence at the indicated time divided
by the confluence taken immediately after the first dose of PPIXNa 2. 1-way ANOVA
followed by Dunnett’s post-hoc analysis was used to compare group means.
****p<0.0001; ***p<0.001, **p<0.01, *p<0.05
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Figure 3-7.

PPIXNa2 increases Caspase 3/7 activity.

Data are represented as the mean ± SEM of the fold change of Caspase 3/7 Glo
luminescence at 72 hours compared to a time 0 measurement conducted immediately
after dosing. 1-way ANOVA followed by Dunnett’s post-hoc analysis was used to
compare group means. ****p<0.0001; ***p<0.001, **p<0.01, *p<0.05
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demonstrate the enzyme-independent formation of PIH from multiple vitamin B 6
analogues and isoniazid, (2) the iron-dependent down-regulation of FECH, and (3) the
hydrazine-mediated up-regulation of ALAS1.
Isoniazid Decreases Human FECH Protein Levels and Increases Human ALAS1
Protein and mRNA Levels, but Does Not Affect FECH mRNA Levels
A previous study (Sachar, Li et al. 2016) reported the regulation of Alas1 and
Fech by isoniazid in mice, we also observed this decrease in Fech protein and increase in
Alas1 protein in C57BL/6 mice livers at 6 weeks of treatment with isoniazid (400 mg/L
in drinking water as described for in vivo study 1) and confirm that these changes occur
independently of hPXR and are not modified by the co-administration of rifampicin (100
mg/kg in chow). (Figure 3-8) These changes would be expected to result in the increase
of PPIX seen due to isoniazid alone (Sachar, Li et al. 2016) and a portion the PPIX
increase associated with hepatotoxicity of hPXR mice treated with rifampicin and
isoniazid concurrently (Li, Lu et al. 2013).Therefore, we first tested the effect of
isoniazid on human ALAS1 and FECH and found similar changes in a much shorter time
period and at lower doses than has been reported to cause toxicity in HepG2/C3A (Nicod,
Viollon et al. 1997, Schwab and Tuschl 2003, Bhadauria, Mishra et al. 2010). Isoniazid
treatment of HepG2/C3A and PHH for 72 hours results in a 50% decrease of FECH
protein in PHH (Figure 3-9A; p<0.01) at doses higher than 50 μM (Figure 3-9B;
p<0.05) and a decrease of 30% in HepG2/C3A (Figure 3-9D; p<0.01) but not of FECH
mRNA (Figure 3-9C and E). This is similar to other reports of iron-dependent FECH
protein down-regulation. Bone marrow aspirates of Irp2 -/- mice have been reported to
display 50% of the Fech activity of wild-type mice (Crooks, Ghosh et al. 2010). This also
corresponds to the 60% decrease observed of FECH activity after administration, of the
N-donor, S-nitroso-N-acetylpenicillamine, to cell lysates overexpressing human
recombinant FECH (Furukawa, Kohno et al. 1995). Treatment of FVB/NJ mice with
isoniazid for 14 days produced a 60% decrease in Fech protein and 3- to 4-fold increase
in Alas1 protein (Sachar, Li et al. 2016). Isoniazid up-regulates the protein levels of
ALAS1 3-fold at 800 μM (Figure 3-10B; p<0.01), but does not up-regulate the mRNA
levels in PHH (Figure 3-10C). Isoniazid does not up-regulate the protein (Figure 3-10D)
and mRNA (Figure 3-10E) levels of ALAS1 in HepG2/C3A at 800 μM.
Iron Levels Modulate FECH Protein Levels
Previous studies (Furukawa, Kohno et al. 1995, Taketani, Adachi et al. 2000,
Crooks, Ghosh et al. 2010) have established the relationship between the [2Fe-2S]
containing FECH and iron levels in murine erythroleukemia cells, macrophage cell line
RAW 264.7, and K562 cells. These studies have shown that FECH is down-regulated in
iron-limiting conditions and is up-regulated in iron-replete conditions. However, this has
not been reported in the liver hepatoma cell line, HepG2/C3A. HepG2 is commonly used
to study hepatotoxicity in vitro and has been used to demonstrate the toxicity of
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Figure 3-8.

In vivo expression of Fech and Alas1 in mouse liver.

Western blot analysis of Fech (A) and Alas1 (B) in C57BL6 mouse liver after 6 weeks
treatment with rifampicin (100 mg/kg chow) and isoniazid (400 mg/L in drinking water).
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Figure 3-9.

Isoniazid decreases human FECH protein.

Western blot analysis of FECH in primary human hepatocytes treated with 10 μM
rifampicin, 10 μM SPA70, 200 μM isoniazid, or a combination of these drugs (A), and a
dose response of isoniazid for 72 hours (B). qRT-PCR analysis of the expression of
FECH in A (C). Western blot analysis of FECH in HepG2/C3A treated with isoniazid for
72 hours (D) and qRT-PCR analysis (E). The mean fold change in expression ± SEM are
represented for the PHH. The mean fold change in expression of 3 biological repeats each
with 3 technical repeats are represented for HepG2/C3A. 2-way ANOVA followed by
Tukey’s post-hoc analysis was used to compare group means for qRT-PCR analysis. 1way ANOVA followed by Dunnett’s post-hoc analysis was used to compare group means
for Western blot analysis. ****p<0.0001; ***p<0.001, **p<0.01, *p<0.05
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Figure 3-10. Isoniazid increases human ALAS1 protein.
Western blot analysis of ALAS1 in primary human hepatocytes treated with 10 μM
rifampicin, 10 μM SPA70, 200 μM isoniazid, or a combination of these drugs (A), and a
dose response of isoniazid for 72 hours (B). qRT-PCR analysis of the expression of
ALAS1 in A (C). Western blot analysis of ALAS1 in HepG2/C3A treated with isoniazid
for 72 hours (D) and qRT-PCR analysis (E). The mean fold change in expression ± SEM
are represented for the PHH. The mean fold change in expression of 3 biological repeats
are represented for HepG2/C3A. HepG2/C3A. 2-way ANOVA followed by Tukey’s
post-hoc analysis was used to compare group means for qRT-PCR analysis. 1-way
ANOVA followed by Dunnett’s post-hoc analysis was used to compare group means for
Western blot analysis. ****p<0.0001; ***p<0.001, **p<0.01, *p<0.05
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rifampicin and isoniazid at millimolar concentrations (Tostmann, Boeree et al. 2008,
Singh, Sasi et al. 2011, Shih, Pai et al. 2013, Elmorsy, Attalla et al. 2017). Additionally,
due to the presence of iron in the FBS added to cell culture medium, the conditions
required for iron-mediated rescue by exogenous iron administration needed to be
established in the media conditions of HepG2/C3A. The iron-specific chelator, 4.7 μM
deferoxamine, decreased protein levels by 60% in HepG2/C3A at higher than 18.8 μM
(p<0.0001), by 40% at 4.7 μM (p<0.0001), and by 10% at 1.2 μM (p<0.01), after 24
hours of treatment in 10% FBS (2.6 μM iron; Figure 3-11A). FeCl3 administration of as
little as 0.1 μM in 1% FBS (0.26 μM iron; Figure 3-11B) increased FECH protein levels
2-fold up to 3-fold at 1 μM in HepG2/C3A after 24 hours of treatment (p<0.0001). FECH
was not increased due to additional iron administration in 10% FBS (2.6 μM iron; data
not shown). The 40% (p<0.05) decrease in FECH protein expression by deferoxamine is
rescued with increasing amounts of exogenously administrated FeCl3 where there is no
significant difference in FECH expression between the combination of 4.7 μM
deferoxamine and 0.1 to 100 μM FeCl3 compared to the vehicle control treatment. There
is a significant (p<0.0001) difference between 4.7 μM deferoxamine and the combination
of 4.7 μM deferoxamine and 100 μM FeCl3 (Figure 3-11C). To derive the media
conditions where iron-limiting conditions can decrease FECH protein levels and where
this can be rescued by exogenous iron supplementation requires a decrease of FECH in
10% FBS (2.6 μM iron) due to 4.7 μM deferoxamine.
The Isoniazid and Vitamin B 6 Conjugate, PIH, Down-Regulates Human FECH
Protein
After establishing that iron-levels affect FECH in our model system and in what
media conditions modulation of iron would produce observable effects for use as positive
biological controls on FECH protein up- or down-regulation, we next tested metabolites
that have been detected in humans following isoniazid treatment: isonicotinic acid,
acetyl-hydrazine, diacetyl hydrazine, acetyl-isoniazid, menadione (ROS), and noc-18
(NOS) (Hughes 1953, Preziosi and Porcellati 1953, Defranceschi and Zamboni 1954,
Johnson 1954, Zamboni and Defranceschi 1954, Kaneo, Kubo et al. 1981, Blair, Mansilla
Tinoco et al. 1985). Suspecting that the well-established vulnerability of FECH iron
depletion played a role, I selected an aroyl hydrazone adduct of isoniazid to test as well.
The aroyl hydrazone selected was an adduct of isoniazid and a vitamin depleted by
isoniazid treatment in humans, vitamin B6. I investigated a variety of isoniazid
metabolites (at 100 μM; as this was near the upper limit of what would be expected in
portal hepatocytes and enabled us to rule out metabolites that do not affect FECH or
ALAS1) on FECH protein expression in HepG2/C3A and found up-regulation of FECH
protein by FeCl3 and down-regulation by deferoxamine (Figure 3-12A) after 16 hours of
treatment similar to previous reports (FeCl3 was used as a positive control for FECH upregulation and deferoxamine was used as a positive control for FECH down-regulation)
(Taketani, Adachi et al. 2000, Crooks, Ghosh et al. 2010). I chose 16 hours because we
expected the effect of isoniazid metabolites to be detected earlier than isoniazid itself but
wanted to limit the amount of time for further breakdown products. An additional
consideration was of the reported long half-life of FECH, which precluded an earlier time
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Figure 3-11. Iron levels affect FECH levels.
Western blot analysis of FECH in HepG2/C3A treated with deferoxamine mesylate at 24
hours in 10% FBS containing serum (A), with FeCl3 at 24 hours in 1% FBS (B) and 10%
FBS (C), and FeCl3 in 10% FBS in the presence or absence of 4.7 μM deferoxamine (D).
The mean fold change in expression ± SEM of 3 biological repeats each with 3 technical
repeats are represented for HepG2/C3A. 1-way ANOVA followed by Dunnett’s post-hoc
analysis was used to compare group means for Western blot analysis. ****p<0.0001;
***p<0.001, **p<0.01, *p<0.05
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Figure 3-12. The effects of isoniazid metabolites on FECH and ALAS1 levels.
Western blot analysis of FECH (A) and ALAS1 (B) in HepG2/C3A treated for 16 hours
with the indicated compound at 100 μM. Western blot analysis (C) and qRT-PCR (D)
analysis of FECH in HepG2/C3A treated for 24 hours with the indicated dose of PIH.
Western blot analysis (E) and qRT-PCR (F) analysis of ALAS1 in HepG2/C3A treated for
24 hours with the indicated dose of hydrazine. Western blot analysis (G) and qRT-PCR
(H) analysis of ALAS1 in primary human hepatocytes treated for 24 hours with the
indicated dose of hydrazine. The mean fold change in expression ± SEM of 3 biological
repeats each with 3 technical repeats are represented for qRT-PCR analysis and Western
blot analysis for FECH, and 3 biological repeats for ALAS1 Western blot analysis. 2-way
ANOVA followed by Tukey’s post-hoc analysis was used to compare group means for
qRT-PCR analysis. 1-way ANOVA followed by Dunnett’s post-hoc analysis was used to
compare group means for Western blot analysis. ****p<0.0001; ***p<0.001, **p<0.01,
*p<0.05
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point. Of the metabolites and reported by-products of isoniazid treatment tested, only PIH
down-regulated FECH levels (Figure 3-12A) by 50%. Note that 300 μM Noc18
decreased FECH protein (data not shown). PIH decreased the FECH protein by up to
40% at greater than 50 μM in a dose-dependent manner in HepG2/C3A (Figure 3-12C;
p<0.0001), but did not affect FECH mRNA (Figure 3-12D). In primary human
hepatocytes, 72 hour daily administration of 50 μM or greater isoniazid was sufficient to
significantly reduce (p<0.05) FECH protein levels by about 50% (Figure 3-9B).
Considering that the treatment of active tuberculosis is 2 months long (first-line
therapy is daily oral doses of rifampicin, isoniazid, pyrazinamide, and ethambutol) and
for latent tuberculosis is 9 months daily oral dose of 5 mg/kg (or 15 mg/kg twice weekly),
and that plasma concentrations of isoniazid were 22-29 μM in a Moroccan population
(Ait Moussa, El Bouazzi et al. 2016).) Another study reported a plasma isoniazid C max of
between 10 μM and 50 μM (Aarnoutse, Kibiki et al. 2017). Therefore, an isoniazid dose
sufficient to decrease FECH liver protein should be achievable. At much higher doses of
isoniazid (800 μM; p<0.01) was required to significantly reduce FECH protein levels by
40%. This could be due to lower intracellular vitamin B6 concentrations between primary
human hepatocytes and HepG2/C3A or a less reactive ortholog of vitamin B 6 in the cell
culture media; 0.001 g/L pyridoxal HCl is in William’s E media, and 0.001 g/L
pyridoxine HCl is found in EMEM media. Pyridoxal HCl is much more efficient at
producing PIH when in the presence of isoniazid than is pyridoxine HCl (Figure 3-13I).
50 μM PIH was sufficient to significantly reduce (p<0.0001) FECH levels in
HepG2/C3A at 24 hours of treatment (Figure 3-12C). Due to the long half-life of FECH
(35 hours), lower PIH doses may exert a more severe effect than was observed in a short
period of treatment (Furukawa, Kohno et al. 1995).
The Isoniazid Breakdown Product, Hydrazine, Up-Regulates ALAS1 mRNA and
Protein
After determining that PIH decreased FECH protein levels, we then tested the
isoniazid metabolites tested for FECH modulation for their potential to up-regulate
ALAS1. ALAS1 protein levels were increased at 16 hours treatment by 5-fold (p<0.001)
by 100 μM hydrazine but were not affected by the isoniazid metabolites and break-down
products isonicotinic acid, acetyl-hydrazine, diacetyl hydrazine, acetyl-isoniazid,
menadione, and noc-18 in HepG2/C3A (Figure 3-12B). Hydrazine increased ALAS1
protein 3-fold at 100 μM (Figure 3-12E; p<0.01) and mRNA 2-fold (Figure 3-12F;
p<0.0001) at 50 μM in a dose-dependent manner in HepG2/C3A at 24 hours of
treatment. Likewise, hydrazine increased ALAS1 protein 3-fold at 50 μM (Figure 3-12G;
p<0.01) and mRNA 1.5-fold above 10 μM (Figure 3-12H; p<0.001) in a dose-dependent
manner in primary human hepatocytes. The dose of isoniazid required to produce a
significant increase (p<0.01) of 3-fold in ALAS1 protein levels is 800 μM. This dose is
far above plasma isoniazid doses in humans. However, N-alkylation of the heme moiety
in CYP450 enzymes and other proteins may lead to decreased levels of these proteins and
ultimate up-regulation of ALAS1 protein levels after depletion of the regulatory heme.
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Figure 3-13. Detection of PIH following isoniazid application.
PIH is formed from isoniazid and pyridoxal (A). LC/MS/MS analysis of PIH in hPXR
and mPxr-/- expressing C57BL/6 mouse livers (B), primary human hepatocytes cell
culture medium (C), and HepG2/C3A cell culture medium in a time dependent (D) and
dose (E) dependent manner after treatment with isoniazid. LC/MS/MS analysis of PIH in
HepG2/C3A cell culture medium treated for 24 hours with various amounts of pyridoxal
5’ phosphate (F), pyridoxal HCl (G), or pyridoxine HCl (H). LC/MS/MS analysis of PIH
in phosphate buffered saline treated with the indicated Vitamin B 6 (1 mM) analogue at
the indicated times and temperatures in the presence (I) or absence (J) of 1 mM isoniazid.
Western blot analysis of FECH in HepG2/C3A treated for 24 hours with pyridoxal
5’phosphate (K) or pyridoxal HCl (L) in the presence or absence of 200 μM isoniazid.
PIH levels are represented as the mean fold change of 3 biological replicates ± SEM for
the in vitro data and as the mean (n = 4-5 per group) ± SEM for the in vivo data. The
mean fold change in expression ± SEM 3 biological repeats each with 3 technical repeats
are represented for Western blot analysis for FECH. 1-way ANOVA followed by
Dunnett’s post-hoc analysis was used to compare group means for Western blot analysis
and LC/MS/MS analysis. ****p<0.0001; ***p<0.001, **p<0.01, *p<0.05
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PIH Is Detected after Treatment of Human Primary Cells, Human Cell Lines, and
Mice with Isoniazid
PIH formation was next detected and characterized in cell culture media with cells
present and mouse liver. 5 nmole/mg tissue PIH is detected in the livers of C57BL/6 mice
treated with isoniazid for 6 weeks (Figure 3-13B), 400 nM PIH is detected in the cell
culture medium of PHH treated for 72 hours (Figure 3-13C) with daily dosing of
isoniazid; and 0.5 μM is detected at 24 hours up to 1.5 μM at 96 hours in the cell culture
medium of HepG2/C3A in a time-dependent manner after a single dose of 200 μM
isoniazid (Figure 3-13D; p<0.0001) and 0.5 μM PIH is detected at 200 μM isoniazid up
to 1.2 μM PIH at 800 μM isoniazid in a dose-dependent manner after 72 hours of daily
isoniazid treatment in HepG2/C3A (Figure 3-13E; p<0.0001). Addition of the vitamin B6
analogues, pyridoxal 5’ phosphate (Figure 3-13F), pyridoxal HCl (Figure 3-13G), and
pyridoxine HCl (Figure 3-13H) result in a further increase of PIH when combined with
isoniazid. 25 μM pyridoxal 5’ phosphate combined with 200 μM isoniazid results in the
formation of 5 μM PIH up to 30 μM PIH at 100 μM pyridoxal 5’ phosphate and 200 μM
isoniazid in HepG2/C3A cell culture medium. 10 μM pyridoxal HCl combined with 200
μM isoniazid resulted in the formation of 3 μM PIH up to 27 μM PIH when 100 μM
pyridoxal HCl combined with 200 μM isoniazid in HepG2/C3A cell culture medium. 50
μM pyridoxine HCl combined with 200 μM isoniazid results in the formation of 1 μM
PIH up to 1.5 μM PIH at 100 μM pyridoxal HCl and isoniazid. The treatment
ofHepG2/C3A with 200 μM isoniazid alone at 24 hours did not decrease FECH protein
(72 hours is required for isoniazid-mediated FECH protein decrease), but the combination
of 200 μM isoniazid with 6 μM pyridoxal 5’ phosphate decreased FECH protein by 50%
up to 70% at 25 μ M pyridoxal 5’phosphate (Figure 3-13K; p<0.0001) or 25 μM
pyridoxal HCl (Figure 3-13L; p<0.05 at 25 μM; p<0.01 at 50 and 100 μM) decreased
FECH protein levels by 50%. 100 μM pyridoxine HCl and 200 μM isoniazid
combination did not affect FECH protein levels (data not shown).
PIH Is Formed in a Reaction between Isoniazid and Vitamin B 6 Analogues
No report exists of a definitive characterization of the formation (Figure 3-13A)
of PIH. Therefore, we next characterized the formation of PIH in enzyme-free conditions.
Briefly, 1 mM of each indicated compound was added to phosphate buffered saline and
allowed to incubate at the indicated temperature for the indicated time and then analyzed
by mass spectrometry for PIH. PIH is formed in a cell- and enzyme-independent reaction
by combining vitamin B6 analogs, such as pyridoxal 5’ phosphate, pyridoxal
hydrochloride, and to a lesser extent pyridoxine hydrochloride (Figure 3-13A, I and J).
The combination of isoniazid with pyridoxal hydrochloride produced two orders of
magnitude higher PIH (30-60 μM, depending on incubation time) than reaction of
isoniazid with pyridoxal 5’ phosphate (the enzymatically active form) formed PIH (0.30.6 μM). The combination of isoniazid and pyridoxine HCl produces a much lower
amount of PIH (0.1 μM) 1 mM PIH spontaneously breaks down to approximately 100
μM isoniazid in 37oC at 96 hours and to a much lower extent in 4oC (Figure 3-14). More
PIH is formed at 37oC following incubation at various times of vitamin B6 analogs

67

Figure 3-14. Detection of isoniazid following isoniazid application.
LC/MS/MS analysis of isoniazid in PBS treated with the indicated compounds for the
indicated time and the indicated temperature with (A) or without (B) 1 mM isoniazid
added. The mean ± SEM of 3 repeats are expressed.
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than is formed at4oC (Figure 3-13I). These data are characteristic of the thermodynamic
dehydration reaction (Figure 3-13A) that produces PIH from vitamin B6 analogs and
isoniazid.
Hydrazine Is Detected after Treatment of Human Primary Cells and Human Cell
Lines with Isoniazid
In PBS, relatively low levels of hydrazine are formed (150 nM hydrazine after
incubation of 1 mM isoniazid for 96 hours; Figure 3-15E). 8 μM hydrazine is detected at
24 hours (p<0.001) treatment of HepG2/C3A with a single dose of 200 μM isoniazid,
which increases to 9 μM at 48 hours, 12 μM at 72 hours, and 17 μM (Figure 3-15A) at
96 hours. In HepG2/C3A cell culture medium treated with 800 μM isoniazid daily for 72
hours there was 22 μM hydrazine detected (Figure 3-15B; p<0.0001), but only 3 μM
hydrazine was detected after 24 hours of treatment (Figure 3-15C; p<0.05). The cell
culture media of 3 donors of primary human hepatocytes were analyzed for hydrazine
concentration after 72 hour treatment of 200 μM isoniazid with media and drug refreshed
daily (Figure 3-15D). The amount of hydrazine detected varied considerably between
donors, 2 donors had approximately 2-5 μM of hydrazine detected in the cell culture
media when treated with isoniazid, but a third donor had approximately 50-120 μM
isoniazid detected dependent on treatment combination. This represents the average of 40
μM hydrazine detected following isoniazid treatment of primary human hepatocytes
(p<0.0001). Indeed, this wide range of hydrazine production could be reflected in the
varied response in ALAS1 induction in similar treatment conditions (Figure 3-10A).
PIH Decreases FECH Protein Levels by Decreasing Iron Availability
Considering the vulnerability of FECH to low iron conditions, especially in the
presence of iron chelators, we next tested whether exogenous iron application would
rescue the 40% decrease in FECH levels at 24 hours from 50 μM PIH-mediated depletion
of the regulatory heme pool over time. Therefore, a lower dose administered over a
period of months may be required for the effect to be observed in vivo. Likewise, twentyfour hour treatment of primary human hepatocytes with 50 μM hydrazine resulted in a
significant 3-fold increase (p<0.01) in ALAS1 protein levels (Figure 3-12G). Indeed,
hydrazine concentrations increase both with length of treatment and with number of
treatments. The formation of hydrazine may depend on amidase activity (Sarich, Adams
et al. 1999) and the activation of hydrazine to interact with cellular proteins may require
activation by P450 enzymes (Nelson, Mitchell et al. 1976, Lauterburg, Smith et al. 1985,
Delaney and Timbrell 1995, Sarich, Adams et al. 1999). Human cell lines and primary
hepatocytes may not quantitatively reflect the in vivo activity of enzymes that metabolize
xenobiotics (Guillouzo, Morel et al. 1993, Bjornsson, Callaghan et al. 2003, Guillouzo
and Guguen-Guillouzo 2008, Turpeinen, Tolonen et al. 2009). Thus, higher levels of
hydrazine may be formed in model systems with more CYP450 activity.
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Figure 3-15. Detection of hydrazine adduct following isoniazid application.
LC/MS analysis of hydrazine-adduct in HepG2/C3A cell culture media at various times
after treatment with a single dose of 200 μM isoniazid (A), various single isoniazid doses
after 24 hours (C), and 3 daily isoniazid doses at 72 hours (B). LC/MS analysis of
hydrazine-adduct in primary human hepatocyte cell culture media at 72 hours after 3
daily doses of 200 μM isoniazid (D). LC/MS analysis of phosphate buffered saline after
96 hour incubation with 1 mM isoniazid at the indicated temperature (E). Hydrazineadduct levels in HepG2/C3A and phosphate buffered saline are represented as the mean ±
SEM of 3 biological replicates. Hydrazine-adduct levels in primary human hepatocytes
are represented as the mean +/- SEM of 3 biological and 3 technical replicates. 2-way
ANOVA followed by Tukey’s post-hoc analysis was used to compare group means for
LC/MS analysis of primary human hepatocytes. 1-way ANOVA followed by Dunnett’s
post-hoc analysis was used to compare group means for LC/MS/MS analysis of
HepG2/C3A and phosphate buffered saline. ****p<0.0001; ***p<0.001, **p<0.01,
*p<0.05
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down-regulation and to associate this with iron chelation directly. In HepG2/C3A
(Figure 3-16A) and PHH (Figure 3-16B), the decrease in FECH protein levels due to 50
μM PIH can be rescued by the co-administration of FeCl3. 50 μM PIH treatment of
HepG2/C3A for 24 hours results in a 40% decrease of FECH protein (p< 0.05) compared
to PBS treatment (Figure 3-16A). The addition of 0.01 μM FeCl3 abrogates the
significance of the decrease in FECH protein due to 50 μM PIH and the addition of 10
and 100 μM FeCl3 results in a significant increase of FECH protein compared to 50 μM
PIH. Isoniazid treatment of PHH for 24 hours results in a 40% decrease of FECH protein
(p< 0.01) that is not rescued by FeCl3 addition (Figure 3-16B). However, PIH treatment
of PHH for 24 hours results in a 40% decrease of FECH protein (p< 0 .01) that is
abrogated by 0.1 and 1 mM FeCl3. PIH (Figure 3-16D), similar to (Figure 3-16C)
deferoxamine, chelates iron. The CAS shuttle assay has iron present and chelation of this
iron results in a decrease of absorbance at 630 nm. In other words, the more free iron
available, the higher the absorbance at 630 nm. This iron chelation is also seen due to the
product of pyridoxal HCl and isoniazid formation at 96 hours (Figure 3-16E; p< 0.0001)
in 37oC in PBS and in HepG2/C3A cell culture medium (Figure 3-16F; p< 0.01) treated
for 24 hours at 50 μM pyridoxal HCl and 200 μM isoniazid and p<0.0001 at 100 μM
pyridoxal HCl and 200 μM isoniazid). Together these data demonstrate the PIH-mediated
iron chelation decreases FECH levels.
Proteomics Profiling of hPXR Mice Treated with Rifampicin and Isoniazid
Introduction
After characterizing the effect of isoniazid metabolites on the heme biosynthesis
pathway that may lead to PPIX accumulation, the possible role of rifampicin was
investigated by TMT-labeled proteomics screening of mice treated with rifampicin and
isoniazid. Previous reports have shown that isoniazid alone is not sufficient for PPIX upregulation of 60-fold (Li, Lu et al. 2013, Sachar, Li et al. 2016). Clustering analysis
revealed similar protein changes within groups (Figure 3-17 and Figure 3-18).
Proteomics profiling identified proteins that (1) were changed in each treatment group
and the overlap between treatment groups and (2) proteins changed in pathways relevant
to heme synthesis and degradation, CYP450 and steroid metabolism enzymes, nuclear
receptors, organic transporters, iron metabolism, oxidative stress, [Fe-S] cluster assembly
machinery, wound healing and inflammation, vitamin B 6 metabolism, and [Fe-S] clustercontaining proteins. 8,466 proteins were identified and quantified. Compared to hPXR
mice administered control food and water, 101 proteins were increased in rifampicin and
isoniazid treated mPXR -/- mice, but were not increased in hPXR mice treated with
rifampicin and isoniazid (Figure 3-19). 179 proteins are up-regulated at a p < 0.01 in
hPXR mice treated with rifampicin and isoniazid compared to hPXR mice fed the control
diet and water (Figure 3-19). 101 proteins are up-regulated in mPxr -/- mice treated with
rifampicin and isoniazid compared to hPXR mice (Figure 3-20) on the control diet and
water. 49 proteins are up-regulated due to the combination of rifampicin and isoniazid in
both hPXR and mPxr -/- mice (Figure 3-20). 21 proteins are up-regulated in hPXR mice
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Figure 3-16. PIH decreases FECH levels by decreasing iron availability.
Western blot analysis of HepG2/C3A (A) and primary human hepatocytes (B) treated
with increasing doses of FeCl3 in the presence or absence of PIH in HepG2/C3A and the
presence and absence of PIH and isoniazid in primary human hepatocytes.
Spectrophotometric analysis of CAS shuttle assay of deferoxamine (C), PIH (D),
biochemical reaction products (E) of pyridoxal HCl and isoniazid, and HepG2/C3A cell
culture medium (F) treated with pyridoxal in the presence or absence of isoniazid (100
μM). The mean fold change in expression ± SEM of 3 biological repeats each with 3
technical repeats are represented for Western blot analysis for FECH in HepG2/C3A. The
mean fold change in expression +/- SEM of donors are represented for Western blot
analysis for FECH in primary human hepatocytes. Spectrophotometric analysis of the
background subtracted absorbance (630 nm) of the CAS shuttle solution is represented as
the mean ± SEM of 3 repeats for deferoxamine and PIH dilution and biochemical
reaction product, and 3 biological repeats each with 3 technical repeats for the
HepG2/C3A cell culture medium. 1-way ANOVA followed by Dunnett’s post-hoc
analysis was used to compare group means for Western blot analysis and
spectrophotometric analysis. ****p<0.0001; ***p<0.001, **p<0.01, *p<0.05
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Figure 3-17. Clustering analysis of top 100 most variable prote ins.
Hierarchical clustering of differentially expressed proteins due to treatment group. Low
expression proteins (peptide sequence matches < 10) were filtered and the top 100 most
variable proteins are displayed. Only changes with a significance of p < 0.01 are
displayed as determined by one-way ANOVA with Dunnett’s post-hoc analysis. Z-scores
are shown where red indicates up regulated and blue indicates down-regulated proteins.
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Figure 3-18. Clustering analysis of hPXR-dependent changes.
Clustering analysis of genes up-regulated in hPXR mice treated with rifampicin and
isoniazid compared to control hPXR mice and down-regulated in mPxr -/- mice treated
with rifampicin and isoniazid. Only changes with a significance of p < 0.01 are displayed
as determined by one-way ANOVA with Dunnett’s post-hoc analysis. Z-scores are
shown where red indicates up regulated and blue indicates down-regulated proteins.
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Figure 3-19. Venn diagram showing the overlap between proteins up-regulated in
hPXR and mPXR -/- mice treated with rifampicin and isoniazid.
Venn diagram displaying proteins up-regulated in hPXR and mPxr-/- mice treated with
rifampicin and isoniazid compared to control mice.

77

Figure 3-20. Venn diagram of the overlap in up-regulated proteins between all
treatment groups.
Venn diagram displaying proteins up-regulated in all treatment groups compared to
control. hPXR_I = hPXR mice treated with isoniazid, hPXR_R = hPXR mice treated with
rifampicin, KO_R_I = mPxr -/- mice treated with rifampicin and isoniazid, hPXR_R_I =
hPXR mice treated with rifampicin and isoniazid.
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treated with isoniazid, but not in other treatment groups, 210 proteins are up-regulated
due to rifampicin alone in hPXR mice, 70 proteins are up-regulated in mPxr-/- mice
treated with rifampicin and isoniazid, and 61 proteins are up-regulated due to rifampicin
and isoniazid in hPXR mice, but not in other groups (Figure 3-20). All of these changes
are significant p< 0.01. Only 4 proteins are up-regulated in all groups and only 13 are upregulated in all hPXR groups (Figure 3-20).
Heme Biosynthesis and Degradation
ALAS1 was highly up-regulated (1.9 fold-change in hPXR mice treated with
rifampicin and isoniazid, 2.6 fold-change in hPXR mice treated with isoniazid, and 1.4
fold-change in mPxr -/- mice treated with rifampicin and isoniazid), but not significantly
across groups (Table 3-1; p = 0.28). Interestingly ALAS2 was significantly (p =0.018)
changed at 1.38 fold in hPXR mice treated with isoniazid and 1.18 fold in mPxr -/- treated
with rifampicin and isoniazid up-regulated, but down-regulated due to rifampicin (0.73
fold) and the combination of rifampicin and isoniazid. Isoniazid up-regulates ALAS1 and
to a lesser magnitude ALAS2 (the presence of which may possibly be due to blood
contamination). Rifampicin may suppress ALAS2 levels in hPXR mice.
Uroporphyrinogen-III synthase (Uros) was significantly changed (p = 0.012) by an
increase of 1.19 fold in hPXR mice treated with rifampicin and isonaiazid and 1.31 fold
in hPXR mice treated with rifampicin and isoniazid as well as 1.38 fold increase in mPxr /- mice treated with rifampicin and isoniazid. These data suggest that Uros may be upregulated by rifampicin in an hPXR-independent manner. Protoporphyrinogen oxidase
(Ppox) is significantly down-regulated (p = 0.013) by all treatments in an hPXR
dependent manner by from 0.69 to 0.85 fold, and the effect may be more pronounced in
hPXR mice compared treated with rifampicin and isoniazid (0.69 fold) to mPxr -/- mice
(0.83 fold). Fech is down-regulated (p < 0.0001) due to all groups, but to a much lower
extent in hPXR mice treated with rifampicin (0.88 fold) to between 0.39 fold to 0.5 fold
in the groups treated with isoniazid. Biliverdin reductase (Blvra) is significantly (p =
0.032), but slightly (0.82 to 0.92 fold) down-regulated in all treatment groups
independent of hPXR status. NADPH-cytochrome P450 reductase (Por) was up-regulated
in both combination groups (1.28 fold to 1.12 fold) and due to rifampicin (1.18 fold), but
was slightly down-regulated due to isoniazid (0.92). In Fech m1Pas Balb/c mouse livers
with increased PPIX levels, Alas1 was increased and Alas2 was decreased (Davies,
Schuurman et al. 2005). Alas2, Ppox, and Fech from a complex in the mitochondria
(Medlock, Shiferaw et al. 2015).
CYP450 and Steroid Metabolism Enzymes
Cyp2b10 is the most up-regulated CYP450 and is significantly (p = 0.0003)
increased by rifampicin (2.49 fold) and rifampicin and isoniazid (4.95 fold) in hPXR mice
but not more than a 10% change in mPxr -/- mice or hPXR mice treated with isoniazid
(Table 3-2). 3-beta-hydroxysteroid dehydrogenase type 4 (Hsd3b4) was the most downregulated significantly (p = 0.0012) due to rifampicin (0.098 fold) in hPXR mice with a.
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Table 3-1.

Heme biosynthesis and degradation.
Fold Change to Control
hPXR

Protein Description

KO

GN

RIF/INH

INH

RIF

RIF/INH

p-Value

FDR

5-aminolevulinate synthase

Alas1

1.90

2.61

1.05

1.41

0.28

0.53

5-aminolevulinate synthase

Alas2

0.86

1.38

0.73

1.18

0.018

0.17

Delta-aminolevulinic acid
dehydratase
Porphobilinogen deaminase

Alad

0.96

1.00

1.02

0.95

0.75

0.87

Hmbs

1.04

0.99

1.10

1.05

0.67

0.8

Uroporphyrinogen-III synthase

Uros

1.19

1.09

1.31

1.38

0.012

0.16

Uroporphyrinogen
decarboxylase
Oxygen-dependent
coproporphyrinogen-III oxidase,
Protoporphyrinogen oxidase

Urod

0.92

1.03

0.94

0.92

0.33

0.58

Cpox

1.13

1.04

1.18

1.15

0.20

0.46

Ppox

0.69

0.81

0.85

0.83

0.013

0.16

Ferrochelatase,

Fech

0.39

0.50

0.88

0.43

0.000002

0.0026

Heme oxygenase 1

Hmox1

1.15

0.86

0.91

1.11

0.34

0.59

Heme oxygenase 2

Hmox2

0.96

0.98

0.89

0.88

0.22

0.48

Blvra

0.84

0.92

0.82

0.92

0.032

0.22

Ugt1a6

1.22

0.96

1.10

1.13

0.30

0.55

Por

1.28

0.92

1.18

1.12

0.019

0.18

Biliverdin reductase A
UDP-glucuronosyltransferase 16
NADPH--cytochrome P450
reductase
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Table 3-2.

CYP450 and steroid metabolism enyzmes.
Fold Change to Control
hPXR

Protein Description

KO

GN

RIF/INH

INH

RIF

p-Value

FDR

1.47

RIF/IN
H
0.53

Cytochrome P450 1A2

Cyp1a2

0.60

0.48

0.037

0.23

Cytochrome P450 2A12

Cyp2a12

0.98

0.78

1.53

0.91

0.022

0.19

Cytochrome P450 2A5

Cyp2a5

1.77

0.62

2.93

1.01

0.00076

0.047

Cytochrome P450 2B10

Cyp2b10

4.96

0.91

2.49

0.98

0.00032

0.030

Cytochrome P450 2C29

Cyp2c29

1.17

1.02

1.56

0.67

0.038

0.23

Cytochrome P450 2D10

Cyp2d10

0.98

0.90

1.03

0.99

0.92

0.97

Cytochrome P450 2D26

Cyp2d26

0.76

0.71

1.13

0.75

0.0021

0.072

Cytochrome P450 2E1

Cyp2e1

1.22

1.18

0.93

1.47

0.00035

0.032

Cytochrome P450 2F2

Cyp2f2

0.61

0.61

0.75

0.52

0.028

0.21

Cytochrome P450 2J6

Cyp2j6

0.98

0.89

1.04

1.06

0.68

0.82

Cytochrome P450 3A11

Cyp3a11

3.89

1.18

4.64

1.31

0.00086

0.050

Cytochrome P450 3A25

Cyp3a25

1.64

0.95

1.36

1.15

0.037

0.23

Cytochrome P450 4A10

Cyp4a10

2.38

1.61

4.45

1.78

0.012

0.15

Cyp7a1

1.08

0.65

0.86

1.85

0.095

0.33

Cyp7b1

0.49

0.55

0.39

0.64

0.12

0.36

Cyp27a1

0.70

0.73

0.82

0.80

0.032

0.22

Cyp51a1

0.94

0.66

1.30

1.56

0.43

0.66

Hmgcs1

1.51

1.29

1.74

2.53

0.036

0.22

Hmgcs2

1.26

1.55

1.23

1.19

0.027

0.20

Hmgcr

1.56

1.27

1.51

1.74

0.35

0.60

Hsd3b4

0.20

1.07

0.10

0.48

0.0012

0.058

Hsd11b1

0.99

1.00

0.83

1.09

0.75

0.87

Cholesterol 7-alphamonooxygenase
25-hydroxycholesterol 7-alphahydroxylase
Sterol 26-hydroxylase
Lanosterol 14-alpha
demethylase
Hydroxymethylglutaryl-CoA
synthase
Hydroxymethylglutaryl-CoA
synthase
3-hydroxy-3-methylglutarylcoenzyme A reductase
3 beta-hydroxysteroid
dehydrogenase type 4
Corticosteroid 11-betadehydrogenase isozyme 1
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lesser decrease (0.20 fold) in hPXR mice treated with rifampicin and isoniazid and a
further reduced decrease (0.48 fold) in mPxr-/- mice treated with rifampicin and isoniazid
Cyp3a11, the mouse CYP3A4 ortholog (Muruganandan and Sinal 2008), was
significantly changed (p = 0.0008) in all treatment groups, but to a much lower
magnitude (1.30 fold) in mPxr -/- mice and hPXR mice treated with isoniazid (1.18 fold)
than in hPXR mice treated with rifampicin (4.64 fold) and treated with both rifampicin
and isoniazid (3.89 fold). Several CYP450s were down-regulated due to isoniazid to a
much higher extent than in the rifampicin only treatments; Cyp1a2 (0.48 fold), Cyp2a12
(0.78 fold), Cyp2a5 (0.62 fold), and Cyp2d26 (0.71 fold). Cyp2e1 was significantly
changed (p = 0.00035) and was increased in hPXR mice treated with rifampicin and
isoniazid (1.22 fold) and with hPXR mice treated with isoniazid (1.18 fold). Cyp2e1 was
also increased in mPxr -/- mice treated with rifampicin and isoniazid (1.47 fold).
Polymorphisms associated with increased CYP2E1 function in humans leads to an
increased incidence of DILI (Leiro-Fernandez, Valverde et al. 2010, Gogtay,
Kapileshwar et al. 2016, Antonenko, Butov et al. 2017). Inhibition of Cyp2e1 has been
shown to be protective against isoniazid-induced hepatoxicity in mice (Lian, Zhao et al.
2017). Cyp2e1 WT mice may be more susceptible to DILI (Cheng, Krausz et al. 2013).
Therefore, the up-regulation of Cyp2e1 by rifampicin in an hPXR-dependent manner may
contribute to DILI.
Nuclear Receptors
Very few transcription factors were up- or down-regulated more than 10%. Hnf1a
is significantly changed (p = 0.026) and down-regulated in all rifampicin treatment
groups (0.79 to 0.87 fold) independent of hPXR status (Table 3-3). The glucocorticoid
receptor (Nr3c1) was significantly (p = 0.49) down-regulated by rifampicin in hPXR mice
(0.88 fold). Nuclear receptor subfamily 5 group A member 2 (Nr5a2) was significantly (p
= 0.016) down-regulated in hPXR mice treated with rifampicin (0.83 fold) and rifampicin
and isoniazid combination (0.80 fold). Human NR5A may up-regulate ALAS1 expression
(Ju, Mizutani et al. 2012).
Organic Transporters
Multidrug resistance protein 1A (Abcb1a) was significantly (p = 0.030) changed
in all rifampicin treatment groups (fold change 1.35 to 1.38) regardless of hPXR status
(Table 3-4). The canalicular multispecific oganic anion transporter 1 (Abcc2) was
significantly (p = 0.009) changed in all isoniazid groups with the hPXR groups with
isoniazid changed 0.84 fold, but the mPxr -/- mice treated with isoniazid and rifampicin
had a fold change of 0.68. The sodium/bile acid co-transporter (Slc10a1) was
significantly changed (p = 0.012) by isoniazid (1.30 fold), rifampicin (0.85), and the
combination of rifampicin and isoniazid (0.88 fold) in hPXR mice. The solute carrier
organic anion transporter family member 1A1 (Slc1a1) was significantly changed (p =
0.025) and is down-regulated in hPXR mice treated with rifampicin (0.55 fold) and the
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Table 3-3.

Nuclear receptors.
Fold Change to Control
hPXR

KO

Protein Description

GN

RIF/INH

INH

RIF

RIF/INH

p-Value

FDR

Aryl hydrocarbon receptor

Ahr

1.09

0.91

1.00

1.26

0.092

0.33

Hepatocyte nuclear factor 1-alpha

Hnf1a

0.87

0.97

0.82

0.79

0.027

0.20

Hepatocyte nuclear factor 4-alpha

Hnf4a

0.95

1.05

0.97

1.08

0.20

0.46

Oxysterols receptor LXR-alpha

Nr1h3

0.94

1.16

1.03

1.02

0.42

0.65

Bile acid receptor

Nr1h4

1.05

1.17

0.98

1.19

0.12

0.36

Retinoic acid receptor RXR-alpha

Rxra

0.88

1.03

0.83

0.95

0.12

0.37

Peroxisome proliferator-activated
receptor alpha
Nuclear receptor subfamily 1
group D member 1
Oxysterols receptor LXR-beta

Ppara

0.85

0.96

0.79

0.94

0.64

0.80

Nr1d1

0.32

0.32

0.51

0.90

0.37

0.61

Nr1h2

1.11

1.14

1.08

1.05

0.62

0.79

Bile acid receptor

Nr1h4

1.05

1.17

0.98

1.19

0.12

0.36

COUP transcription factor 1

Nr2f1

0.98

1.04

0.94

1.00

0.67

0.82

COUP transcription factor 2

Nr2f2

0.98

1.04

0.94

1.00

0.67

0.82

Nuclear receptor subfamily 2
group F member 6
Glucocorticoid receptor

Nr2f6

1.01

1.04

0.97

1.08

0.45

0.68

Nr3c1

0.91

1.03

0.88

0.96

0.049

0.25

Nr5a2

0.80

1.00

0.83

0.97

0.016

0.17

Nuclear receptor subfamily 5
group A member 2
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Table 3-4.

Organic transporters.
Fold Change to Control
hPXR

Protein Description

KO

GN

RIF/INH

INH

RIF

RIF/INH

p-Value

Multidrug resistance protein 1A

Abcb1a

1.39

1.08

1.40

1.35

0.030

FD
R
0.21

Multidrug resistance protein 1B

Abcb1b

1.26

1.06

1.27

1.19

0.13

0.38

Abcb4

1.22

1.03

1.11

1.11

0.41

0.64

Abcb11

1.00

0.85

1.01

0.88

0.051

0.25

Abcc2

0.85

0.85

1.04

0.68

0.0094

0.14

Slc10a1

0.88

1.31

0.85

0.92

0.019

0.18

Slco1a1

0.77

1.01

0.55

1.29

0.025

0.20

Multidrug resistance protein 3
Bile salt export pump
Canalicular multispecific organic
anion transporter 1
Sodium/bile acid cotransporter
Solute carrier organic anion
transporter family member 1A1
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combination of rifampicin and isoniazid (0.77 fold), but are up-regulated in mPxr -/- mice
treated with rifampicin and isoniazid (1.29 fold). Abcb1a was up-regulated and Abcc2,
Slc10a1, and Slco1a1 was down-regulated in Fech m1Pas Balb/c mice (Davies, Schuurman
et al. 2005).
Iron Metabolism
Lactotransferrin (Ltf) was significantly (p = 0.036) down-regulated in all
treatment groups (Table 3-5). Ltf was most down-regulated in mPxr -/- mice treated with
rifampicin and isoniazid (0.27 fold) and down-regulated to a lesser extent in hPXR mice
(0.38 to 0.40 fold). Ferritin light chain (Ftl1) was significantly (p = 8.42 X 10-5) downregulated in all treatment groups. Ftl1 is most severely down-regulated in hPXR mice
treated with rifampicin and isoniazid (0.28 fold), followed by hPXR mice treated with
isoniazid (0.36 fold), mPxr-/- mice treated with rifampicin and isoniazid (0.44 fold), than
hPXR mice treated with rifampicin (0.58 fold). Abcb7 is significantly changed (p = 0.019)
by 0.83 fold in hPXR mice treated with rifampicin and isoniazid to 0.79 fold in hPXR
mice treated with rifampicin and a more modest decrease in mPxr -/- mice treated with
rifampicin and isoniazid (0.91 fold). Ftl1 was up-regulated in Fech m1Pas Balb/c mice
(Davies, Schuurman et al. 2005).
Oxidative Stress
Phospholipid hydroperoxide glutathione peroxidase (Gpx4) was significantly
changed (p = 0.0015) in hPXR mice treated with rifampicin (1.56 fold) and the
combination of rifampicin and isoniazid (1.44 fold) and to a lower extent mPxr -/- mice
treated with rifampicin and isoniazid (Table 3-6). Many isoforms of glutathione S
transferase (Gst) mu, which detoxicfies electrophilic compounds and cluster on
chromosome 1p13.3 were significantly changed (p < 0.0001). Gstm1, 2, 3, 4, 5, 6, and 7
were increased 1.59 to 3 fold in hPXR mice treated with rifampicin and isoniazid, slightly
decreased 0.79 to 0.87 fold in hPXR mice treated with isoniazid, slightly increased in
mPxr-/- mice treated with rifampicin and isoniazid 1.16 to 1.61 fold, and with the highest
magnitude increase in hPXR mice treated with rifampicin 1.55 fold to 4.5 fold. The
increase due to rifampicin in hPXR mice was a higher magnitude than the increase in the
combination therapy for each protein. GSTM1 has been shown to be protective in humans
treated with anti-tubercular drugs and null alleles have been associated with a higher
incidence of hepatotoxicity (Gupta, Singh et al. 2013, Li, Long et al. 2013, Singla, Gupta
et al. 2014). Gsta1 was changed in a similar manner to the mu isoforms. Gstt2 was
significantly changed (p = 0.033) due to rifampicin and isoniazid (1.40 fold) and
rifampicin (1.51 fold). Catalase was also significantly changed (p = 0.038) and increased
in hPXR mice treated with both rifampicin and isoniazid (1.16 fold) and by rifampicin
(1.45 fold). NAD(P)H dehydrogenase [quinone] 1 (Nqo1) was significantly changed (p =
0.00027) and was increased in hPXR mice treated with rifampicin and isoniazid (1.52
fold) and rifampicin (2.6 fold) and in mPXR -/- mice treated with rifampicin and isoniazid
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Table 3-5.

Iron metabolism.
Fold Change to Control
hPXR

KO

Protein Description

GN

RIF/INH

INH

RIF

RIF/INH

p-Value

FDR

Serotransferrin

Tf

1.33

1.04

1.15

1.11

0.144145

0.397184

Transferrin receptor protein 1

Tfrc

1.28

0.98

1.13

1.14

0.46

0.68

Lactotransferrin

Ltf

0.40

0.38

0.38

0.27

0.036

0.23

Transferrin receptor protein 2

Tfr2

0.99

1.02

0.82

0.86

0.13

0.38

Hereditary hemochromatosis
protein homolog
Ferritin light chain 1

Hfe

0.93

0.92

0.90

0.94

0.70

0.84

Ftl1

0.28

0.36

0.58

0.44

8.42E-05

0.014

Ferritin heavy chain

Fth1

0.47

0.63

0.70

0.59

0.097

0.33

Cytoplasmic aconitate hydratase

Aco1

1.05

1.00

1.08

1.00

0.53

0.73

ATP-binding cassette sub-family B
member 7

Abcb7

0.83

0.98

0.79

0.91

0.019

0.18
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Table 3-6.

Oxidative stess.
Fold Change to Control
hPXR

Protein Description

GN

Glutathione synthetase

Gss

RIF/INH

KO

INH

RIF

RIF/INH

p-Value

FDR

0.95

0.80

0.91

0.76

0.084

0.31

Phospholipid hydroperoxide
glutathione peroxidase
Glutathione S-transferase Mu 1

Gpx4

1.44

1.05

1.56

1.23

0.0016

0.064

Gstm1

1.59

0.80

2.50

1.19

7.23E-06

0.0034

Glutathione S-transferase Mu 2

Gstm2

2.01

0.85

2.96

1.61

5.54E-06

0.0034

Glutathione S-transferase Mu 3

Gstm3

3.02

0.87

4.54

1.33

4.5E-06

0.0034

Glutathione S-transferase mu 4

Gstm4

1.50

0.84

2.37

1.28

9.418E-06

0.0034

Glutathione S-transferase Mu 5

Gstm5

1.35

0.88

1.79

1.14

5.69E-05

0.011

Glutathione S-transferase Mu 6

Gstm6

1.67

0.79

2.41

1.16

1.25E-05

0.0038

Glutathione S-transferase Mu 7

Gstm7

1.57

0.81

2.30

1.16

1E-05

0.0034

Glutathione S-transferase A1

Gsta1

1.72

0.86

2.70

1.40

0.00019

0.023

Glutathione S-transferase theta-1

Gstt1

1.08

1.12

1.30

0.92

0.22

0.48

Glutathione S-transferase theta-2

Gstt2

1.40

0.99

1.51

1.01

0.034

0.22

Fumarylacetoacetase

Fah

0.93

0.97

0.93

0.99

0.62

0.79

Catalase

Cat

1.16

1.02

1.44

1.08

0.038

0.23

Superoxide dismutase

Sod2

0.82

0.92

0.85

0.93

0.052

0.26

NAD(P)H dehydrogenase [quinone]
1

Nqo1

1.52

0.87

2.60

1.92

0.00027

0.029
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(1.92 fold). Nqo1 was decreased in hPXR mice treated with isoniazid (0.87 fold). Nqo1 is
protective against APAP- induced hepatotoxicity and is up-regulated in liver injury from
APAP (Hwang, Kim et al. 2015) and primary biliary cirrhosis (Aleksunes and Klaassen
2012). Gpx4, Gstm1, and Gstm5 were up-regulated in Fech m1Pas Balb/c mice (Davies,
Schuurman et al. 2005).
[Fe-S] Cluster Assembly Machinery
Cysteine desulfurase (Nfs1) was significantly (p = 0.042) changed in hPXR mice
by rifampicin and isoniazid (0.89 fold) and rifampicin (0.84 fold) and to a lower extent in
mPxr -/- mice treated with rifampicin and isoniazid (0.90 fold), but changed less than 4%
due to isoniazid in hPXR mice (Table 3-7). Adrenodoxin (Fdx1) was significantly (p =
0.016) decreased by all treatments, and may be decreased by isoniazid to a greater degree
than rifampicin. Fdx1 was slightly decreased by rifampicin in hPXR mice (0.84 fold), to a
greater degree by isoniazid (0.77 fold), and is most down-regulated by the combination of
rifampicin and isoniazid in hPXR mice (0.64 fold). Fdx1 is also down-regulated in mPxr /- mice treated with rifampicin and isoniazid (0.79 fold). Iron-sulfur cluster co-chaperone
protein (Hscb) is significantly changed (p = 0.0056). Hscb is increased to the greatest
degree in mPxr -/- mice treated with rifampicin and isoniazid (1.44 fold), less of an
increase was observed in hPXR mice treated with rifampicin (1.40 fold), and to a lower
extent in the other treatment groups. Hscb is increased in hPXR mice treated with
rifampicin and isoniazid (1.23 fold) and in hPXR mice treated with rifampicin (1.20 fold).
Iron-sulfur cluster assembly 1 homolog (Isca1) was significantly changed (p = 0.0037) by
down-regulation in all treatment groups from 0.66 to 0.81 fold. Putative transferase
CAF17 homolog (Iba57) was significantly (p = 0.0090) increased in hPXR mice treated
with rifampicin (1.15 fold) and mPxr -/- mice treated with rifampicin and isoniazid (1.14).
BolA-like protein 3 (Bola3) was significantly (p=0.012) changed in hPXR mice treated
with isoniazid (0.91 fold) and the combination of rifampicin and isoniazid (0.89 fold), but
was increased in hPXR mice treated with rifampicin (1.12 fold). Anamorsin (Ciapin1)
was significantly changed (p = 0.0095) and was up-regulated across treatment groups.
Ciapin 1 was increased 1.34 fold in hPXR mice treated with rifampicin, 1.28 fold when
treated with the combination of rifampicin and isoniazid, 1.19 fold when treated with
isoniazid alone, and 1.10 fold in mPxr -/- treated with rifampicin and isoniazid.
Wound Healing and Inflammation
Protein-glutamine gamma-glutamyltransferase 2 (Tgm2) was significantly
changed (Table 3-8; p = 0.0058). Tgm2 was up-regulated in hPXR mice treated with
rifampicin and isoniazid (1.12 fold) and rifampicin alone (1.19 fold). Tgm2 was downregulated in hPXR mice treated with isoniazid (0.81 fold) and mPxr -/- mice treated with
rifampicin and isoniazid (0.88 fold). Collagen alpha-1 (IV) (Col4a1) and collagen alpha1 (VI) (Col6a1) were significantly changed with p values of 0.0033 and 0.0091
respectively. Col4a1 and Col6a1 were increased in hPXR mice treated with rifampicin
and isoniazid (1.27 and 1.10 fold, respectively). Col4a1 and Col6a1 were decreased in
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Table 3-7.

[Fe-S] cluster assemblymachinery.
Fold Change to Control
hPXR

KO

Protein Description

GN

RIF/INH

INH

RIF

RIF/INH

p-Value

FDR

Cysteine desulfurase

Nfs1

0.89

0.96

0.84

0.90

0.042

0.24

Isoform 2 of Low molecular weight
phosphotyrosine protein phosphatase
Frataxin, mitochondrial

Acp1

0.96

0.98

1.03

1.00

0.63

0.80

Fxn

0.84

0.98

0.89

0.88

0.11

0.35

Ferredoxin-fold anticodon-binding
domain-containing protein 1 homolog
Adrenodoxin

Fdxacb1

1.06

0.96

1.09

1.15

0.94

0.98

Fdx1

0.64

0.77

0.84

0.79

0.0016

0.064

NADPH:adrenodoxin oxidoreductase,

Fdxr

0.83

0.93

0.85

0.91

0.16

0.42

Stress-70 protein

Hspa9

1.07

1.07

0.94

1.05

0.32

0.57

Iron-sulfur cluster co-chaperone
protein
GrpE protein homolog 2,
mitochondrial
GrpE protein homolog 1

Hscb

1.23

1.20

1.40

1.44

0.0056

0.11

Grpel2

1.24

1.18

1.04

1.19

0.78

0.89

Grpel1

1.10

1.07

0.98

1.05

0.69

0.83

Glutaredoxin-related protein 5

Glrx5

1.60

1.69

1.24

1.39

0.078

0.30

Iron-sulfur cluster assembly 1
homolog
Iron-sulfur cluster assembly 2
homolog
Putative transferase CAF17 homolog

Isca1

0.76

0.68

0.66

0.81

0.0037

0.095

Isca2

0.90

0.91

1.13

1.02

0.20

0.46

Iba57

1.00

0.98

1.15

1.14

0.0090

0.14

Nfu1

0.82

0.98

0.90

1.01

0.13

0.37

NFU1 iron-sulfur cluster scaffold
homolog
NFU1 iron-sulfur cluster scaffold
homolog, mitochondrial (Fragment)
BolA-like protein 3

Nfu1

0.82

0.99

0.87

0.96

0.059

0.27

Bola3

0.89

0.91

1.12

1.03

0.012

0.15

Iron-sulfur protein

Nubpl

1.27

1.77

1.37

0.91

0.067

0.29

Cytosolic Fe-S cluster assembly factor

Nubp1

1.07

0.91

0.94

1.03

0.33

0.58

Cytosolic Fe-S cluster assembly factor

Nubp2

1.03

1.06

1.01

1.14

0.35

0.60

Anamorsin

Ciapin1

1.28

1.19

1.34

1.10

0.0095

0.14

Bola2

0.98

0.90

0.92

0.88

0.58

0.77

Cytosolic Fe-S cluster assembly factor

Narfl

1.00

1.01

1.06

1.01

0.65

0.81

Probable cytosolic iron-sulfur protein
assembly protein
MMS19 nucleotide excision repair
protein homolog

Ciao1

0.96

1.03

0.98

1.12

0.10

0.34

Mms19

0.96

0.96

0.97

1.07

0.22

0.48

BolA-like protein 2
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Table 3-8.

Wound healing and inflammation.
Fold Change to Control
hPXR

KO

Protein Description

GN

RIF/INH

INH

RIF

RIF/INH

p-Value

FDR

Glutamine synthetase

Glul

0.85

1.03

0.72

1.17

0.16

0.41

Carbonic anhydrase 3

Ca3

1.23

1.14

1.18

1.19

0.81

0.91

Transforming growth factor-betainduced protein ig-h3
Protein-glutamine gammaglutamyltransferase 2
SPARC

Tgfbi

0.88

0.75

0.60

0.69

0.44

0.67

Tgm2

1.12

0.81

1.19

0.88

0.0059

0.12

Sparc

0.85

0.86

0.72

0.83

0.089

0.32

Collagen alpha-1(III) chain

Col3a1

1.94

0.34

0.28

0.35

0.056

0.26

Collagen alpha-1(IV) chain

Col4a1

1.27

0.86

0.83

0.90

0.0033

0.089

Collagen alpha-1(VI) chain

Col6a1

1.10

0.67

0.47

0.63

0.0091

0.14

Annexin A2

Anxa2

1.43

0.89

0.94

1.08

0.30

0.55

Annexin A5

Anxa5

1.56

0.98

1.57

1.22

0.032

0.22

Bgn

1.37

0.94

0.74

1.08

0.44

0.67

G1/S-specific cyclin-D1

Ccnd1

1.40

0.69

1.24

1.03

0.19

0.45

T-lymphocyte activation antigen
CD86

Cd86

1.08

0.86

1.03

0.96

0.13

0.38

Biglycan
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the other treatment groups from 0.83 to 0.90 fold and 0.47 to 0.67 fold, respectively.
Annexin A5 (Anxa5) was significantly changed (p = 0.031). Anxa5 was increased by 1.56
fold in hPXR mice treated with rifampicin and isoniazid and rifampicin alone, but less
than 2% change was observed in hPXR mice treated with isoniazid. Anxa5 was also
decreased in mPxr -/- treated with rifampicin and isoniazid (1.22 fold).
Vitamin B 6 Metabolism
The vitamin B6 metabolism enzymes pyridoxal kinase (Pdxk), pyridoxal
phosphate phosphatase (Phospho2), and pyridoxal-dependent decarboxylase domaincontaining protein 1 (Pdxdc1) were not significantly changed (Table 3-9). Pyridoxal
phosphate phosphatase (Pdxp) was significantly changed (p = 0.0004) by 1.49 fold in
hPXR mice treated with rifampicin and isoniazid, 2.18 fold in hPXR mice treated with
rifampicin alone, and 1.34 fold in mPxr -/- mice treated with rifampicin and isoniazid.
Pdxp dephosphorylates pyridoxal 5’ phosphate to 4-pyridoxic acid, but also
dephosphorylates pyridoxine 5’ phosphate, and pyridoxamine 5’ phosphate (Jang, Kim et
al. 2003). Increased degradation of vitamin B6 by up-regulation of Pdxp by rifampicin
may reduce the amount of PIH formed and this may be protective. Further investigation
is warranted to determine into this effect that may further deplete vitamin B 6 levels and
contribute to the development of peripheral neuropathy.
[Fe-S] Cluster Containing Proteins
There is not a significant global down-regulation of Fe-S containing proteins due
to isoniazid (Table 3-10). NADH dehydrogenase [ubiquinone] iron-sulfur protein 8
(Ndufs8) was significantly (p = 0.0012) changed. Ndufs8 was decreased in all treatment
groups (only 4% decrease due to isoniazid in hPXR mice) by 0.91 fold in hPXR mice
treated with rifampicin and isoniazid, 0.82 fold in hPXR mice treated with rifampicin,
and by 0.75 fold in mPxr -/- treated with rifampicin and isoniazid. Succinate
dehydrogenase [ubiquinone] iron-sulfur subunit (Sdhb) was significantly changed (p =
0.035). Sdhb was decreased in hPXR mice treated with rifampicin and isoniazid (0.86
fold) and with rifampicin alone (0.92 fold), but changed less than 1% in hPXR mice
treated with isoniazid and in mPxr -/- treated with rifampicin and isoniazid. The changes
in Sdhb may be hPXR mediated by rifampicin and further decreased by isoniazid
administration. NADH dehydrogenase [ubiquinone] iron-sulfur protein 7 (Ndufs7) was
significantly changed (p = 0.012) and was increased in hPXR mice treated with isoniazid
(1.14 fold) and mPxr -/- mice treated with rifampicin and isoniazid (1.23 fold). NADH
dehydrogenase [ubiquinone] iron-sulfur protein 4 (Ndufs4) was significantly changed (p
= 0.034) and increased by isoniazid (1.12 fold) and rifampicin (1.10 fold) in hPXR mice
and increased in mPxr -/- mice treated with rifampicin and isoniazid (1.23 fold). Ironresponsive element-binding protein 2 (Ireb2) was significantly (p = 0.039) increased in
all treatment groups 1.18 to 1.42 fold. Fdx, Fech, Fdx and Fech were significantly
decreased by isoniazid treatment. Cisd1, Cisd2, and Cisd3 are non-significantly downregulated by approximately 10% by isoniazid. The NADH dehydrogenase [ubiquinone]
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Table 3-9.

Vitamin B 6 metabolism.
Fold Change to Control
hPXR

Protein Description

KO

GN

RIF/INH

INH

RIF

RIF/INH

p-Value

FDR

Pdxk

1.07

1.05

1.13

1.17

0.75

0.87

Pyridoxal phosphate phosphatase

Pdxp

1.49

0.95

2.18

1.34

0.00049

0.038

Pyridoxal phosphate phosphatase

Phospho2

1.04

1.08

1.07

1.04

0.90

0.96

Pdxdc1

0.97

1.03

1.01

1.02

0.84

0.92

Pyridoxal kinase

Pyridoxal-dependent decarboxylase
domain-containing protein 1
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Table 3-10.

[Fe-S] cluster containing proteins.
Fold Change to Control
hPXR

Protein Name

KO

GN

RIF/INH

INH

RIF

RIF/INH

p-Value

FDR

NADH dehydrogenase [ubiquinone]
iron-sulfur protein 3
NADH dehydrogenase [ubiquinone]
iron-sulfur protein 2
CDGSH iron-sulfur domaincontaining protein 1
NADH dehydrogenase [ubiquinone]
iron-sulfur protein 8
Succinate dehydrogenase
[ubiquinone] iron-sulfur subunit
NADH dehydrogenase [ubiquinone]
iron-sulfur protein 7
NADH dehydrogenase [ubiquinone]
iron-sulfur protein 4
NFU1 iron-sulfur cluster scaffold
homolog
NFU1 iron-sulfur cluster scaffold
homolog, mitochondrial (Fragment)
Iron-sulfur protein NUBPL

Ndufs3

0.94

1.09

1.01

1.09

0.74

0.86

Ndufs2

1.00

1.04

1.03

1.04

0.65

0.81

Cisd1

0.90

0.97

0.98

1.03

0.14

0.39

Ndufs8

0.91

0.96

0.82

0.75

0.0012

0.058

Sdhb

0.86

0.99

0.92

0.99

0.036

0.22

Ndufs7

1.00

1.14

1.09

1.20

0.012

0.15

Ndufs4

0.94

1.12

1.10

1.23

0.033

0.22

Nfu1

0.82

0.98

0.90

1.01

0.13

0.37

Nfu1

0.82

0.99

0.87

0.96

0.059

0.27

Nubpl

1.27

1.77

1.37

0.91

0.067

0.29

Iron-sulfur cluster assembly enzyme

Iscu

0.95

1.01

0.96

0.98

0.84

0.93

NADH dehydrogenase [ubiquinone]
iron-sulfur protein 6
NADH dehydrogenase [ubiquinone]
iron-sulfur protein 5
CDGSH iron-sulfur domaincontaining protein 2
Iron-responsive element-binding
protein
2-oxoglutarate and iron-dependent
oxygenase domain-containing protein
2
Probable cytosolic iron-sulfur protein
assembly protein
Iron-sulfur cluster assembly 2
homolog, mitochondrial
CDGSH iron-sulfur domaincontaining protein 3
2-oxoglutarate and iron-dependent
oxygenase domain-containing protein
3
Aldehyde oxidase 1

Ndufs6

0.94

0.96

0.86

0.82

0.13

0.38

Ndufs5

0.87

0.97

0.91

1.03

0.22

0.48

Cisd2

0.90

0.88

0.89

0.82

0.94

0.98

Ireb2

1.19

1.21

1.42

1.28

0.039

0.23

Ogfod2

1.11

0.97

1.15

0.99

0.51

0.71

Ciao1

0.96

1.03

0.98

1.12

0.10

0.34

Isca2

0.90

0.91

1.13

1.02

0.20

0.46

Cisd3

0.84

0.88

1.02

1.07

0.060

0.27

Ogfod3

1.03

0.98

0.91

0.87

0.25

0.51

Aox1

1.30

0.82

1.65

1.48

0.0023

0.075

Xdh

0.70

0.70

0.75

0.98

0.0079

0.13

Xanthine dehydrogenase/oxidase
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or complex 1 is composed of multiple sub-units and contains 8 [Fe-S] clusters; multiples
of [2Fe-2S], [4Fe-4S], and [3Fe-4S]. Ndufs8 is significantly down-regulated by isoniazid,
but contains 2 [4Fe-4S] clusters. (Loeffen, Smeitink et al. 1998) Sdhb contains 3 [Fe-S]
clusters; [2Fe-2S], [4Fe-4S], and [3Fe-4S] and is down-regulated by rifampicin and
isoniazid in hPXR mice. Aox1 and Adh are [2Fe-2S]-containing proteins that are also
down-regulated by isoniazid. The effect of isoniazid on [Fe-S] clusters may be specific to
[2Fe-2S] clusters.
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CHAPTER 4.

DISCUSSION

Previous Animal Models of Isoniazid DILI
Isoniazid displays different hepatotoxic patterns dependent on dose and animal
model. Different groups have examined the role of isoniazid in anti-tubercular therapy
DILI and have reached different conclusions. Therefore, the role of isoniazid in antitubercular therapy toxicity remains elusive. Studies performed in rats and human liver
microsomes continue to form the consensus for the isoniazid/hydrazine model of liver
injury (Mitchell, Zimmerman et al. 1976, Nelson, Mitchell et al. 1976). A single large
dose (300 mg/kg) of isoniazid did not result in liver necrosis, but six lower oral doses
(100 mg/kg) produced small amounts of necrosis when the rats were pre-administered
phenobarbital (Nelson, Mitchell et al. 1976). However, administration of acetylhydrazine increased the amount of necrosis compared to the administration of acetylisoniazid. Further, the application of radiolabeled acetyl-isoniazid showed that the acetyl
group was detected bound to cellular proteins and that the inhibition of the acetylisoniazid to acetyl-hydrazine conversion decreased the necrosis seen after acetylisoniazid, but not acetyl-hydrazine application. Thus, isoniazid acetylation and
hydroxylation to acetyl-hydrazine and the interaction of further hydrolyzed acetylhydrazine with cellular proteins was the suggested route of toxicity. A contemporary
study may support this model with the findings that low N-acetyl transferase (NAT)
activity is associated with increased risk of hepatic damage with the suggestion that the
majority of acetyl-hydrazine is oxidized by CYP3A4 and 2E1 (Zabost, Brzezinska et al.
2013). This model is problematic in that it may not completely recapitulate the pathology
seen in clinic in combination therapy because the effects observed due to the combination
of rifampicin and isoniazid are a cholestatic pattern of injury and this relatively short
dosing regimen would not recapitulate chronic toxicity. This model may fit the clinical
pattern seen in acute, hepatocellular isoniazid toxicity resulting from large doses of
isoniazid, but not chronic, cholestatic rifampicin and isoniazid toxicity.
Treatment of rats with acetyl hydrazine or acetyl isoniazid can cause
hepatotoxicity, but isoniazid treatment itself does not cause toxicity in rats (Black,
Mitchell et al. 1975, Nelson, Mitchell et al. 1976). When the acetyl group is radio-labeled
in acetyl isoniazid, but not the aromatic ring, covalent binding of liver proteins was
observed (Mitchell, Zimmerman et al. 1976, Nelson, Mitchell et al. 1976). This suggests
that the toxicity observed in rats after treatment of acetyl isoniazid was due to the
breakdown product of acetyl isoniazid, acetyl hydrazine. However, high doses of
hydrazine administered to mice resulted in hepatotoxicity, but not high doses of acetyl
hydrazine (Richards, Chau et al. 2004). There is no validated animal model that captures
the chronic cholestatic pattern of hepatotoxicity seen in humans taking rifampicin and
isoniazid as part of a multi-drug anti-tubercular therapy (Boelsterli and Lee 2014). A
previous report (Li, Lu et al. 2013) that linked hPXR to rifampicin and isoniazid
hepatotoxicity in mice only shows bile plugs on histopathologic examination without
semi-quantitative histopathologic scoring of lesions. Multiple high doses of isoniazid can
cause hepatocellular toxicity in rats pre-treated with phenobarbital, but this does not
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recapitulate the human pattern of toxicity. (Mitchell, Zimmerman et al. 1976) Rats could
be a poor model system due to the lack of a gall bladder which may be required for
cholestatic hepatotoxicity or due to the differences in isoniazid bound proteins in rat,
mouse, and human microsomes (McKennis, Yard et al. 1956, Metushi, Cai et al. 2014).
There are two large differences in bile storage in mice and rats. The first is that mouse
bile is more concentrated than rat bile when excreted into the duodenum (McMaster
1922). Indeed, bile does not become more concentrated in rat even in stasis, whereas it
does in the mouse. The other difference is that the gall bladder serves as a reservoir in
mice and secretes bile upon relaxation of the sphincter of Oddi by cholecystokinin
induced by a fatty meal. In contrast, the sphincter of Oddi is relaxed in rats. Bile in rats is
not concentrated in the gall bladder, but in the liver unlike in mice whose livers see much
lower concentrations of bile acid constituents. Therefore, it may be inappropriate to draw
too many conclusions about cholestatic liver injury from rat models.
Failure to Re -Capture DILI Phenotype in Mouse Model
The Hepatotoxicity of PPIX
The relationship between PPIX and hepatotoxicity has been reported previously
(Davies, Schuurman et al. 2005, Lyoumi, Abitbol et al. 2011, Liu, Yan et al. 2015). The
mechanism of toxicity may depend on the site of PPIX accumulation. For example, the
intracellular accumulation of PPIX in hepatocytes is associated with a hepatocellular
subtype of liver injury, whereas extracellular accumulation in the bile is associated with a
cholestatic subtype. The site of accumulation differs between strains of mice.
BALB/cm1Pas and C57BL/6m1Pas mice have a point mutation in the Fech gene and express
a protein with less than 5% of the activity of the original enzyme (Davies, Schuurman et
al. 2005). These mice develop phototoxicity and are more vulnerable to griseofulvin
induced hepatotoxicity. Female C57BL/6m1Pas and BALB/c m1Pas mice were compared at
12-14 weeks of age. C57BL/6m1Pas mice had porphyrin deposits in Kupffer cells and
hepatocytes, whereas in BALB/c m1Pas porphyrin was deposited into bile canaliculi
(Lyoumi, Abitbol et al. 2011). BALB/cm1Pas mice had 7-fold increases in AST and ALT, 8fold increase in ALP, and a 71-fold increase in total bilirubin. However, the changes in
LFTs for C57BL6m1Pas mice were less marked. C57BL/6 mice had a 4-fold increase in
AST, a 5-fold increase in ALT, a 1.5-fold increase in ALP, and a 2.5-fold increase in
bilirubin. The pattern of PPIX deposition matches the pattern in the degree of LFT
changes; the ALT/ALP ratio for BALB/c m1Pas mice of 0.74, a more than 2-fold increase in
ALP, and a 71-fold increase in total bilirubin suggested an intrahepatic cholestatic type of
liver injury (Robles-Diaz, Garcia-Cortes et al. 2015). Unfortunately, the authors did not
test for direct bilirubin so a splenic or hematological source cannot be ruled out. On the
other hand, the ALT/ALP ratio for C57BL/6m1Pas mice is 2.7 and is associated with a more
than 2-fold increase in ALT and a less than 2-fold increase in ALP suggesting a
hepatocellular type of liver injury. Interestingly, C57BL/6m1Pas mice had 8-fold higher
liver PPIX levels than BALB/c m1Pas mice, but histopathological signs of bile duct
destruction and sclerosing cholangitis were observed only in BALB/c m1Pas mice.
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Therefore, PPIX accumulation via genetic disruption of the heme biosynthetic enzyme,
FECH, is associated with a pattern of hepatotoxicity that is dependent upon the site of
PPIX accumulation and this may differ between mouse strains.
PPIX accumulation has been associated with pharmacologic disruption of heme
biosynthesis by both isoniazid and griseofulvin. Griseofulvin treatment of 14 days in
male FVB/NJ mice leads to an increase of PPIX, bile acids, and GSH in the liver.
Griseofulvin is metabolized by CYP450 enzymes to reactive metabolites that form
adducts with PPIX and N-methyl PPIX which may inhibit Fech. Griseofulvin upregulates Alas1 expression. These changes resulted in increased liver PPIX that was
associated with a bile duct blockage that resulted in increased bile acids that were not
associated with an increase in the enzymes responsible for bile acid synthesis (Liu, Yan
et al. 2015).
A recent report detailed the role that hPXR plays in rifampicin and isoniazid
induced hepatotoxicity (Li, Lu et al. 2013). This report discussed the finding of bile
plugs, high levels of PPIX in the bile, a 5-fold increase in ALT, a 2.2-fold increase in
ALP, and an ALT/ALP ratio of approximately 0.5 in hPXR, but not WT or mPxr -/- mice
treated with rifampicin and isoniazid compared to control hPXR mice. Rifampicin treated
hPXR mice had a 2-fold increase in ALT and a 1.5-fold increase in ALP. There was no
increase in ALT or ALP when hydrazine or acetyl-hydrazine was added with rifampicin,
but ALP and ALT increased only when isoniazid was administered with rifampicin. In
hPXR mice, rifampicin or isoniazid alone had a 5-fold increase in bile PPIX and
rifampicin and isoniazid combination treated mice had a 60-fold increase in bile PPIX. In
hPXR mice treated with both rifampicin and isoniazid, the addition of ALA resulted in a
10-fold increase in ALT and ALP. Semi-quantitative histopathologic scores were not
included in this report, nor were severe histopathologic signs of liver injury observed
apart from bile plugs and signs of bile stasis. There is hPXR-mediated PPIX accumulation
associated with elevated LFTs due to the combination of rifampicin and isoniazid with an
unfortunately mild degree of histopathologic change. The phenotype may have been
relatively mild, but the changes were hPXR-dependent. This phenotype may have been
achievable if the length of my study may have led to an increase in liver injury in two
control mice that may have been due to age.
Other studies have observed hPXR-independent DILI due to the combination of
rifampicin and isoniazid in mice in other strains of mice. Female WT CD-1 mice treated
via oral gavage with 75 mg/kg isoniazid and 150 mg/kg rifampicin for 1 week had
increased liver weight/body weight ratio, increased ALT, increased ALP, reduced GSH,
and increased caspase 3 cleavage. The observed hepatotoxicity was attenuated with coadministration of ursodeoxycholic acid, which is an hPXR agonist (Chen, Xu et al. 2011).
This toxicity is observed in mice expressing WT mPxr and is therefore independent of
hPXR. Male ICR mice treated via intraperitoneal injection with 75 mg/kg isoniazid and
150 mg/kg rifampicin for 21 days had elevated ALT and AST, 1.25-fold increase in liver
PPIX, and decreased Fech protein levels. These effects were attenuated by coadministration of curcumin (Kluth, Banning et al. 2007, He, Guo et al. 2017). Several
studies have shown that a low magnitude of increase in liver PPIX may not be required
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for hepatotoxicity. Male FVB/NJ wild type mice were treated with 400 mg/L isoniazid in
the drinking water and had 2-fold increase in liver PPIX at 3 days, 4-fold at 7 days, and
8-fold at 14 days with a 60% decrease in Fech protein and a 6-fold increase in Alas1
protein at 3 days through 14 days without significant mRNA changes. However, this was
not associated with hepatotoxicity via LFTs or histopathology. There is strong literature
evidence to support the relationship between PPIX and cholestatic liver injury. However,
I was not able to reliably or robustly induce PPIX accumulation in our mouse model. I
only robustly observed a 3-6 fold increase in liver PPIX in my in vivo studies. All of
these models lack evidence of definitive pathologic change, semi-quantitative
histopathologic examination.
Attempt to Establish an Animal Model of Rifampicin and Isoniazid DILI
I was unable to induce a robust hepatotoxicity phenotype in the hPXR mouse
model. The hepatotoxicity associated with combination anti-tubercular therapy is
cholestatic, whereas the hepatotoxicity associated with either rifampicin or isoniazid
alone is hepatocellular (Li, Lu et al. 2013, Boelsterli and Lee 2014, Wang, Pradhan et al.
2016). Furthermore, the combination therapy, due in part to the use of lower doses, is
chronic and typically develops after weeks or months of treatment. However, the
hepatotoxicity of the monotherapy is more typically acute and observed relatively quickly
after the administration of a supra-clinical dose, especially in the case of isoniazid (Li, Lu
et al. 2013, Boelsterli and Lee 2014, Wang, Pradhan et al. 2016). Additionally, the
molecular mechanism of cholestatic or hepatocellular pattern of liver injury would be
different from the other and may differ in the dependence upon hPXR status. Therefore,
to recapitulate the hepatotoxicity phenotype in hPXR mice, a relatively narrow set of
conditions may be required. A set of conditions, I was unable to recapitulate.
Findings of In Vivo Studies
In Vivo Study 1. The first mouse study (6 weeks, 100 mg/kg chow rifampicin,
and 400 mg/L water isoniazid) resulted in no increase in serum liver function enzyme
levels, no significant histopathologic change, and a slight increase in liver PPIX levels.
Rifampicin was added to the food because it was much less water soluble than isoniazid.
The increase in PPIX levels was much less than the increase observed in hPXR mouse
models with a hepatoxicity phenotype (Li, Lu et al. 2013). However, it was similar to the
increase observed due to isoniazid treatment alone (Sachar, Li et al. 2016). Isoniazid
decreased Fech protein levels and increased Alas1 protein levels in an hPXR-independent
manner (Figure 3-8). Rifampicin increased Cyp3a levels in an hPXR-dependent manner
(Figure 4-1). There was no significant differences in total bilirubin, direct bilirubin, ALT,
or ALP (Figure 4-2). There was no significant hepatopathic lesions observed by
histologic analysis.
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Figure 4-1.

In vivo study 1 Cyp3a expression.

Western blot analysis of Cyp3a in C57BL6 mouse liver after 6 weeks treatment with
rifampicin (100 mg/kg chow) and isoniazid (400 mg/L in drinking water).
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Figure 4-2.

In vivo study 1 endpoint LFTs.

Analysis of endpoint LFTs. ALT (A), ALP (B), total bilirubin (C), and direct bilirubin
(D) are displayed. Data are represented as the mean ± SEM.
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In Vivo Study 2. The second mouse study (6 months, 300 mg/kg chow
rifampicin, and 1.2 g/L water isoniazid) resulted in a significant increase in of direct
bilirubin and ALP in hPXR mice treated with both rifampicin and isoniazid (Figure 4-3).
Rifampicin increased Cyp3a protein expression (Figure 4-4) in an hPXR-dependent
manner. Isoniazid decreased (Figure 4-4) Fech expression and increases Alas1
expression. Histopathological examination (which was not reported previously (Li, Lu et
al. 2013) revealed the presence of hepatopathic lesions in hPXR mice treated with
rifampicin and isoniazid (Figure 4-5). However, the difference in the scoring of these
lesions between drug treatment groups in hPXR mice was not significant (Figure 4-6).
This was due the presence of hepatopathic lesions in 2 control treatment hPXR mice.
These mice were not older than other mice in the study, but at 8-10 months of age these
mice may have developed liver disease spontaneously. However, these mice were not
older than other mice in the study. Additionally, the Grubb’s test did not identify either of
these data points as an outlier.
In the context of the sole previous report of hPXR-dependent rifampicin and
isoniazid DILI in mice, the phenotype reported was replicated with more moderate
changes in terms of ALP and direct bilirubin (Figure 4-3) (Li, Lu et al. 2013). However,
ALT had no significant increase and histopathologic scoring reveal a significant increase
only in bile pigment (Figure 4-5). Additionally , many previous other studies reported
hPXR-independent rifampicin and isoniazid DILI have moderate, but significant changes
in LFTs, but not pathologic scoring (Chen, Xu et al. 2011, He, Guo et al. 2017).
In Vivo Study 3. Two problems with in vivo study 2 were the intragroup
variability and the low magnitude of histologic change. I addressed the variability by
administering rifampicin and isoniazid via oral gavage. I addressed the low magnitude of
changes by calculating the doses for study 2 based on (1) the estimated doses, (2)
literature reports, and (3) converting the human dose to the mouse dose. The third mouse
study (3.5 months, 80 mg/kg rifampicin and 75 mg/kg isoniazid administered by daily
oral gavage) was monitored for hepatotoxicity by weekly serum collections and analysis
of the liver function enzymes, ALT and ALP. At 3.5 months, no significant increases due
to any treatment was observed in liver function tests throughout the duration of the study.
The doses of rifampicin and isoniazid used in study 3 were lower than literature reports
of doses reported to cause hepatotoxicity after oral administration in mice (Chen, Xu et
al. 2011), lower than the doses used in study 2 (for isoniazid), and lower than the doses I
calculated based on the dose commonly administered in humans.
Suitability of Pyrazinamide Inclusion
Pyrazinamide is only used in combination treatment of M. tuberculosis to reduce
the duration of treatment. Pyrazinamide is a prodrug that is activated by a bacterial
enzyme. The PZase/nicotinamidase ecoded by the M. tuberculosis gene, pncA, converts
pyrazinamide to pyrazinoic acid. Pyrazynoic acid accumulations in M. tuberculosis at
acidic pH and causes cytosolic acidification (Zhang, Shi et al. 2013). Pyrazinamide can
also be activated by hypoxanthine oxidase to from the active form, 5-OH pyrazinoic acid.
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Figure 4-3.

In vivo study 2 endpoint LFTs.

ALP (A), ALT (B), direct bilirubin (C), and total bilirubin (D) are represented. Data are
expressed as the mean ± SEM. 1-way ANOVA followed by Dunnett’s post-hoc analysis
was used to compare group meansl. ****p<0.0001; ***p<0.001, **p<0.01, *p<0.05
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Figure 4-4.

In vivo study 2 gene expression changes.

Protein levels in livers of study mice. For 6 months, mice were provided 300 mg
rifampicin/kg in chow and 1.2 g/L isoniazid in water ad libitum. Livers were flash-frozen,
homogenized, and lysed before western blotting analysis was performed. Cyp3a (A, B),
Alas1 (C, D; shorter band is mature form), and Fech (E, F) levels are displayed.
HepG2/C3A transiently transfected with MT (lipid only), NT3 (non-targeting siRNA),
siRNA targeting gene being probed for, empty vector (EV), or target (FECH/ALAS1) are
used as controls. The lower band recognized by the Alas1 antibody is the mature, active
form of Alas1. Cyp3a (G), Fech (H), and Alas1 (I.) mRNA expression in the livers of
C57BL/6 mPxr -/- and hPXR mice. For 6 months, mice were provided 300 mg
rifampicin/kg in chow and 1.2 g/L isoniazid in water ad libitum. Mice were euthanized,
and their livers were collected and stored in RNAlater (Thermo Fisher; Waltham, ME) at
-80°C. RNAlater was removed and liver slices were washed with PBS before
homogenization on the Bullet Blender Storm 24 Homogenizer (Thomas Scientific;
Swedesboro, NJ). RNA was extracted and analyzed by qRT-PCR. The ΔΔCT method
was used to normalize fold change in expression to expression in the control group of
each mouse strain. 2-way ANOVA followed by Tukey’s post-hoc analysis was used to
compare group means. ****P<0.0001; ***P<0.001, **P<0.01, *P<0.05
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Figure 4-5.

Representative liver micrographs of in vivo study 2 mice.

20X Micrographs. Slides are stained with Hematoxylin and Eosin. Arrows indicate bile
plugs.
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Figure 4-6.

Histopathologic scores of in vivo study 2 mice.

Semi-quantitative histopathologic scoring was performed by a board certified vertinary
pathologist. Total hepatotopathy (A), inflammation score (B), karyomegaly (C), steatosis
(D), bile pigment (E), and necrosis (F) scores. Data are expressed as the mean ± SEM. 1way ANOVA followed by Dunnett’s post-hoc analysis was used to compare group
meansl. ****p<0.0001; ***p<0.001, **p<0.01, *p<0.05
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Indeed, 5-OH pyrazinamide, 5-OH pyrazinoic acid, and pyrazinoic acid were associated
with purine metabolism products in patients, but was not associated with hepatotoxicity
(Cao, Mi et al. 2018). Pyrazinamide is a pyrazine analogue of nicotinamine and is both
bactericidal and bacteriostatic. Pyrazinamide is typically administered as a dose of 15-30
mg/kg/day. Adding pyrazinamide to an anti-tubercular therapy regimen that contains
rifampicin and isoniazid results in a significant increase in the incidence of hepatotoxicity
(Chang, Leung et al. 2008). 0.8% of patients developed hepatotoxicity while taking a
combination of rifampicin and isoniazid, whereas 2.6% of patients taking pyrazinamide,
rifampicin, and isoniazid. The adjusted odds ratio for developing hepatotoxicity when
taking pyrazinamide, isoniazid, and/or rifampicin was 2.8 compared to taking only
isoniazid and pyrazinamide. Likewise, the combination of pyrazinamide with rifampicin
was significantly more likely to cause hepatotoxicity than preventative treatment
isoniazid alone with an odds ratio of 2.6 (van Hest, Baars et al. 2004). Inclusion of
pyrazinamide to the animals being administered rifampicin and isoniazid would have
likely increased the incidence and severity of liver injury based on observations from
previous reports. However, this hepatotoxicity from pyrazinamide, rifampicin, and
isoniazid would not have the evidence to suggest it was preventable by hPXR
antagonism.
Significance of PIH and Hydrazine Findings
Iron sulfur [2Fe-2S] clusters bind a [Cys-X-Cys-X-Cys-X-Cys] motif. Four
cysteine residues are conserved between Drosophila and humans, Cys-196, Cys-403,
Cys-406, and Cys-411 are ligands for the [2Fe-2S] cluster in FECH (Crouse, Sellers et al.
1996). NOS inhibits Fech in rat hepatocytes and purified recombinant human FECH
(Kim, Bergonia et al. 1995, Rouault and Klausner 1996). A labile iron sulfur [2Fe-2S]
cluster is found in animal ferrochelatase but is missing from the analogous plant,
bacterial, and yeast enzymes (Dailey, Finnegan et al. 1994, Ferreira and Gong 1995, Day,
Parsons et al. 1998). Therefore the [2Fe-2S] cluster does not appear to be necessary for
catalysis. However, in mammal enzymes, when this structure is targeted by NOS,
degradation of FECH/Fech are increased (Sellers, Johnson et al. 1996). Indeed, NOS
decrease the visible absorption spectrum of the [2Fe-2S] cluster of human and mouse
FECH as observed by EPR spectroscopy (Kim, Bergonia et al. 1995, Rouault and
Klausner 1996, Sellers, Johnson et al. 1996). The yeast enzyme was affected by NOS to a
much lower degree, presumably due to the lack of the [2Fe-2S] cluster. Iron limiting
conditions have previously been reported to decrease FECH protein levels, this was
shown to be due to the formation of an unstable protein with a half-life of about 1 hour
compared to the protein formed in iron replete conditions with a half-life of over 35 hours
(Crooks, Ghosh et al. 2010). Therefore, the iron-limiting conditions in the presence of the
vitamin B6-isoniazid conjugate, PIH, may lead to the formation of a FECH protein that is
less stable than the form formed in iron-replete conditions.
Isonicotinic acid, hydrazine, acetylisoniazid, acetyl hydrazine, diacetyl hydrazine,
and hydrazone derivatives of pyruvic and α-ketoglutaric acids have been identified as
metabolites of isoniazid (Hughes 1953, Preziosi and Porcellati 1953, Defranceschi and
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Zamboni 1954, Johnson 1954, Zamboni and Defranceschi 1954, Kaneo, Kubo et al. 1981,
Blair, Mansilla Tinoco et al. 1985). The aroyl hydrazone iron chelator, PIH, was the only
one tested found to decrease FECH protein levels (Figure 3-12A and Figure 3-12C).
This down-regulation was found to be iron-dependent (Figure 3-16A and Figure 3-16B).
The iron-limiting condition induced by deferoxamine has previously been shown to
reduce the half-life of FECH formed after treatment (Crooks, Ghosh et al. 2010). This
may be due to reducing the availability of iron to form [2Fe-2S] clusters or an effect at
another point in iron-sulfur cluster assembly machinery. Further studies such as EPR
spectroscopy of FECH formed following PIH application similar to a previous report
(Sellers, Johnson et al. 1996) to observe if purified recombinant FECH formed in the
presence of PIH differ from those formed in iron-replete conditions. Likewise, a
proteomics analysis following isoniazid treatment in mice might elucidate additional
possible mechanisms and other [2Fe-2S] containing proteins that may be affected by PIH.
Isoniazid treatment has been linked to peripheral neuropathy secondary to vitamin
B6 depletion (Aita and Calame 1972, Mahashur 1992) and may be associated with
conjugation of isoniazid to the vitamin B6 species, pyridoxal, pyridoxine, and pyridoxal
5’ phosphate, resulting in decreased pyridoxal levels in humans and rats (Carlson,
Anthony et al. 1956, Sevigny, White et al. 1966, Demiroglu and Dundar 1997, Cilliers,
Labadarios et al. 2010). Isoniazid-induced vitamin B6-dependent peripheral neuropathy is
treated in part by the administration of vitamin B 6. Further studies would be necessary to
study the potential relationship of vitamin B6 levels to hepatotoxicity in anti-tubercular
therapy. Hydrazine increases ALAS1 protein (Figure 3-12E and Figure 3-12G) and
mRNA (Figure 3-12F and Figure 3-12H) levels, but we did not elucidate the mechanism
by which hydrazine up-regulates ALAS1. However, hydrazine has been previously
reported to N-alkylate, deactivate, and increase the turnover of CYP450 enzymes
(Battioni, Mahy et al. 1983, Ator, David et al. 1987, Jenner and Timbrell 1994, Wen,
Wang et al. 2002). If this leads to a decrease in the regulatory heme pool, then this could
be expected to result in ALAS1 up-regulation at both the protein and mRNA levels
(Zheng, Shan et al. 2008). Previous studies have elucidated the role of heme regulation
on ALAS1 levels (Kolluri, Sadlon et al. 2005, Yoshino, Munakata et al. 2007, Zheng,
Shan et al. 2008, Gotoh, Nakamura et al. 2011, Kubota, Nomura et al. 2016).
Cholestatic liver injury due to rifampicin and isoniazid is associated with PPIX
accumulation and heme biosynthesis disruption. The heme biosynthesis disruption
observed in animal systems (Sachar, Li et al. 2016) after isoniazid administration also
affects the human proteins (Figure 3-9 and Figure 3-10). Furthermore, the effects are not
due to isoniazid itself, but due to a metabolite of isoniazid, hydrazine (Figure 3-12 and
Figure 3-15), and a vitamin B6 conjugate, PIH (Figure 3-12 and Figure 3-13). PIH
forms in an enzyme-independent reaction between multiple vitamin B 6 orthologs and
isoniazid (Figure 3-13) and decreases FECH protein levels in an iron-dependent manner
(Figure 3-16). Hydrazine is formed in the culture media of primary human hepatocytes
and HepG2/C3A and may require metabolic activation of isoniazid to achieve high
concentrations (Figure 3-15). Hydrazine up-regulates ALAS1 at the mRNA and protein
levels (Figure 3-12). Together these effects would begin to explain the observed increase
in PPIX accumulation after isoniazid co-administration.
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Significance of Proteomics Profiling Findings
Proteomics profiling revealed protein changes in hPXR mice treated with
rifampicin and/or isoniazid and changes in mPxr -/- mice treated with rifampicin and
isoniazid compared to hPXR control mice. With these treatments it is possible to tell what
changes are due to the drug combination and what changes are dependent on hPXR status
and what changes are due to the single therapy of either drug or due to the combination
therapy in hPXR mice. The analysis revealed down-regulation of heme biosynthesis
genes (Alas2, Ppox, and Fech) that participate in a mitochondrial protein complex
(Medlock, Shiferaw et al. 2015). This complex or the individual proteins of this complex
were decreased by the combination (Table 3-1) of rifampicin and isoniazid in hPXR
mice. Further validation of these findings may elucidate what level (transcriptional,
translational, or post-translational) that these changes occur and reveal the heme
biosynthesis metabolite (the Ppox substrate, PPG or the Fech substrate, PPIX) that
accumulates from these changes.
Proteomics profiling also identified CYP450 enzyme changes and the differences
due to drug treatment and hPXR status (Table 3-2). High CYP2E1 activity has been
reported to contribute to an increased incidence of isoniazid DILI in humans (LeiroFernandez, Valverde et al. 2010, Gogtay, Kapileshwar et al. 2016, Antonenko, Butov et
al. 2017). In mice, Cyp2e1 has not been associated with a protective effect on the
development of isoniazid DILI in mice, but pan-CYP450 inhibitors have been shown to
affect the development of DILI in mice (Mitchell, Thorgeirsson et al. 1975, Mitchell,
Zimmerman et al. 1976, Lauterburg, Smith et al. 1985, Lauterburg, Todd et al. 1985).
Analysis revealed an hPXR-independent increase in Cyp2e1 protein in mice due to the
combination of rifampicin and isoniazid.
The nuclear receptors, Hnf1a, Nr3c, and Nr5a were significantly changed and are
down-regulated due to rifampicin and isoniazid (Table 3-3). The glucocorticoid receptor
(Nr3c) and Nr5a may be down-regulated due to rifampicin in hPXR mice. Hnf1a may be
down-regulated due to rifampicin in an hPXR-independent manner. Other nuclear
receptors were not significantly changed, suggesting that changes observed in target
genes may be due to activation of these nuclear receptors.
The organic transporters Abcb1a, Abcc2, Slc10a1, and Slco1a were significantly
changed (Table 3-4). Rifampicin may have increased Abcb1a in an hPXR-dependent
manner, which could result in increased efflux of xenobiotic substrates of Abcb1a taken
in combination with anti-tubercular therapy. Abcc2 may have been decreased due to
isoniazid independent of hPXR-status. Slc10a1 and Slco1a1 may be decreased due to
rifampicin dependent on hPXR status.
Ltf modulates the immune system, both innate and adaptive responses, and a
decrease may be expected to produce an exaggerated immune response to injury (Actor,
Hwang et al. 2009). Indeed Ltf is significantly decreased by at least 60% in all treatments
compared to control hPXR mice (Table 3-5). Ftl11 is down-regulated in all treatment
groups, with the highest magnitude of decrease (72%) in hPXR mice treated with both

109

rifampicin and isoniazid. Low ferritin levels are a clinical sign of iron deficiency and
could reflect low iron levels possibly caused by long-term exposure to an iron chelator.
However, this is less likely as Ftl1 was also decreased in rifampicin treated hPXR mice,
but to a lower magnitude to all isoniazid-containing treatments. Abcb7 is an iron
transporter and deficiency is associated with refractory anemia with ring sideroblasts
from intracellular iron accumulation in erythrocytes. Abcb7 may be decrease in and
hPXR-independent manner by rifampicin. This effect could be compensatory to low-iron
levels or a direct effect of drug treatment.
Profiling analysis revealed many changes in proteins involved in relieving
oxidative stress (Table 3-6). Multiple GST mu isoforms were up-regulated by rifampicin
a possibly hPXR-dependent manner. There was an approximately additional 1 fold higher
increase in hPXR mice treated with rifampicin and isoniazid compared to mPxr -/- mice
treated with rifampicin and isoniazid. Additional GST isoforms up-regulated where
Gsta1 and Gstt2. GSTM1 has been reported to be protective in humans treated with
rifampicin and isoniazid. Null alleles of GSTM1 in humans may lead to increased
incidence of DILI (Roy, Chowdhury et al. 2001, Huang, Su et al. 2007, Lucena, Andrade
et al. 2008, Bing, Xiaomeia et al. 2011, Monteiro, El-Jaick et al. 2012, Gupta, Singh et al.
2013, Li, Long et al. 2013, Tang, Deng et al. 2013). This response may be protective to
xenobiotic exposure by conjugating allowing for the elimination of xenobiotics. Cat was
also increase due to rifampicin in a possibly hPXR-dependent manner and may be
protective by neutralizing H2O2. Nqo1 is up-regulated in APAP-induced DILI and is
protective against the development of DILI (Hwang, Kim et al. 2015). Nqo1 is increased
in an hPXR-independent manner due to rifampicin and isoniazid and to a greater extent
due to rifampicin alone. These changes support the hypothesis that oxidative stress may
play a role in the response of mouse liver protein expression to rifampicin and isoniazid
treatment.
Multiple [Fe-S] cluster assembly proteins are down-regulated by rifampicin and
isoniazid (Table 3-7). Nfs1, Fdx1, Hscb, Isca11, and Bola3 are decreased by the
combination of rifampicin and isoniazid in both hPXR and mPxr -/- mice. Whether these
changes are direct effects of drug treatment or are compensatory to other changes is
unclear, but it does not seem to be due to isoniazid alone. However, with these decreases
the ability to produce [Fe-S] clusters and the proteins that contain them may be reduced.
Histopathologic examination revealed signs of toxicity in hPXR mice treated with
rifampicin and isoniazid in combination and with rifampicin alone in the mice whose
livers were used for proteomics profiling (Table 4-1). This was not significant because
two mice not included in the proteomics analysis had high histopathologic scores.
However, the control hPXR mice used in the proteomics analysis had lower levels of
hepatotoxicity, whereas hPXR mice treated with rifampicin and isoniazid and rifampicin
alone all had much higher histopathogic score (Table 4-1). Correspondingly, upregulation of the genes related to wound healing Tgm2, Col4a1 and Anxa5 were increased
in hPXR mice treated with rifampicin and isoniazid (Table 3-8).
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Table 4-1.

Histopathologic score of mice in proteomics analysis.

RIF
Treatment:
U
Sample ID: T
HP Score: 102 102

hPXR
RIF/INH
I
K
L
166 163 50

111

Control
A C
8
0

INH
N O
0 48

mPXR -/RIF/INH
Z AA
16 8

Pdxp was significantly increased due to rifampicin alone and in combination with
isoniazid in hPXR mice and due to the combination of rifampicin and isoniazid in mPxr -/mice (Table 3-9). Multiple [Fe-S] cluster assembly machinery proteins are downregulated (Table 3-10). Two [Fe-S]-containing proteins were down-regulated by
isoniazid that contained multiple [Fe-S] clusters, some of which are [2Fe-2S] clusters.
Multiple [2F-2S]-containing proteins are down-regulated due to isoniazid, but not all
these proteins were decreased. Proteomics analysis has revealed many changes due to
rifampicin and isoniazid treatment in mice that need be validated.
Significance of Physiochemical Findings
The proposed hepatotoxicity mechanism of PPIX posits that PPIX precipitates in
bile canaliculi, possibly upon binding with bile acids and phospholipids. This
precipitation of PPIX and bile acid constituents may lead to bile stasis and bile pigment
plugs observed in enlarged canaliculi upon histologic examination. This has not before
been shown to be the mechanism by which PPIX contributes to cholestatic
hepatotoxicity. Therefore, I demonstrated that PPIX is insoluble at the higher
concentrations reported in hepatotoxicity and that PPIX binds to bile acid constituents
and that this binding may be affected by the presence of rifampicin and isoniazid. The
hepatotoxicity mechanism of PPIX also presumes that extracellular PPIX is more
hepatotoxic than intracellular PPIX (Lyoumi, Abitbol et al. 2011). Thus, I selected a
polar species of PPIX, the disodium salt, which is not membrane permeable. I then found
that exogenous treatment of PPIX (I cannot exclude cellular import conclusively)
significantly decreased the viability of HepG2/C3A cells.
The mechanism of PPIX induced cholestatic hepatotoxicity observed in
BALB/cm1Pas mice (Lyoumi, Abitbol et al. 2011) and as reported in hPXR transgenic
C57BL/6 mice (Li, Lu et al. 2013), is dependent upon PPIX efflux to the bile and that
retention in hepatocytes results in a less severe and hepatocellular pattern of
hepatotoxicity. Therefore, PPIX would be expected to contribute to toxicity upon efflux
from hepatocytes. This efflux would be expected to be dependent upon ABCG2-mediated
transport of PPIX and has been reported as such previously (Aust, Obrist et al. 2004).
Therefore, the expected role of isoniazid or rifampicin upon ABCG2 activity, would be to
increase possibly by transcriptional up-regulation rather than by inhibition by isoniazid.
(He, Guo et al. 2017) Indeed, I report here that isoniazid does not inhibit human or
mouse ABCG2/Abcg2-mediated transport of pheophorbide A or PPIX.
Future Studies
The exact molecular mechanism and specific contribution to toxicity from both
rifampicin and isoniazid should be elucidated before re-attempt of the in vivo study is
made. When these conditions are known after revelation from mechanistic studies, the
animal equivalent dose I calculated should be a starting point. Future studies to undertake
as indicated by the results of this study would broadly be to (1) validate the proteomics
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profiling findings, (2) successfully observe the DILI phenotype in mouse, (3) to
specifically define the mechanism by which PIH and hydrazine affect heme biosynthesis
proteins, and (4) to fully elucidate the effects of the physiochemical properties of PPIX
on the development of DILI.
To Validate and Expand the Proteomics Profiling Results
The proteomics data set derived by TMT labeled LC/LC/MS/MS revealed
additional potential contributions to hepatotoxicity from rifampicin as well as potential
mechanism by which isoniazid affected Fech and Alas1. Down-regulation of a
mitochondrial heme synthesis protein complex may have been indicated. Further
validation of these findings may elucidate at what level that these changes occur and
reveal the heme biosynthesis metabolite (the Ppox substrate, PPG or the Fech substrate,
PPIX) that accumulates from these changes.
Network analysis of transcription factor target gene networks may identify
potential transcription factors that are activated in addition to hPXR that may play a role
in the development of hepatotoxicity. Several organic transporters were changed due to
rifampicin and isoniazid and these changes may reflect disrupted bile flow either by
being contributory to cholestasis or by being compensatory. Additionally, potential
changes were observed that could be reflective of chronically low iron levels. The timing
and severity of changes in the expression of Fech could be improved by modulation of
iron levels as well as modulation of pyridoxal phosphorylation.
Changes in [Fe-S] cluster assembly machinery proteins observed from the
proteomics analysis could be related to the potential for [Fe-S] cluster incorporation into
Fech, forming a stable protein able to clear PPIX. Up-regulation of CYP450 enzymes due
to rifampicin could be the major contribution of rifampicin to hepatotoxicity observed in
hPXR mice treated with rifampicin and isoniazid. To confirm, one would need to robustly
induce phenotype then test multiple specific and pan inhibitors of CYP450 enzymes in
the presence of rifampicin and isoniazid. Confirmation of these changes would reveal
additional conditions to improve the likelihood of obtaining a hepatotoxic phenotype due
to rifampicin and isoniazid treatment in hPXR mice.
To Successfully Observe the DILI Phenotype in Mouse
The inclusion of pyrazinamide to the rifampicin and isoniazid combination
treatment of hPXR mice may cause a more severe toxicity, but may be (1) too severe to
be reversed or (2) not hPXR-dependent and not reversible by hPXR antagonism.
However, pyrazinamide inclusion should be one of several conditions tested for a pilot
study to induce hepatotoxicity in hPXR mice. Pyrazinamide inclusion to anti-tubercular
regimens containing rifampicin and isoniazid more than doubles the incidence of
hepatotoxicity (Centers for Disease and Prevention 2001, Chang, Leung et al. 2008). No
evidence exists that hPXR plays a role in the hepatotoxicity of pyrazinamide (Shehu, Li
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et al. 2016). Additionally, the hepatotoxicity of pyrazinamide may be by a separate
mechanism than either rifampicin or isoniazid and the combination of rifampicin an
isoniazid. A metabolite of pyrazinamide, 5-hydroxypyrazinoic acid, may be responsible
for the toxicity seen after pyrazinamide administration and is dependent on an unidentified amidase (Shih, Pai et al. 2013). The pattern of hepatotoxicity is hepatocellular
and this study was conducted in rats and caution should be used when extrapolating these
results to mice or humans.
The isoniazid dose used in study 3 (70 mg/kg/day) was too low considering the
estimated dose in study 2 (220 mg/kg/day), previous literature reports (75 mg/kg/day),
and the calculated dose (185 mg/kg/day) (Chen, Xu et al. 2011, He, Guo et al. 2017).
Indeed, 300 mg/kg for a month in mPxr expressing C57BL/6 was not toxic (Metushi, Cai
et al. 2014). The dose used in the 3rd in vivo study (70 mg/kg) was lower than the dose
used in the 1st in vivo study (73.3 mg/kg). The histopathologic score would have been
significant for study 2 in hPXR mice treated with rifampicin and isoniazid, but two mice
in the hPXR control group had liver injury possibly due to age. Therefore, the goal of
study 3 was to use a higher and more controllable dose of rifampicin and isoniazid to
induce hepatotoxicity at an earlier time-point. It was believed that my calculated and
proposed doses were too high. Therefore, I used half of the isoniazid dose I had
calculated from the human dose and found was in the range used therapeutically in mice
to treat M. tuberculosis infection.
To successfully recapitulate the DILI phenotype reported previously, (Li, Lu et al.
2013) (1) doses should be selected based on the literature evidence, mouse equivalent
dose calculations, and pilot experiments, (2) multiple diet formulations containing
various amounts of vitamin B6 analogues should be considered, (3) small pilot studies
using only hPXR control mice and hPXR mice treated with rifampicin and isoniazid
should be performed first to find the conditions of DILI, (4) the role of PPIX should be
elucidated to understand if additional conditions to promote toxicity are necessary, and
(5) the hPXR mice need to be back-crossed to reduce the variability in drug response.
To Fully Elucidate the Role of the Physiochemical Properties of PPIX upon the
Development of DILI
A full characterization of the contribution of the physiochemical properties of
multiple species of PPIX should be undertaken to understand the molecular mechanism
by which PPPIX contributes to hepatotoxicity. Previous reports that have reported PPIX
in association with hepatotoxicity, have detected PPIX by mass spectrometry which may
not be able to differentiate between PPIX species with different metal ions coordinated
(Li, Lu et al. 2013). This is especially necessary given that the toxic effect of PPIX may
be exerted when in an extracellular space (Davies, Schuurman et al. 2005, Lyoumi,
Abitbol et al. 2011). Therefore, physiochemical rather than the biologic effects of PPIX
accumulation may be more imported in the DILI associated with PPIX accumulation.
Future studies should seek to (1) demonstrate conclusively by comparing Km values that
rifampicin and/or isoniazid affect binding of bile acid constituents, (2) determine the
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solubility of multiple species of PPIX and the conditions present in the bile that may
modulate the solubility of PPIX, and (3) demonstrate the exact molecular mechanism of
the in vitro hepatotoxicity of PPIX because it will be necessary to understand the in vivo
mechanism of hepatotoxicity. PPIX is strongly associated with hepatotoxicity, but a
definitive answer and mechanism has not been reported.
To Elucidate the Mechanism by which Hydrazine Up-Regulates ALAS1 and PIH
Down-Regulates FECH
Low iron levels regulate FECH by preventing the formation of a stable protein by
decreasing iron levels by chelation (Taketani, Adachi et al. 2000, Crooks, Ghosh et al.
2010), whether this is by disrupting iron metabolism, transport, or storage, direct
destruction of the [Fe-S] cluster of FECH, or by the disruption of the [Fe-S] cluster
assembly machinery proteins remains to be see. Further studies such as EPR
spectroscopy of FECH formed following PIH application similar to a previous report
(Sellers, Johnson et al. 1996) to observe the if purified recombinant FECH formed in the
presence of PIH differ from those formed in iron-replete conditions. Likewise, a
proteomics analysis following isoniazid treatment in mice might elucidate additional
possible mechanisms and other [2Fe-2S] containing proteins that may be affected by PIH.
EPR spectroscopy could directly observe malformation of the [Fe-S] cluster.
Proteomics profiling data suggest that additional [2Fe-2S] cluster-containing
proteins may be down-regulated by isoniazid in addition to FECH. Proteomics profiling
also revealed that several proteins involved in the assembly of [Fe-S] cluster proteins
were also down-regulated by isoniazid. Future studies to determine if there is a global
decrease in [2Fe-2S] cluster containing proteins by defects in [Fe-S] cluster assembly
machinery, or another aspect of Fe-mediated protein stability involved are warranted.
Proteomics profiling also provided insights into the possible mechanism by which
hydrazine up-regulates ALAS1. Multiple CYP450 enzymes are down-regulated by
isoniazid (Table 3-2). This could be due to isoniazid and hydrazine covalently binding to
and destroying heme-containing proteins (Battioni, Mahy et al. 1983, Ator, David et al.
1987, Jenner and Timbrell 1994, Wen, Wang et al. 2002). This destruction of
hemoproteins could lead to a compensatory up-regulation of the heme biosynthesis
pathway once the inhibitory effect of the regulatory heme pool is removed (Srivastava,
Borthwick et al. 1983, Kolluri, Sadlon et al. 2005, Zheng, Shan et al. 2008). Directly
measuring the increase in protein size by mass spectrometry when adducted to hydrazine
would confirm this mechanism in hPXR mice.
Conclusions
Tuberculosis kills millions of humans every year. A significant portion of these
deaths is from anti-TB therapy failure due to withdrawal of first-line drugs due to DILI.
This is more likely in vulnerable populations (Ungo, Jones et al. 1998, Yee, Valiquette et

115

al. 2003, Breen, Miller et al. 2006). I propose additions to the understanding of the
mechanism of rifampicin and isoniazid DILI whereby separate metabolites of isoniazid
modulate the heme biosynthesis pathway (Figure 4-7). Models of anti-TB DILI have
been used for over 50 years (Mitchell, Zimmerman et al. 1976, Nelson, Mitchell et al.
1976). These early models were useful, but due to the lack of the gallbladder in rats, were
not fully elucidative. Indeed, the absence of the gallbladder in the rat may interfere the
development of the clinicopathologic pattern of anti-TB DILI of liver injury observed in
the livers Of Mice and Men.
In conclusion, I report that the physiochemical properties of PPIX may contribute
to the toxicity associated with PPIX accumulation, metabolites of isoniazid modulate the
heme biosynthesis pathway in a manner associated with an increase in PPIX levels, and
that rifampicin treatment of mice results in gene changes that may contribute to PPIX
accumulation and hepatotoxicity.

Figure 4-7.
isoniazid.

The proposed mechanism of regulation of heme biosynthesis by

Vitamin B6 analogues form PIH in the presence of isoniazid. PIH chelates iron and
prevents the stabilization of FECH. Isoniazid breaks down to hydrazine and hydrazine
up-regulates ALAS1 at the transcriptional level. Both effects may be expected to raise the
levels of liver protoporphyrin ix and lead to cholestatic liver injury.
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